annual report new challenge new thinking feel well live longermission global quest improve quality human life enable people feel well live long spirit undertake quest enthusiasm entrepreneur excite constant search innovation value performance achieve integrity attain success world class global leader people contribute passion unmatched sense urgency strategic intent want indisputable leader industry glaxosmithkline plc english public limited company business segment itshare list london stock exchange glaxosmithkline operate principally industry new york stock exchange segment pharmaceutical prescription pharmaceutical history development company vaccines glaxosmithkline plc subsidiary associate consumer healthcare overthecounter medicine undertaking constitute major global healthcare group oral care nutritional healthcare engage creation discovery development manufacture marketing pharmaceutical annual report review consumer healthrelate product report annual report glaxosmithkline plc glaxosmithkline corporate head office london forthe year end st december preparedin operational headquarters philadelphia accordancewith united kingdom requirement research triangle park usa operation summary report year annual review country product sell country intend investor need detail principal research development rd facility annual report produce separate document uk usa japan italy spain belgium theannual review include joint statement product currently manufacture country chairmanand chief executive officer summary major market group products usa review operation summary financial statement france japan uk italy germany spain summary remuneration report glaxosmithkline plc public limited company annual review issue shareholder incorporate th december english law annual report issue shareholder elect th december company acquire glaxo receive itboth document available wellcome plc smithkline beecham plc english glaxosmithkline corporatewebsiteat wwwgskcom public limited company way scheme arrangement merger company website glaxo wellcome smithkline beecham glaxosmithkline website wwwgskcom give additional major global healthcare business information group information available website constitute annual reportglaxosmithkline glaxosmithkline plc annual report year end st december content report director financial summary joint statement chairman chief executive officer description business corporate governance remunerationreport operate financial review prospect financial statement director statement responsibility independent auditor report consolidated statement profit loss consolidate statement total recognise gain loss consolidate statement cash flow consolidated balance sheet reconciliation movement consolidate equity shareholder fund company balance sheet note financial statement investor information financial record financial information international financial reporting standard ifrs shareholder return shareholder information share capital taxation information shareholder cross reference form f glossary term annual report approve board director onndmarch publish onthmarch contact detail glaxosmithkline financial summary restate growth statutory result cer turnover trading profit profit taxation earningsnet income basic earning share p p dividend share p p merger restructure disposal subsidiary trade profit profit taxation earningsnet income earning share p business performance turnover trading profit profit taxation adjust earningsnet income adjust earning share p p groupas multinational business operate country earn revenue incur cost currency result group report sterling affect movement exchange rate sterle overseas currency average exchange rate prevail period translate result cash flow overseas subsidiary associate undertaking joint venture sterling period end rate translate net asset undertaking currency influence translation usdollar euro japanese yen order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year cer represent growth constant exchange rate represent growth actual exchange rate year business performance primary performance measure management present exclude merger item integration restructuring cost disposal business management believesthat exclusion item providesa bettercomparison way business manage givesan indication performance group term element revenue expenditure local management able influence completion programme group reporting result statutory basis growth rate present compare result business performance result statutory result management consider comparison statutory result business performance result give appropriate indication group performance period review commentary present basis state cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event forwardlooke statement involve inherent risk uncertainty group caution investor number important factor include document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor pagestoof annual reportglaxosmithkline joint statement chairman chief executive officer know challenge pipeline focus develop new medicine vaccine treat disease unmet medical need cancer year glaxosmithkline alzheimer disease potential pleased report achieve important new product financial business objective example believe cervarix promise vaccine candidate cervical cancer potential major contribution healthcare globally annual report predict bestselle vaccine expect file cervarix european challenging year feel impact generic competition union international markets paxiland introduction generic wellbutrin glaxosmithkline manage year thank underlie great opportunity lie ahead year work strength business fact glaxosmithkline ensure great understanding key stakeholder value strong company today year ago innovative medicine continue contribution finding solution healthcare funding crisis broadbase portfolio fastgrowing product continue seek new way improve access medicine focus control cost enable absorb loss people need able pay billion business generic achieve corporate responsibility principle continue guide way cent increase global pharmaceutical sale turnover business separate corporate responsibility report billion grow cent constant exchange rate cer available glaxosmithklinewebsite explain progress achieve guidance earning share ep principle year line business performance ep cer eps grow cent pence acknowledgement acknowledge gratitude contribution expect fast growth ep percentage sir christopher hogg sir peter job retired cer growth low doubledigit range international board end sir christopher chair glaxosmithkline financial reporting standard ifrs basis drive period see company derive benefit strong growth key product continue efficiency merger meet challenge cause loss operation exciting phase growth come patent protection major product new compound vaccine currently development start contribute performance year john coombe chief financial officer retire board glaxosmithkline st march john serve glaxosmithkline large promising glaxosmithkline predecessor company exemplary pipeline industry project clinical development manner year play major role guide end february include new chemical company postmerger period establish entity nce product line extension vaccine glaxosmithklinea leader global pharmaceutical compound nce move phase ii trial industry include compound treat hiv diabetes blood disorder multiple sclerosis datum expect thank depart director substantial anticipate launch new contribution glaxosmithkline wish product include rotarixfor rotavirus vesicarefor overactive future bladder bonivafor osteoporosis avandarylfor diabetes requip restless leg syndrome enteregfor postoperative bowel disorder sir christopher gent jeanpierre garnier nonexecutive chairman chief executive officer glaxosmithklineglaxosmithkline description business description business discuss strategy activity resourcesandthe operate environment business identifie development achievement follow heading strategy strategy buildthe good product pipeline industry achievecommercial operational excellence improve access medicine bethe good place good people good work investincommunitie consumer healthcare global manufacturing supply product competition pharmaceutical consumerhealthcare regulatory environment regulation intellectual property responsibility environmenthealth safety discussion group management structure corporate governance procedure set corporate governance pagesto remuneration report give detail group policy director remuneration amount earn director senior management pagesto discussion group operate financial performance financial resource give operate financial review andprospect pagesto report glaxosmithkline group mean glaxosmithkline plc subsidiary undertaking thecompany mean glaxosmithkline plc glaxosmithkline share mean ordinary share ofglaxosmithkline plc p american depositary share ad represent glaxosmithkline share report figure quote market size market share market growth rate relate month end th september orlater available glaxosmithkline estimate base onthe recent datum independent external source value sterle relevant exchange rate figure quote product market share reflect sale glaxosmithkline licensee brand name appear italic report trademark own andor license glaxosmithkline associate company theexception baycoland levitra trademark bayerhepsera trademark gilead service country include usa integrilina trademark cor therapeutic micropump trademark flamel technologies nicoderm trade mark sanofiaventis elan novartisor glaxosmithkline certain country natrecor trademark sciosand janssen navelbine trademark pierre fabre mdicament vesicare trademark yamanouchi pharmaceutical bonivabonvivaatrademarkof roche enterega trademark adolor corporation pritor trademark boehringer ingelheim certain country license group glaxosmithkline description business strategy glaxosmithkline business goal indisputable bethe good place good people good work leader pharmaceutical andconsumerhealthcare industry single great source competitive advantage achieve goal require meet key challenge organisationis people group ambition face industry society place great people apply energy passion difference world skill intellect key improve productivity research development component successful implementation group ensure patient access new medicine strategy work environment support inform empower reach consumer traditional healthcare resilient workforce group value draw professional diverse knowledge perspective experience style glaxosmithkline develop strategy focus global community detail give page number key business driver order meet challenge investincommunitie buildthe good product pipeline industry glaxosmithkline continue build history community group aim create thebestproductpipeline investment programme theseprovide supportfor well industry benefit patient consumer society healthcare delivery education underserved community include develop focus portfolio strategy support world group active engagement pipeline manage life cycle compound numerous external stakeholder include world health launch prescription medicine overthe organisation member notforprofit community counter productswhere appropriate strategy include fund communityle initiative world donate selective inlicense efficient execution development medicine support humanitarian effort communitybase commercialisation supply chain process healthcare programme longterm commitment help bring sustainable change community glaxosmithkline rd organisation measure productivityby detail give pagesto number innovation product createsand commercial value product ability address committocorporate responsibility unmet need consumer includespatient healthcare glaxosmithkline commit connect business decision professional budget holder regulator ethical social environmental concern corporate perspective constitute valuable new product responsibility integral embed way detail give pagesto business achievecommercial operational excellence glaxosmithkline publish set ofcorporate glaxosmithkline link research commercial operation closely responsibilityprinciple provide guidance standard order maximise value portfolio compound thegroupis committed set approach aredevelope testedmarketing campaign andsale effort area standard ethical conductresearch areplanne appropriate market group aim innovation product customer access medicine build strong relationship patient consumer employment practice human right community investment ultimateusersof medicine care environmentleadership advocacy engagement stakeholder groupreportsannually common approach management process business progress uphold principle corporate function internationally diverse talented responsibility reportwhich available website management team order create sustain competitive wwwgskcom advantage market detail give page improve access medicine glaxosmithkline create extensive programme design improve healthcare people limited access medicine develop develop world set theimprove access medicinessection thisreport pagedescription business glaxosmithkline build good product pipeline industry research development pharmaceutical find candidate compound research development rdoperate global basis early research role genetic employ staff site mainly uk usa early stage find new medicine require essentially belgium canada france india italy japan spain component target show affect mechanism addition rd partnership company worldwide important pathological process human diseaseand order benefit particular skill expertise compoundsable modulate behaviour specific target available particular location target validation process glaxosmithkline aim identify gene relevant common disease focus patient large unmet medical need major patient burden glaxosmithkline strategic intent indisputable disease arise complex interaction leader industryitssuccessisdependent vibrant number gene variant environmental factor productiverdfunction support exist product challenge significant identify gene predispose develop new way help patientsrdi increasingly patient particular disease understand rolesin seek view patient understandthe important progression lead new way intervene disease aspect disease impact live gene interest identify asthma noninsulin addition todiscussionswith key opinion leader glaxosmithkline dependent diabetesfurther genetic association study devote resource dialogue patient phenotype patientsare way schizophrenia unipolar family information shape drug depression obesity alzheimer disease rheumatoid arthritis development programme new medicine ready osteoarthritis metabolic syndromechronic obstructive pulmonary launch glaxosmithkline know bring clear benefit disease copd coronary artery disease acute coronary patientslive syndrome productivity glaxosmithkline justly proud reputation apply continue high priority challenge scientific excellence forefront advance increase productivity improve science harness find new medicine quickly possible manage entire rd organisation resource example thegroup help optimallyfocusedon discovery development new understandingof disease process forward development medicine scientific initiative enhance imaging technique validate act surrogate productivity discuss programme identify marker disease allow increasingly accurate prediction association disease gene facilitate linkage clinical effect lead molecule drug candidate cellular target disease identify glaxosmithkline embarkingon later stage development area research likely produce new way efficient useof resource help patient increase automation screen compound provide lead compound quickly discovery research high quality improvement discovery research dr produce lead compound form imaging technique allow early decision basis drug discovery effort centresof excellence compound progress addition great use automation drug discovery cedd dr provide cedds laboratory environment expansion electronic overhighquality new lead compound activity collection clinical trial information allow scientist define target investment dr focus increase productive discovery development quality quantity lead compound available process year rd complete current phase investment glaxosmithkline product development pipeline set page automation open new combine facility show considerable breadth depth end highthroughput screen highthroughput chemistry february glaxosmithkline hadpharmaceutical upper providenceusa enable screen vaccine project development clinic million compound success ratio consistently increase investment period addition molecular imaging centre excellence mouse upper merion usawas open provide platform develop noninvasive multimodal imaging technology preclinical application glaxosmithkline description business build good product pipeline industry continue compound progress phase clinical development number discovery project list table progress nonclinical safety testing early phase clinical development undertaken cedd compound continue rigorous nonclinical clinical commercial assessment lead proof concept decision month compoundproduct mechanism indication longacte beta agonist inhale asthmacopd sodium dependent glucose transport sglt inhibitor type diabete histamine h antagonist dementia calcium antagonist osteoporosis beta adrenergic agonist overactive bladder oral pleuromutilin treatment respiratory tract infection longacte beta agonist inhale asthmacopd interleukin receptor antagonist copd lipoproteinassociate phospholipase inhibitor atherosclerosis nk antagonist urinary incontinence vanilloid receptor antagonist acute migraine kinesin spindle protein ksp inhibitor cancer parathyroid hormone agonist osteoporosis factor xa inhibitor prevention stroke atrial fibrillation dna antiviral vaccine hiv noncannabinoid agonist inflammatory pain melaninconcentrate hormone antagonist obesity p kinase inhibitor rheumatoid arthritis copd corticotrophin releasing factor crf antagonist depression anxiety irritable bowel syndrome ibs requip xr nonergot dopamine agonist restless legssyndrome rls product submission anumber significant dossier submit regulatory authority major region summarise table product countryregion description bonvivaboniva eu usa monthly oral dose regimen ibandronate bisphosphonate treatment osteoporosis entereg usa alvimopan peripheral muopioid receptor antagonist postoperative ileus hepsera japan adefovir rnadirecte dna polymerase inhibitor treatment hepatitis b lexiva japan fosamprenavir hiv aspartyle protease inhibitor treatment hiv product approval approval receive number new product summarise table countryregion product approval date description bonviva eu february daily oral dose regimen ibandronate bisphosphonate treatment osteoporosis flolan pah japan june epoprostenol prostacyclin agonist treatment pulmonary arterial hypertension hepsera japan october adefovir rnadirecte dna polymerase inhibitor treatment hepatitis b lexiva japan december fosamprenavir hiv aspartyl protease inhibitor treatment hiv telzir eu july fosamprenavir treatment hiv vesicare usa november solifenacin muscarinic acetylcholine receptor antagonist treatment overactive bladder inlicense yamanouchidescription business glaxosmithkline select bestcandidatemolecule early development process metabolicrate safety compound evaluate laboratory animal prior testing centre excellence drug discovery human test require animal human fundamental step turn lead compound mandate highly regulate governmental agency drug candidate optimise potency efficacy safety animal research page intrinsic characteristic molecule ii demonstrate validity therapeutic hypothesis pcd researcher investigate appropriate dosage form eg tablet early clinical trial result candidate step inhale develop formulation enhance drug facilitate rapid informed decisionmake creative effectiveness facilitate ease use patient solution issue inevitably arise phase process support analytical method drug synthesis development cedd focus specific disease area product formulation delivery scale meet design nimble entrepreneurial increase supply requirementsultimately lead technical range skill resource require drive midstage transfer process method manufacture development project lead optimisation key new product supply process partnership rd decision point demonstration proof concept major global manufacturing supply ensure robust product investment fund largescale clinical trial develop largescale commercial manufacturing launch seven cedd base europe usa improve rds productivity new drugdelivery system predictive technology particle engineering process biopharmaceutical centre stevenage uk innovation use particle engineering process innovation cardiovascular urogenital disease centre upper merion enhance ability manufacture consistently highquality usa product efficiently metabolic viral disease centre research triangle park usa worldwide development microbial musculoskeletal proliferative disease include provide focus development process major cancer centre upper providence usa functional component clinical medical biomedical datum neurology gastrointestinal disease centre harlow uk regulatory safety integrate single management psychiatry centre verona italy organisation worldwide developmentwwd respiratory inflammation centre stevenage uk creation medicine development centre cedd responsible identify optimal drug mdcswhich provide focus latestage developmentwas candidate desire biological effect assess complete embed organisation mdc safety development characteristic preclinical screen responsible create value delivery product involve animal achieve development plansmanage daytoday operational activity cedds responsible proving compound safe latestage development portfolio maximise global efficacious patient smallscale clinical trial proof commercial potential product optimise delivery concept decision point portfolioand ensure strong partnership cedd decision information available global commercial strategy gcs order deliver differentiate date justifie compound progression latestage drug product value development necessary largescale clinical trial development process regulatory function conduct register commercialise product maintain dialogue regulatory agency major major investment announce september market ensure development programme well establish preclinical research facility neurodegenerative focus generate datum require grant disease singapore facility team licence dialogue facilitate glaxosmithkline ability scientist focus new therapy treatment respond efficiently emerge requirement safety neurodegenerative illness alzheimer disease efficacy data parkinson disease schizophrenia rdmodel cedd continue progress significant number new compound dose human initial genetic research preclinical global commercial evaluation efficacy patient discovery research development strategy convert candidate medicine preclinical development centre preclinical development pcd participate wide range medicine activity drug development process optimise excellence development selection compound potential development tic rch centre launch marketplace enhancement exist product drug devise convenient formulation discovery rch glaxosmithkline description business build good product pipeline industry continue mdc base major uk site pharmacogeneticbase information provide prescribing therapeutically align follow physician key information help select medicine dosemost likely therapeutic benefit patient cardiovascularmetabolic infectious disease include disease thedevelope clinical trialgovernance worldddw conduct clinical trial require medicine musculoskeletalinflammationgastrointestinalurology safe effective glaxosmithkline priority protect neuroscience psychiatryneurology participant future patient clinical trial sponsor oncology group irrespective place conduct respiratory accord international standard good clinical practice matrix team responsible maximise worldwide applicable law regulation protocol review development opportunity product remit external regulatory agency relevant country information need support registration safety require protocol consider ethic review programme price formulary negotiation available committee remit cover site study require commercial input global commercial strategy place safety datum routinely collect development ensure early stage regional marketing need fully program report national regional regulatory integrate development plan careful prioritisation agency line applicable regulation additionally phase development ensure high potential review internally safety signal glaxosmithkline integrate portfolio achieve context patient need global safety board responsible internally approve pivotal study investigate issue relate patient safety mdc collaborate early stage cedd define arise development programme addition target product profile new molecule integrate clinical compliancedepartment monitor compliance good technical development manufacturing function ensure clinical practice standard conduct analysis rapid effective launch delivery productto patient report clinical trial remit cover glaxosmithkline site innovative clinical programme lead molecule run trial clinical research organisation cro cedd develop crossfunctional project team investigator perform clinical research group behalf programme key measure productivity number result audits regularly review rd active subject clinical trial eachyear wwd increase global risk management compliance board audit number active subject clinical trial significantly committee thelast year order increase need demonstrate safety efficacy product glaxosmithkline take step information clinical trial widely easily available gold passdesignation asset high value strategic itestablishe clinical trial register public websiteon importance glaxosmithklinerequire specific organisational clinical trial dataispublishe regulatory authority visibility urgency meet patient need continued world continue fully inform datum way organisation resource generate reassured safety focus developmentsonly small number asset efficacy glaxosmithkline product clinical trial register receive gold passstatus time enable organisation enhance ability clinician informed clinical fully align product radafaxine judgement benefit patient depression lapatinib cancercontinue progress andthree project receive thegold passstatus global commercial strategy year global commercial strategy gcs organisation provide combine new longacte betaagonist integrate global commercialisation strategic direction new inhale corticosteroidfor treatment rda support development regional marketing asthma andcopdthe second chemokine receptor campaign product emerge rd maximise portfolio antagonist hiv infection project value product life cycle additiondata cyclooxygenase inhibitor generate support add value product assessment improvement quality patient live development role genetics reduction overall cost healthcare use glaxosmithkline believe pharmacogenetic research glaxosmithkline product correlation genetic datum response medicine provide valuable information help improve decision making extend use exist product drug development positive impact key product launch important establish cause pipeline attrition ielack efficacy adverse drug additional way patient help reaction clinical trial design result rd collect investigate otherillnessesmay treat sample clinical development study identify development additional dosage form pharmacogenetic information help predict patient convenient patient development reflect response prospectively collect efficacy andsafety study feedback patient medical profession clinical trial becomestandard element development result continue research disease cause information intend define patient group likely respond good treatment individual likelyto suffer adverse event compound progress development clinicdescription business glaxosmithkline line extensionsubmission anumber ofproductline extension submit regulatory authority major region summarise table product countryregion description arixtra eu usa fondaparinux synthetic factor xa inhibitor thepreventionof deep vein thrombosis abdominal surgery arixtra eu usa fondaparinux prevention deep vein thrombosis medical condition augmentin es japan syrup formulation amoxicillin betalactam antibiotic clavulanate beta lactamase inhibitor treatment otitismedia children boniva usa label intermittentintravenous dose regimen ibandronate bisphosphonatefor treatment osteoporosis epzicom japan fix dose combination reverse transcriptase inhibitor treatment hiv infection imigran stat dose japan thehydroxytryptamine agonist sumatriptan selfinjection device treatment ofmigraine requip japan additional strength ropinirole nonergot dopamine agonist parkinson disease seretide eu labelling use initial maintenance therapy asthma combination salmeterol longacte betablocker fluticasone corticosteroid seretide diskus japan use treatment asthma copd combination salmeterol fluticasone dry powder inhaler serevent eu chlorofluorocarbonfree formulation pressurise aerosol contain salmeterol treatment asthma andcopd ventolin usa chlorofluorocarbonfree formulation salbutamol shortacte beta agonist pressurise aerosol dose counter wellbutrin xl usa indication treatment seasonal affective disorder dopaminenoradrenaline reuptake inhibitor bupropion zefix japan labelling use lamivudine reverse transcriptase inhibitor treatment liver cirrhosis ziagen qd japan reverse transcriptase inhibitor abacavir treatment hiv zovirax japan cream formulation dna polymerase inhibitor aciclovir use treatment herpe simplex infection line extension approval approval receive number significant new indication formulation exist product summarise table product countryregion description approval date advair diskus usa april labelling paediatric twicedaily dose asthma combination salmeterol longacte betablocker fluticasone corticosteroid dry powder device arixtra usa june fondaparinux synthetic factor xa inhibitor thetreatmentof deep vein eunovember thrombosis flovent usa chlorofluorocarbonfree formulation pressurise aerosol dose counter contain fluticasone corticosteroidfor treat asthma kivexaepzicom usaaugust afixe dose combination oftworeverse transcriptase inhibitor treatment eu december hivinfection japan december paxil cr usa january control release formulation paroxetine selective serotonin reuptake inhibitor intermittent treatment premenstrual dysphoric disorder requip eu june ropinirole nonergot dopamine agonist restless leg syndrome seretide eu january label paediatric twicedaily dose combination salmeterol long act betablocker fluticasone corticosteroid pressurise aerosolfor treatment asthma seretide eu march dose counter formulation salmeterol treatment asthma copd serevent diskus japan february dry powder formulation salmeterol treatment asthma copd zefix japan october labelling use lamivudine reverse transcriptase inhibitor combination hepserafor treatment hepatitis b ziagen qd japan december reverse transcriptase inhibitor abacavir treatment hiv glaxosmithkline description business build good product pipeline industry continue example lifecycle management include new indicationfor collaborative adi partnership early cytokinetic inc seretideadvairmake important asthma medicine available oncology mitotic kinesin inhibitor shionogi co hiv use child year kivexaepzicom neurology programme potential broadbase discovery single tablet combine active molecule collaboration antimicrobial oncology metabolic neurology successful treatment hiv order simplify dose tanabe seiyaku co ltd broadbase neurology gi urology patient line extension form significant overall diabetes respiratory exelixis inc oncology inflammation portfolio recent examples augmentin esxr seroxatpaxil theravance inc asthma ranbaxy laboratories ltd broad base crand wellbutrin xl achieve million sale neurosearch central nervous system adi partnership establish academic institution number ofproduct lineextension submit supplement internal target validation activity provide well regulatory authority major region access tissue sample patient population clinical study submission summarise page glaxosmithkline academic adi partner uk approval receive number significant usa long term collaborative relationship new indication formulation exist product group commit fund year approval summarise page option renew additional year manage portfolio inlicense research collaboration resource available exploit opportunity arise glaxosmithkline continue identify compound group limited improve productivity progress enhance portfolio create innovative collaboration compound later phase development consequently ensure group regard partner choice put demand rdresource large small company important look objectively portfolio ensure subject inlicense comarkete copromotion progress asset prosecute efficiently possible key agreement project reach significant milestone review month product management board pmbwhich responsible albugontm glp albumin fusion protein preclinical determine individual asset achieve preset development type diabetes fromhuman genome science criterion pass phase development body exclusive marketing integrilinin europe glycoprotein gp lead jointly chairman rd thepresident llbllla inhibitor currently treat patient unstable pharmaceutical operation include thepresident angina nonstsegment elevation myocardial infarction region global manufacturing supply addition millennium pharmaceuticals inc head major function rd broad alliance develop commercialise novel medicine variety therapeutic areasincluding bacterial pmb actively manage overall portfolio infection respiratory urinary incontinenceand gastrointestinal annual portfolio review exercise thorough careful theravance inc assessment asset drug discovery worldwide development lead prioritisation project basis addition glaxosmithkline enter number commercial value unmet medical need agreement party codevelop comarket allow identification alternative approach balance certain compound arrangement range milestone group asset efficiently include use external payment party acquire right intellectual partner development outlicense product long property joint venture develop commercialise specify fit strategic portfolio compound agreement group obligation payment future specify milestone follow annual portfolio prioritisation review cedd achieve financial commitment summarise able select programme pursue internallyotherasset noteto financial statement commitment develop novel partnership scheme know alternativediscovery initiative adi glaxosmithkline discontinuation partner share risk reward business rd carry risk failure commensurate extension arrangement scientific knowledge compound effect lead adi partnership biotechnology company compound identify possess positive activity pharmaceutical company explore different approach drug validate target prove safe introduce discovery form recent year continue provide human feasible manufacture commercial scale increase opportunity exploit productivity new glaxosmithkline rd endeavour ensure far possible technology additional focus place adis risk ameliorate extensive predictive testing early add tanabe collaboration form new partnership possible development process despite effort nikem research central nervous system diversa corp ultimate test product remain point antiinfective toyama chemical co ltd antibacterialsand administer large number patient disease meiji seika kaisha ltd latestage project terminate phase ii include neuropathic painvestipitant dyspepsia depression anxiety piboserod atrial fibrillation talnetant overactive bladderdescription business glaxosmithkline research development vaccine group currently rd project programme relevance develop world seven aim vaccine rd conduct glaxosmithkline biological produce vaccine medicine disease centre rixensart belgium include related activity disproportionately affect develop country clinical development regulatory strategy commercial strategy scale packaging support function primary group work close collaboration external partner production vaccineswith exception ofinfluenza vaccine worldwide search new treatment disease isproduce atthe groupsstateoftheart facility develop world partnership key order maximise germany scientist employ devoted combine expertise talent pharmaceutical industry discover new vaccine develop costeffective academia discover develop new medicine convenient combination vaccine prevent infection cause develop world medical problem worldwide discovery work involve publicprivate partnership remain essential fund research collaborator academia thebiotech industry worldwide commercially viable market potential product allow identification new vaccine candidate group continue work closely government express yeast bacteria mammalian cell purify united nations agency global funding body high level area example glaxosmithkline pyridone project follow formulation vaccine involve award medicine malaria venture project mix antigen select novel proprietaryadjuvantswhich year rapid successful progress find drug design stimulate good appropriate immune candidate newly select candidate move response human step evaluate safety preclinical development efficacy candidate vaccinewhich involve animal animal research preclinical proof concept establish candidate vaccine test clinical trial healthy ethical regulatory scientific reason research animal individual evaluate safety effective vaccine remain small vital research development new induce immune response protect body disease medicine vaccine glaxosmithkline use animal encounter later natural set largescale field trial alternative number require healthy individual follow establish safety efficacy test group strive exceed regulatory standard care cross section population result obtain use animal use undergoe internal external clinical trial development quality production process review assure standard facility combine regulatory file vast majority oftheexperimental method use animal submit authority country glaxosmithkline actively engage research develop vaccine available validate test avoid use animal research biological long track record develop reduce number need animal research make vaccine available develop world unnecessary pain suffering scrupulously avoid preferential price pioneer new south vaccine strategy glaxosmithkline understand use animal research new rotavirus vaccine involve develop totally purpose command high level public interest unique novel clinical regulatory strategy ensure glaxosmithkline public policy position care ethical use vaccine register available area animal research information report world medicalneed great available website wwwgskcom secretariat recently cervarix vaccine prevention cervical cancer receive gold passstatus detail gold passprogramme disease develop world continue investment research disease affect develop world essential longterm improvement healthcare people live region include resolution challenge drug resistance poor patient compliance glaxosmithkline response challenge microbial musculoskeletal proliferative disease cedd responsibility drug discovery unit dedicate find new medicine disease base tre canto spain work undertake tre canto focus malaria tuberculosis work group hivaid vaccine mean glaxosmithkline address prevention treatment world health organization priority disease glaxosmithkline description business build good product pipeline industry continue glaxosmithklinespipeline chartbelowshow glaxosmithkline new chemical entity nce product line extension pleand vaccine pipeline evolution project clinic show increase level productivity particularly inphase ii thisis expect tolead increasein phase iii registration come year phase nce multiple indication count oncence later phase count indication pipeline pipeline late stage growth nce phase iiiregistration nce phase ii nce phase ple vaccine product development pipeline product development pipeline set outon follow pagesshow considerable breadth depthat end february glaxosmithkline hadpharmaceutical vaccine project development whichare cliniccomprise new chemical entity product line extension vaccine content drug development portfolio change time new compound progress discovery development development market owe nature drug development processmany thesecompound especially early stage investigationmaybe terminate progress development competitive reason new project preclinical development disclose project type identify key v vaccine phase evaluation clinical pharmacology usually conduct p pharmaccine volunteer compound shionogiglaxosmithkline pharmaceuticals phase ii determination dose initial evaluation llc joint venture efficacy conduct small number patient inlicense alliance relationship party phase iii large comparative study compound versus placebo date submission andor establish treatment patient date firstregulatory approval maa establish clinical benefit safety eu approval letter al approvable letter maa marketing authorisation application europe nda new drug application usadescription business glaxosmithkline estimate filing date compoundproduct type indication phase maa nda cardiovascular metabolic urogenital lppla inhibitor atherosclerosis lppla inhibitor atherosclerosis p kinase inhibitor atherosclerosis rheumatoid arthritis copd factor xa inhibitor prevention stroke atrial fibrillation lppla inhibitor atherosclerosis ii adenosine aa agonist dyslipidaemia ii ppar delta agonist dyslipidaemia ii odiparcil indirect thrombin inhibitor prevention thrombotic complications ii cardiovascular disease deep vein thrombosis dvt prophylaxis arixtra synthetic factor xa inhibitor treatment acute coronary syndrome iii coreg cr beta blocker hypertension congestive heart failure daily iii na noratak recombinantbtype natriuretic peptide acute heart failure lll na arixtra synthetic factor xa inhibitor prevention ofdvt abdominal surgery submit sjul sjul arixtra synthetic factor xa inhibitor prevention ofdvt medical condition approve ajan sfeb arixtra synthetic factor xa inhibitor treatment ofdvt approve anov ajun metabolicprojects sodium dependent glucose transport type diabete sgltinhibitor melanin concentrate hormone antagonist obesity ppar pan agonist type diabete ii dpp iv inhibitor type diabete ii sgltinhibitor type diabetes ii solabegron beta adrenergic agonist type diabete overactive bladder ii avandamet xr ppar gamma agonist plus metformin type diabete extend release iii avandaryl ppar gamma agonist plus sulphonylurea type diabetes fix dose combination approvable alaug infectious disease oral pleuromutilin treatment respiratory tract infection phospholipid antiendotoxin emulsion sepsis ii chlorproguanildapsone antifolate artemisinin treatment uncomplicated malaria ii na artesunate cda topical pleuromutilin bacterial skin infection iii sitamaquine aminoquinoline treatment visceral leishmaniasis iii na etaquine aminoquinoline malaria prophylaxis adult iii tbd antiviral dna antiviral vaccine hiv infections aspartyl protease inhibitor hiv infections ii nonnucleoside reverse transcriptase inhibitor hiv infections ii ccr antagonist hiv infections ii epzicomkivexa reverse transcriptase inhibitor hiv infection combination tablet approve adec aaug musculoskeletal inflammation gastrointestinal urology calcium antagonist osteoporosis calcium antagonist osteoporosis cathepsin k inhibitor osteoporosis osteoarthritis nki antagonist urinary incontinence uialso depression anxiety chemotherapy induce postoperative nausea vomit p kinase inhibitor rheumatoid arthritis atherosclerosis copd parathyroid hormone agonist osteoporosis p kinase inhibitor oral rheumatoid arthritis copd corticotrophin releasing factor crfi antagonist irritablebowelsyndrome ibs depression anxiety entereg peripheral muopioid antagonist ibs solabegron beta adrenergic agonist overactive bladder type diabete endothelial cell adhesion molecule inhibitor inflammatory bowel disease ii selective ino inhibitor rheumatoid arthritisalso migraine asthma ii dual alpha integrin antagonist vla inflammatory bowel disease multiple sclerosis ii talnetant nk antagonist ibs schizophrenia ii avandia ppar gamma agonist rheumatoid arthritis ii entereg peripheral muopioid antagonist chronic opiate induce bowel dysfunction constipation ii mepolizumab antiil monoclonal antibody hypereosinophillic syndrome asthma eosinophilic esophagitis iii avandia ppar gamma agonist psoriasis iii avodart alpha blocker alpha reductase inhibitor plus alpha blocker benign prostatic hyperplasia fix dose combination iii avodart alpha reductase inhibitor reduction risk prostate cancer iii bonivabonviva bisphosphonate treatment postmenopausal osteoporosis submit sdec intermittent iv dose bonivabonviva bisphosphonate treatment prevention postmenopausal osteoporosis submit ssep smay monthly oral dose entereg peripheral muopioid antagonist post operative ileus submit sjun vesicare muscarinic antagonist overactive bladder approve na anov glaxosmithkline description business build good product pipeline industry continue estimate filing date compoundproduct type indication phase maa nda neuroscience histamine h antagonist dementia endothelin antagonist stroke selective inos inhibitor migraine alsorheumatoid arthritis asthma gap junction blocker migraine epilepsy neuropathic pain dual acting cox inhibitor acute chronic pain condition include neuropathic pain schizophrenia vanilloid antagonist acute migraine endothelin antagonist stroke ht antagonist schizophrenia dementia mixed htdopaminergic antagonist schizophrenia nk antagonist depression anxiety noncannabinoid cb agonist inflammatory pain corticotrophin releasing factor crf antagonistdepression anxietyalso ib radafaxine noradrenalinedopamine reuptake inhibitor fibromyalgia neuropathic pain requip xr nonergot dopamine agonist restless legssyndrome rls radafaxine noradrenalinedopamine reuptake inhibitor depression ii radafaxine noradrenalinedopamine reuptake inhibitor rls ii ns triple htnoradrenalinedopamine reuptake depression ii inhibitor dual acting cox inhibitor acute chronic pain migraine ii tbd tbd glycine antagonist smoking cessation ii reuptake inhibitor nk antagonist depression anxiety chemotherapy induce ii postoperative nausea vomitingand ui dual alpha integrin antagonist vla multiple sclerosis inflammatory bowel disease ii vestipitant paroxetine nk antagonist selective serotonin depression anxiety ii talnetant nk antagonist schizophrenia ib ii avandia ppar gamma agonist alzheimer disease ii lamictal sodium channel inhibitor bipolar disorder acute treatment iii na lamictalxr sodium channel inhibitor neuropathic pain epilepsy nda daily iii lamictal xr sodium channel inhibitor schizophrenia iii requip cr nonergot dopamine agonist parkinson disease daily control release iii formulation trexima ht agonist naproxen migraine fix dose combination iii na wellbutrin xl noradrenalinedopamine reuptake inhibitor seasonal affective disorder submit sdec requip nonergot dopamine agonist rls approve ajun adec wellbutrin xl noradrenalinedopamine reuptake inhibitor depression approve aaug oncology kinesin spindle protein ksp inhibitor cancer elacridar oral bioenhancer cancer thrombopoietin agonist thrombocytopaenia ii recombinant human il immunomodulator immunologicallysensitive cancer melanoma renal cellii nk antagonist chemotherapy induce postoperative nausea ii vomiting depression anxietyandui kinesin spindle protein ksp inhibitor non small cell lung cancer tumours ii vascular endothelial growth factor solid tumours ii tyrosine kinase inhibitor vestipitant nk antagonist postoperative nausea vomiting chemotherapy ii induce nausea vomit ethynylcytidine selective rna polymerase inhibitor solid tumours ii lapatinib erbb egfr dual kinase inhibitor breast cancer renal lung bladder gastric iii head neck cancer hycamtin topoisomerase inhibitor ovarian cancer line therapy iii hycamtin topoisomerase inhibitor small cell lung cancer second line therapy iii oral formulation nelarabine guanine arabinoside prodrug acute lymphoblastic leukaemia lymphomas iii hycamtin topoisomerase inhibitor small cell lung cancer second line therapy approve anovdescription business glaxosmithkline estimate filing date compoundproduct type indication phase maa nda respiratory long act beta agonist asthma chronic obstructive pulmonary disease copd long act beta agonist asthma copd il antagonist copd p kinase inhibitor oral copd rheumatoid arthritis atherosclerosis p kinase inhibitor oral copd rheumatoid arthritis long act beta agonist copd copd asthma combination ii glucocorticoid agonist muscarinic antagonist copd ii selective inos inhibitor oral asthmaalso migraine rheumatoid arthritis ii long act beta agonist copd copd asthma combination ii glucocorticoid agonist long act beta agonist copd copd asthma combination ii glucocorticoid agonist glucocorticoid agonist asthma copd combination long acting ii beta agonist allergic rhinitis chemokine ccr antagonist oral asthma allergic rhinitis glucocorticoid agonist asthma copd combination long acting ii beta agonist pde iv inhibitor inhale copd ii mepolizumab antiil monoclonal antibody asthma hypereosinophillic syndromeand ii eosinophilic esophagitis avamysallermistglucocorticoid agonist allergic rhinitis iii seretideadvair beta agonistinhale corticosteroid copd mortality claim iii seretide beta agonistinhale corticosteroid asthma initial maintenance therapy submit saug na serevent beta agonist asthma copd noncfc inhaler submit sapr na ariflo pde iv inhibitor oral copd approvable aloct seretideadvair beta agonistinhale corticosteroid asthma noncfc inhaler approve ajun aloct oct hepatitis vaccine hepatitis e recombinant hepatitis e prophylaxis ii fendrixextra strength recombinant extra strength hepatitis b prophylaxis prehaemodialysis approve anov afeb hepatitis b haemodialysis patient paediatric vaccine rotarix live attenuate oral rotavirus prophylaxis lll streptorix conjugate pneumoniae disease prophylaxis child iii n meningitidi conjugate meningitis prophylaxis submit combination priorixtetra live attenuate measle mump rubella varicella prophylaxis submit sapr vaccine hiv recombinant hiv prophylaxis fflu improve subunit influenza prophylaxis pneumoniae elderly recombinant pneumoniae disease prophylaxis varicellazoster recombinant varicella zoster prevention dengue fever attenuate tetravalent vaccine prophylactic use il epsteinbarr virus recombinant ebv prophylaxis ii mosquirix recombinant malaria prophylaxis ii staphylococcal antibodiesmonoclonal antibody prevention staphylococcal infection ii cervarix recombinant prophylaxis human papillomavirus hpv infection iil simplirix recombinant genital herpe prophylaxis iii boostrix subunit adolescentadult booster diphtheria tetanus approve aoct sjun pertussis pharmaccine breast cancer therapeutic recombinant treatment breast cancer neu p recombinant treatment prostate cancer l mage recombinant treatment lung cancermelanoma ii glaxosmithkline description business achieve commercial operational excellence glaxosmithkline undertake range activity maximise glaxosmithkline comply relevant industry code commercial potential intellectual propertyby introduce practice training provide employee position innovative product market possible accelerate require understand group marketing requirement process bring new product market increase brand particularly sale representative monitor process recognitionand ensure patient access new marketing activity include group internal audit medicine pharmaceutical consumer healthcare independent review approval businessesfocus way improve exist performance commercial operational excellenceinitiative patient advocacy patientadvocacy initiative demonstrate significant worldwide sale force excellence progress inception rationale strategy glaxosmithkline sale force rank high survey centre enhance access groupsmedicine healthcare professionalsworldwidesalesforceexcellence market public private payer influence availability wsfe aim improve customer satisfaction improve reputation patientcentric group time available physician learn new medicine initially launch usprogramme expand clinical study precious wsfe initiative sale critical initiative strategic plan world representative strengthen product knowledge learn deliver year patient advocacy leader summit philadelphiawas patientspecific treatment option efficiently attend people represent twentythree effectively research show sale visit highly effective country continent additionallypatient advocacy team representative engage physician dialogue patient europe share good practice type support message visual aid illustrate establish processesto optimise interactionwith patientgroup clinical result european centre excellence group introduce single global sale model pharmaceutical europehas introduce new business model focus treat patient dialogue enhanceitsability compete increasingly challenging glaxosmithkline medicine appropriate effective environment model establish centre excellence toadminister itsafely end year field key therapeutic area respiratory metabolic people group key market train new business capability ascommercial excellence portfolio approach management centre developpaneuropean strategy entire sale organisation immerse wsfe bring implement consistently region model cultural change raise ethical standard helps build drive swift adoption brand strategy campaign longterm trusting relationship healthcare community reduce cost duplication new model focus ensure new asset launch europe marketing excellence optimal datum support approval reimbursement goal global marketingexcellence initiative help undiagnosed patient seek physician help second procurement ensure receive appropriate treatment example glaxosmithkline annually spend billion non uk official estimate million people suffer type production relate party purchase worldwide cover diabete cent remain undiagnosed area include medium travel rd marketing diagnose cent remain untreated purchase manage procurement behalf internal treat significant number undertreated customersandfocuson deliver good value group way patient achieve level health approach cover assurance supply service quality cost treatment provide optimal circumstance andinnovation theprocess deliver saving excess glaxosmithkline marketing initiative implement programme million year merger overcome barrier proper diagnosis treatment programme begin effect societal cost disease improve process decrease extent glaxosmithkline product group ongoing improvement processesto increase choose patient treatment thegroup benefit quality good service improve speed reliability performance deliver saving procurement function glaxosmithkline recognise industry initiate rigorous supplier selection monitoring process excellence marketing receive variety award key area expenditureand compliance use acknowledge success campaign award preferred supplier high operational excellence expert programme independently judge expert globalmanufacturing andsupply support number glaxosmithkline commit marketing ethical business functionsby helpingtosolve problem responsible patientcentred corporate policy rigorous control structured wayand focus efficiently govern marketing activity apply employee activity add great value glaxosmithkline supplierscontractor agent policy require market promotional activity base valid scientific project future evidence comply applicable law regulation project future fundamental review consumer business sector policy include additional requirement healthcare business modelto increase competitiveness guidance sale growth undertake model implement detail give pagedescription business glaxosmithkline improve access medicine access healthcare develop world voluntarylicence glaxosmithkline grantedfivevoluntarylicencesto access healthcare develop country remain major african generic company manufacture sale arvs challenge global community problem root public private sector subsaharan africa povertyand lack political willcontinue demand licencesbuild group agreement aspen significant mobilisation resource true spirit partnership pharmacaresubsaharan africas large generic companyfirst tackle share responsibility sector global sign september demonstrate glaxosmithkline society group mandate expertise ongoing commitment increase access essential medicine resource address underlie problem exist innovative solution glaxosmithkline continue play vital role commitment rd disease particularly prevalent look ahead develop world programme preferential pricing glaxosmithkline continue build product pricing antiretroviral arvs antimalarial vaccine partnership commitment help improve healthcare willingness seek innovative solution develop world significant increase fund voluntary licencing arrangement global community need important maintain incentive rd protection intellectual preferential pricing arrangement property example cure vaccine glaxosmithkline offer vaccine key organisation hivaid vaccination programme develop country preferential price year group set single sustainable achieve sustainable progress notforprofit price arvs antimalarial wide occur significant barrier stand way well range customer develop country undefinition access healthcare tackle share responsibility subsaharan africa project fullyfunded sector global society government international agency global fund fight aid tb malariaand president charity academic institution pharmaceutical industry emergency plan aid relief mean notforprofit price offer total country access healthcare develop world glaxosmithkline commit contribute health improvement sustainable manner price arvs glaxosmithkline play active role improve healthcare antimalarial set level profit people limited access medicine direct cost cover allow supply sustain group bridge access commitment access programme long require group undertake reduce provide million worth medicine qualify low price possible reduction income resident medicare beneficiary announce price reduction possible glaxosmithkline orange cardprogramme offer qualify senior citizen cent discount outpatient preferential pricing improve access group hassigne glaxosmithkline medicine individual agreement coveringof world poor country sign programme group commit supply arvs preferential price customer include government maintain programme medicare prescription benefit nongovernmental organisation ngo hospital academic place institution private employer group found member rxa multi offer notforprofit price require sustainable framework company card programme seven major participate combine group commitment preferential pricing pharmaceutical company offer saving usa commitment government develop world avoid widely prescribe medicine rxparticipant save price referencing preferentially price medicine cent usual prescription help prevent product diversionglaxosmithkline take step end million people join minimise threat diversion able supply programme country combivir epivir trizivirin special access pack similar effort underway secure widespread regulatory addition glaxosmithkline pharmaceutical approval retrovirand epivir syrupaccess pack register company create rx accessa saving programme differentiate red oppose traditional white combivirand qualified individual usa lack prescription drug epivirtablet number international market coverage rx access participate company group successfully register itsarvsunder offer saving cent usual pharmacy european union antidiversion regulation continue cost medicine encourage country necessary step ensure introductionand strict enforcement ofappropriate antidiversion measure glaxosmithkline description business good place good people well work glaxosmithkline people individual develop global leadership position target job move different business geographie glaxosmithkline commit create good place variety programmesare offer internally develop leader good people good work manager innovate inspire execute performance reward communication involvement reward philosophy programme development underscore senior management conference hold february allow glaxosmithkline commitment performance culture delegate brief directly member performance base payshare awardsshare option corporate executive team key challenge face group performance development planning contribute retention debate strategy address event key talent superior performance accomplishment recognise individual madeoutstande contribution business target annual performance development planning pdp second global leadership survey conduct process ensure thatindividual set business goal align manager gauge opinion critical corporate strategy set behavioural goal create issue culture confidence group future result development plan pdps review year show significant improvement item compare culminate end year review factor result compare global benchmark manager rate compensation decision highly foster alignment personal goal performance integrity central operating glaxosmithkline mission foster environment ethic glaxosmithkline recent leadership survey show integrity survey cent manager proud cent believe people department glaxosmithkline gladly refer friend commitment performance integrity family member work glaxosmithkline commitment flexible working flexitime regard improvement area manager report teleconference remote working flexible work schedule glaxosmithkline continue enhance environment recognise employee work good environment place people able good work engage help integrate work personal life manager make change necessary compete effectively business function develop action plan address diversity area improvement glaxosmithkline diversity initiative focus improve group continually seek way improve efficiency performance respond diverse need employee effectiveness employee communication order maximise customer external stakeholder second annual awareness critical information diverse global audience multicultural marketing diversity award entrant stream video project underway whichwill allow senior country highlight innovative activity demonstrate executive communicate frequentlywithemployee business impact global management population gender cent male cent female moredetail health wellbee diversity measure corporate responsibility report global policy employee health support mandatory section employment practice standard integrate employee health safety group commit employment policy free environmental requirement standard apply discrimination potential exist staff ground groupsfacilitie operation worldwide age race ethnic national origin gender sexual orientation base year datum theglobal health experience faith disability glaxosmithkline commit offer people health area identify additional focus disability access range recruitment career musculoskeletal mental health condition relate opportunity material handle multidisciplinary team work set baselinesalign reporting develop intervention effort recruitment help reduce incidence impact condition whilst voluntary turnover cent glaxosmithkline future iscommitte continue enhanceitsrecruitment process candidate care transform recruitment process customer human resource service information system experience aim build positive relationship glaxosmithkline human resource delivery strategy design seek join stay group technology humanresource service information deliver low cost highly effective talent management leadership development channel easy job candidate employee individual create development plan yearly retire access information employment compensation pdp process key talentisthen identify talent review benefit policy programme include intuitive conduct business function individual give personalise web base tool available employee feedback development need key talent develop location new position assignment course pool successor identify vicepresidentposition critical position organisationdescription business glaxosmithkline invest community success partnership glaxosmithkline operate single charitable foundation number small countrybase foundations canada glaxosmithkline continue build history community czech republic france italy romania spain north investment programme support well healthcare delivery carolina usa grant foundation education underserved community world include investment total group active engagement numerous external stakeholder include world health organization glaxosmithkline member percent club give member notforprofit community fund oneper cent itsprofit tax good cause communityle initiative world donate medicine recognise large giver ftse company support humanitarian effort communitybase healthcare previous year programme long term commitment help bring sustainable change community globalhealthprogramme eliminate lymphatic filariasis community investment group effort help rid world disable disease lymphatic filariasis lfcontinuedin close partnership glaxosmithkline global community investment activity government ofendemiccountrie partner value atmillion equivalent cent group organisation thegrouphas commit donate profit tax comprise product donation antiparasitic drug albendazole requiredto treat million cash give million inkind donation million billion people risk country cost millionto manage deliver community programme thancountrie sixth year programmemillion albendazole treatment worthmillion wholesale acquisition cost product donation follow donate tocountrie theglobal elimination programme productdonation total million start overmillion people havereceive donate albendazole cumulative total ofmillion treatment patient assistant program egyptand pacific island complete minimum million round mass drug administration preliminary result look impressive albendazole lf million addition donate albendazole tabletsthe group give grants millionand staff expertise support activity humanitarian product donation million global alliance eliminate lf glaxosmithkline positive action hivaid positive action glaxosmithkline year pioneer global programme work community affect aid glaxosmithkline cash givingwastargete primarily health supportscommunitybase organisationstodelivereffective hiv education initiative aids education prevention healthcare servicesnew programme launch latin america asia central breakdown ofcashgive total million easterneuropeto address emerge epidemic positive action work partner support health programme country include education raise awareness aid man kenya provide ukprisoner education prevent blood art culture borne disease environment train trainers health socialcare worker african organisation promote partnership asia improve patient understand treatment provide support thousand community delegate regional international aids conference uk glaxosmithkline contribute millionin continue corporate programme charitable activity support glaxosmithkline african malaria partnership organisationsin health medical research science glaxosmithkline african malaria partnership support education art environment addition group behavioural development programme work african company uk provide million community country follow addition senegal programme purpose corporate programme north america focus group disburse grant improve public education access well healthcare millionthree year commitment partner freedom child seniorcitizenswith fund ofmillionin hunger african medical research foundation amref addition nearlymillionwa donate group usbase plan international programme expect benefit business regional community activity nearly million people focus particularly young child pregnant woman encourage effective prevention measure prompt treatment antenatal malaria management glaxosmithkline description business invest community continue phase group support british lung foundations baby breathe phase initiative personal hygiene sanitation education easy programme year grant funding provide education thousand school child inkenya pilot scheme run region uk zambia nicaragua peru improve health hygiene thissupportsparent carer ofbabie child fight infectious diseasesin groupcommitte fivewithrecurringch problem year fund extendthe programmeintouganda partnership ministry health amref education initiative achievement phase recognisedwith world group effort improve public science education business award support millennium development goal include year grant national board industry award disease prevention education professional teaching standard increase number science teacher pursue certification innorth carolina humanitarian product donation philadelphia glaxosmithkline donate essential product grant center corporate citizenship antibiotic nonprofit partner include americare chamber commerce links department education map international project hope response humanitarian programme review education impact economy relief effort community healthcare example group philadelphia education fund receive grant donate product follow flood bangladeshhurricane middle grade matterscampaign improve middlelevel education usa caribbean typhoon philippine child aged conflict sudan asian tsunami glaxosmithkline continue support inspire innovative total value groupshumanitarian product scheme postdoctoral researcher research education donation wasmillion exclude albendazole donate scheme develop partnership imperial college london lymphatic filariasis elimination programme product specialist schools trust milliondonation donation valuedat wholesale acquisition cost year inspire place postdoctoral researcher specialist wholesale list pricenot include discount standard science school assist science teaching industry method science summer free librarybase science education community initiative programme philadelphia area teach basic scientific glaxosmithkline dedicate strengthen fabric concept continue receive support grant community whereit operatesthrough provide health th year child participate education initiative support local civic cultural programme science world awardwinning institution improve quality life glaxosmithkline international education programme use webbase resource contribution improve healthcare include threeyear grant promote discussion science issue child millionwhich help expand children school inover country receive grant health fund referral management initiative rmi seven state ensure continuity specialist medical care highrisk employee involvement child homeless glaxosmithkline employee encourage contribute theirlocal community employee volunteer scheme thegroup support arthur ashe institute urban health support vary world include employee time grant total year core funding cashdonation charity employeesvolunteerand community health empowerment programtoprovide matching gift programme country glaxosmithkline health education lowincome neighbourhood non offer taxefficientmethodsfor employee givingin accordance traditional venuessuch church shop local taxation guideline glaxosmithklinecontinue itsyear partnership barretstown usa group matched ireland lenvol france provide lifechanging activity employee retiree gift value million programme back medical community foreuropean group match million employee donation child cancer lifethreatening illness help themto glaxosmithklineand united way campaigngive combine rediscover theirconfidenceselfesteemand participate fullyin contributionof million addition glaxosmithkline everyday life receive investment volunteer excellencegive programme provide respectively grant charitable organisationswhere employee annual impact award recognise excellence work partner volunteer hour year nonprofit community health organisation uk glaxosmithkline make difference programme uk great philadelphia area usa charity provide grant nonprofit organisation receivedunrestricte award work deal diverse register charity base employee involvement issue domestic community violence sexual health young peopleand child abuse medical research provide uk medical charity breakthrough breast cancer cystic fibrosis trust debra ehlersdanlos support group motor neurone disease associationdescription business glaxosmithkline consumer healthcare current business global brand concept team glaxosmithkline consumer healthcare manufacture market aquafresh consumer brand healthcare industry organisation sensodyne structure responsibility global regional local level dental care cold sore operation span majority world geography panadol sell principally major trade channel grocery smoke control pharmacy brand market regulatory future group include centre excellence global spectrum prescription free sale project management medical marketing emarketing support environment consumer healthcare business function reorganise effectively serve new operate challenging model consumer demand well quality well value lead market brand cent global sale improve performance brand large market territory retailer consolidate globalise generally anchor market lead development strengthen negotiation power business market enjoy central rd competitor find condition equally challenging resource include brand lucozade ribena horlick compete aggressively element tum anddr good marketing mix enterprise brand cent global sale cycle times innovation reduce remain valuable local brand manage new model retain local responsibility brand communication new strategy innovation enterprise brand support vision consumer healthcare business global regionallyfocuse resource enable application fast grow consumer healthcare group good practice crosspollination innovation innovation centre consumer deliver science success consumer healthcare new business model order conduct business effectively current reflect sale growth global lead market environment consumer healthcare business strategy enterprise brand operating model redesign new model implement operational target research development consumer healthcare deliver fast sale growth achieve vigorous focus deliver new product development tightly align rd align closely new consumer healthcare consumer need new model effectively weld operating model structure global brand rd marketing commercial operating unit mirror commercial structure rd team pair new culture provide future group team locate principal centre consumer healthcare rd weybridge uk great focus alignment simplicity proliferation parsippany usa colocation site duplication bureaucracy term innovation centre focus rd well fast way work dilution identification rapid development novel product local knowledge implementation power bring benefit consumer overthecounter otc oral care nutritional healthcare market new structure focus new operating model brand growth opportunity consequently brand split category business structure centre global brand lead market brand enterprise brand global brand cent global sale brand sale multiple market similar positioning develop effectively global approach new team call future group create group assume responsibility consumer market understand brand equity strategy innovation pipeline communication future group comprise dedicated resource idea generation innovation development cover product package communication mix glaxosmithklinedescription business global manufacturing supply glaxosmithkline large portfolio product range regional pharma supply tablet toothpaste inhaler complex capsule regional pharma supply focus key activity different pack size presentation supply product key region supply product important particular market manufacture medicine begin development tailor packaging meet specific local requirement key therapeutic active ingredient bulk active select formulation focus regional pharma supply team reduce cost global manufacturing supply gms develop manufacture glaxosmithkline compete effectively process scale volume production active compound market site country regional pharma primary manufacturing site convert active compound supply finish dosage formulation responsibility secondary manufacturing site new product global supply gms operate single global network site new product global supply focus ensure country year gms produce tonne bulk appropriate technical competency exist support rapid active billion pack package successful new product introduction work closely rd deliver sale country world development team ensure secure supply support approximately new product line extension key brand sell market global launch year distribution division focal point develop introduce new secondary manufacturing technology gms adopt lead edge practice develop people gms coordinate primary supply operation ensure optimal expect derive benefit alignment division value stream secure source supply high quality product approach introduce new product site country new product global supply compliance regulatory requirement customer expectation operational excellence good class cost gmsha develop set metric common methodology drive improvement particular focused organisation increase robustness manufacturing process reduce waste maintain high quality standard extensive supply division leadership education carry reinforce culture geographic supply chain structure continuous improvement staff empower solve problem supply division site group base rigorous control structured way give common business driver area expertise commercial capability drive stepchange performance implement activity support division describe improvement rapidly manufacture network formation glaxosmithkline merger rationalisation primary supply andantibiotic operational excellence initiative reduce number primary supply antibiotic focus ensure supply manufacture site cent high quality competitively price bulk active drive improvement primary technology process external supplier support delivery maximum value antibiotic manufacturing spend billion external supplier franchise combine primary secondary approach year include purchase active ingredient chemical cost competitive supply response market opportunity intermediate partfinishe finished product gms take customer need site country appropriate step protect supply chain disruption primary supply andantibiotic result interrupt external supply appropriate stock level contract alternative register supplier consumer healthcare supply consumer healthcare supply focus deliver highquality vaccine supply chain competitivelyproduce product offer capability vaccine manufacturing locate primarily rixensart wavre rapid new product introduction highly innovative belgium site france germany hungary competitive business far short time frame joint venture china russia manage vaccine pharmaceutical new technology fundamental supply chain involve anticipate market need flexible platform lower cost provide flexibility operation approach able meet fluctuation demand site country consumer healthcare supply base forecast different market firm order health authority mass vaccination campaign bulk filling packaging carefully balanced stocking vaccine help manage shortterm increase demand increase prompt disease outbreak increase demand public owe disease awareness campaignsdescription business glaxosmithkline product competition pharmaceutical product antiviral combivir combination retrovirand epivir consolidated glaxosmithkline principal pharmaceutical product presently position reverse transcriptase inhibitor direct therapeutic area analysis salesby cornerstone multiple antihiv product regimen therapeutic area description principal product physician acceptance clearly demonstrate value place setout minimise pill burden face patient turnover therapeutic area ziageni reverse transcriptase inhibitor product potency respiratory ease use resistance profile allow play significant central nervous system role variety highly active tolerate andsimplified hiv antiviral treatment regimen antibacterialsantimalarial triziviris combination combivirand ziagen combine metabolic antihiv therapie tablet twice daily administration vaccine oncology emesis epzicomkivexa approve fda august cardiovascular urogenital combination epivirand ziagenthat take tablet oncedaily dose hivaid combination antihiv drug lexivatelzir protease inhibitor treatment hiv product version approve indication tolerate convenient agenerase market available supersede lexiva take twice daily daily boost ritonavir respiratory seretideadvair combination sereventand flixotide offer zeffixhas approve marketing usa europe china alongacte bronchodilator antiinflammatory single market treatment chronic hepatitis b inhalerit approve treatment asthma copd valtrexis treatment episodic genital herpe flixotidefloventand becotidebecloventare inhale steroid long term suppression reduction transmission genital treatment inflammation associated asthma copd herpe zoster shingle cold sore chicken pox valtrex supersede zovirax treat herpe infection sereventis longacting bronchodilator treat asthma copd ventolinis selective shortacting bronchodilator antibacterial antimalarial treat bronchospasm augmentinis broadspectrum antibiotic suitable flixonaseflonaseand beconaseare intranasal preparation treatment wide range common bacterial infection treatment perennial seasonal rhinitis particularly effective respiratory tract infection augmentin esis extra strength suspension specifically central nervous system cns design treat child recurrent persistent middle ear seroxatpaxilis selective serotonin reuptake inhibitor ssrifor infections augmentin xris extra strength tablet form treatment depression panic obsessive compulsive disorder adult combat difficult treat infection post traumatic stress disorder social anxiety disorder premenstrual zinnatis oral antibiotic primarily communityacquire dysphoric disorder general anxiety disorder infection lower respiratory tract wellbutrini antidepressant available usa normal malaroneis oral antimalarial treatment sustainedrelease sr daily formulation prophylaxis malaria cause plasmodium falciparum imigranimitrexis ht receptor agonist treatment lapdapis effective tolerate therapy treatment ofsevere frequent migraine cluster headache malaria develop reference product sector naramigamergeis publicprivate collaboration new migraine product lamictal establish treatment epilepsy indicate bipolar disorder requipi specific dopamine dd receptor agonist indicate treatment ofparkinson disease glaxosmithklinedescription business product competition continue metabolic cardiovascular urogenital avandiais potent insulin sensitise agent act coregis alphabeta blocker prove underlie pathophysiology type diabete effective intreate patient mild moderate severe heart failure heart attack hypertension glaxosmithkline sole avandametis combination avandiaand metformin hci marketing rights usa canada generic version medicine target insulin resistance decrease product available canada glucose production convenient pill levitrais pde inhibitor indicate male erectile dysfunction avandaryl fixeddose combination avandia amaryl glaxosmithkline copromotion rightsin usaand sanofiaventis productwas approve canada markets october fda approvable letter receive glaxosmithkline work fda bring avodartis ari inhibitor currently indicate benign prostatic resolution outstanding issue hyperplasia large clinical outcome study underway examine efficacy prevention prostate cancer vaccine arixtra fraxiparinewere acquire glaxosmithkline market range hepatitis vaccine havrix divestiture require merger sanofiand aventis protect hepatitis engerixbagainst hepatitis b arixtraa selective factor xa inhibitor indicate twinrixis combine hepatitis b vaccine protect prophylaxis deep vein thrombosis lead pulmonary disease vaccine available adult embolism hip fracture surgeryknee replacementand hip paediatric strength replacement surgery indicate treatment deep infanrix range paediatric vaccine combination infanrix vein thrombosis andpulmonary embolism provide protection diphtheria tetanus pertussis fraxiparineis lowmolecular weight heparin indicate whooping cough infanrix pentapediarix provide additional prophylaxis thromboembolic disorder particularly deep vein protection hepatitis b polio infanrix hexa thrombosis pulmonary embolism general surgery add protection haemophilus influenzae type b orthopedic surgery treatment deep vein thrombosis cause meningitis prevention clotting hemodialysis glaxosmithkline market priorix measle mump european marketing right tointegrilinwere acquire rubella vaccine typherix vaccine protection typhoid gp iibiiia inhibitor approve eu prevention fever varilrix vaccine varicella chicken pox early myocardial infarction addition group market range vaccine prevent meningitis umbrella mencevax category include betnovate thehigher potency dermovate oncology emesis new cutivatewhich antiinflammatory steroid zofrani prevent nausea vomiting associate product treat skin disease sucha eczema psoriasis chemotherapy radiotherapy cancer available relafena nonsteroidal antiinflammatory drug treatment bothoral injectable form approve use arthritisand zantac treatment peptic ulcer disease prevention treatment postoperative nausea vomit range ofgastric acid relate disorder hycamtinis second line treatment ovarian cancer forsmall cell lung cancer bexxaris treatment patient cd follicular non hodgkin lymphoma transformation disease refractory rituximab relapse follow chemotherapydescription business glaxosmithkline pharmaceutical competition antiviral major competitor hiv market include gilead bristol myers pharmaceutical industry highly competitive squibb abbott merck pfizer glaxosmithkline principal competitor large international pharmaceutical company substantial resource glaxosmithkline pioneer role hiv market company major product mention retrovirand epiviracte cornerstone combination therapyand available combivirin single tablet launch pharmaceutical subject competition ziagen agenerasetrizivir lexiva andepizcom broaden product period patent protection thegroup portfolio hiv product patent generic version manufacturer generic product typically donot bear significant research development valtrexhas strengthen group position antiherpe cost consequently areable offer product area zoviraxface competition generic aciclovir valtrex considerably low price thebrande competitor research zoviraxcompete novartis famvir zeffixwa development base pharmaceutical company normally antiviral market treat hepatitis b gilead hepsera seek achieve sufficiently high profit margin sale volume second glaxosmithkline marketing right hepserain period patent protection repay original key market investment generally substantial fund research forthe future competition generic product generally occur antibacterial antimalarial patent major market expire increasingly patent challenge generic version augmentinand ceftinzinnatare available prior patent expiry claim innovator patent usa augmentinha lose patent protection valid andor infringe generic product country europe augmentinxrand augmentinescompete follow loss patent protection generic product rapidly broad range brand generic antibiotic capture large share market particularly usa malarones safety profile convenient dose regiman helped product strong position versus mefloquine glaxosmithkline believe remain competitive dependent malaria prophylaxis discovery development new product effective marketing exist product metabolic pharmaceutical industry introduction new product major competitor avandiais takeda chemical acto process competitor affect pricing level result copromote eli lilly usa change pattern product use assurance product outmoded notwithstanding patent vaccine trade mark protection addition increase government glaxosmithkline major competitor vaccine market include pressure physician patient use generic sanofipasteur sp merck wyeth engerixband havrix pharmaceutical brandname medicine increase compete vaccine produce sp merck comvax competition product long protect patent recombivax hb hepatitis b vaqta avaxim hepatitis infanrixsmajor competitor sps range dtpabase respiratory combination vaccine glaxosmithkline respiratory franchise drive growth seretideadvair gain patient competitor product oncology emesis cannibalisation sereventand flixotideflovent major zofran presently provide glaxosmithkline leadership respiratory competitor singulair merck especially position antiemetic market competitor company usa europe symbicort astrazeneca spiriva include roche sanofiaventis recently merck major pfizerboehringer ingelheim competitor diverse cytotoxic market include bristol myers squibb sanofiaventis pfizer novartis glaxosmithkline cns disorder cytotoxic portfolio lead hycamtinand navelbine currently hold major competitor usa paxilareits generic formsas relatively small market position generic fluoxetine generic form eli lillys prozac zoloft pfizer forest laboratory celexa lexapro cardiovascular urogenital principal competitor usa wellbutrinaregeneric forms glaxosmithkline markets coregin usa major bupropion generic form ssris effexor xr wyeth competitor toprol xl generic betablocker avodart product paxil crand oncedaily wellbutrin xlhelp retain compete directly merck proscar bph market strong presence antidepressant market give glaxosmithkline copromotion right usa availability generic paroxetinein usa generic competition country levitrawhich face competition seroxatpaxil commence uk number pfizer viagra lillyicos cialis market glaxosmithklinedescription business product competition continue consumer healthcare product oral care lead oral care product toothpaste mouthwashe glaxosmithkline principal consumer healthcare product aquafresh sensodyne macleansand odolbrand major area analysis sale area isset name range toothbrush sell aquafresh dr bestnames addition denture care product available principally polident poligripand coregabrand name otc medicine nutritional healthcare oral care lead product category lucozade glucose energy nutritional healthcare sport drink ribena blackcurrant juicebase drink rich vitamin c horlick range milkbase malt food chocolate drink sale cent high cer term decline cent sterling term consumer healthcare competition glaxosmithkline hold lead global position key major product necessarily sell market consumer product area worldwide second large category product oral care large otc medicine nutritional overthecounter medicine healthcare hold lead position uk india analgesics panadol ireland dermatological zovirax main competitor include major international company abreva colgatepalmolive johnson johnson pfizer procter gamble gastrointestinal tum unilever wyeth addition company citrucel compete glaxosmithkline certain market respiratory tract contac beecham major competitor product otc medicine smoking control commit usa metamucil laxative pepcid indigestion nicorette private label smoking control product nicoderm cq niquitin cq uk lemsip cold remedy nurofen anadin nicabate cq analgesics nicorette nicotinell smoking control natural wellness support abtei treatment oral care aquafresh oral care major competitor colgatepalmolive colgate dr good procter gamble crest macleans nutritional healthcare major competitor horlicksare odol ovaltine milo malt food chocolate drink odol med competitor ribenaare primarily local fruit juice product polident lucozadecompete energy drink poligrip sensodyne nutritional healthcare lucozade ribena horlick overthecounter medicine lead product panadol widely available paracetamolacetominophen analgesic nicorettegum usa nicoderm niquitin cqandnicabaterange smoke control product tumsa calciumbase antacid citrucellaxative contac treatment cold abtei natural medicine vitamin range andzoviraxand abrevafor treatment cold sore group obtain otc marketing right orlistat usa fda approve prescription product obesity management market roche xenicaldescription business glaxosmithkline regulatory environment regulation pharmaceutical international market country outside usa europe regulatory environment continue extremely glaxosmithkline operate highly regulate environment varied challenging glaxosmithkline anticipate regional countryspecific law regulation define datum introduction new product continue require substantial require safety efficacy pharmaceutical product effort time expense comply regulatory requirement govern testing approval manufacturing labelling marketing drug regulatory requirement major price control factor determine whethera marketable product manycountrie price pharmaceutical product successfully developedand time expense control law government influence price associate development control national healthcare organisation bear large cost supply product consumer recent regulation process government healthcare reform country france spain glaxosmithklineadopte common technical germany restrict pricing reimbursement document format marketing application major supplement thisis single format register product usa recent legislation healthcare reform crossborder accept regulatory authority regionsthese trade acceleration generic market increase patient application prepare submit electronically contribution increase focus pricing currently government price control private sector harmonisation activity global regional level purchase federal legislation require pharmaceutical ongoing success standardisation manufacturer pay prescribe rebate certain drug order regulatory environment varied change rapidly national eligible reimbursement medicaid federal regulatory authority jurisdiction high standard healthcare programme technical appraisal consequently introduction new pharmaceutical product generally entail lengthy medicare approvalprocess medicare prescription drug improvement european union currently procedure modernization act provide limited immediate benefit obtain marketing authorisation medicinal product medicare patient disable year old form government sponsor discount card centralise procedure application direct replace comprehensive outpatient drug benefit theeuropean medicine evaluation agency lead benefit intend administer number private authorisation valid member state compulsory organisationsthatwill construct benefit structure consistent product derive biotechnology optional new federal law market benefit medicare patient activesubstance innovative medicinal product law provide strong incentive manufacturer mutual recognition procedure applicable negotiate price plan sponsor bill provide majority conventional medicinal product operate explicit government price control seniorcitizensalready mutual recognition national marketing authorisation drug coverage great increase demand likely agreement reach resolve tobe population lowincome seniorcitizenswho procedure bind arbitration coverage lowincome seniorcitizenswill receive subsidy new eu legislation implement end premium deductible copayment associate improve centralised procedure increase comprehensive benefit range product compulsory mutual law change way drug administer insurgerie recognition procedure thedecentralise procedure clinic hospital outpatient department reimburse intended facilitate agreement member state instead reimbursement base price publish amend implementation new legislation independent pricing servicesdoctorand clinic reimbursement bring number change example increase base actual market price report manufacturer post marketing safety monitor new type conditional audit government formula hospital product approval outpatient reimbursement change grant marketing authorisation afford group protection government direct devise new costbase methodology period competitor rely confidential datum regulatory file basis marketing authorisation new eulegislation time harmonise datum protection period submission route fda introduce new focus call critical path initiative thisis intend enable innovation drug development hopefully allow rapid development approval need medicine initiative investigate use pharmacogenomic surrogate marker efficacy thing manufacture innovation tool rapidly develop produce safe effective drug unmet medical need glaxosmithklinedescription business regulatory environment continue value money basic patent position respect significant product increasingly necessary demonstrate value follow money new product particular impacton drug budget augmentinthe patent key active ingredient potassium expenditure burden disease treat clavulanate expire market italy b market need satisfy healthcare purchaser generic competition exist market value money additional hurdle product avandia avandametthe patent active ingredient acceptance regulatory test ofsafety efficacy rosiglitazone expire acin usa quality delay bring effective improve bin europe patent commercial form active medicine market reduce effective patent ingredient rosiglitazone maleate expire protection time usa bin europe litigation challenge validity marketsespecially usa europe patent protect product ongoing usae increasingly difficult significantly improve therapy avodartthe patent active ingredient dutasteride obtain premium price exist medication valuebase normal expiry usa bin europe pricing difficult toapplyin circumstance usa possible price product reflect value combivirthe patent specific combination lamivudine possible predict extent zidovudine expire usa groupsbusiness affect future legislative bin europe regulatory development relate specific pharmaceutical coregglaxosmithkline exclusive licensee product price patent active ingredient carvedilol expire regulation consumer healthcare epivirthe patent active ingredient lamivudine consumer healthcare industry subject national regulation expire acin usa bin europe testing approval manufacturing labelling marketing flixotidefloventand flixonaseflonasein usa patent product country high standard technical active ingredient fluticasone propionate expire appraisal entail lengthy approval process new product european country protection expire march b launch imigranimitrexthe patent active ingredient sumatriptan national regulatory authorisation require approve expire cin usa bin europe switch product prescription otc requirements b italy litigation challenge validity patent include longterm experience quality safety efficacy protect product ongoing usae product wide patient population datum confirm relevant condition selflimite easily lamictal patent active ingredient lamotrigine diagnose consumer expire acpaediatric extension pende usa bin countries europe litigation challenge intellectual property validity patent usa recently settlede intellectual property key business asset glaxosmithkline levitrad glaxosmithkline copromotion right effective legal protection intellectual property critical patent active ingredient vardenafil ensure reasonable return investment rd intellectual expire usa property protect patent trade mark register lexivatelzirglaxosmithkline exclusive licensee design copyright domain registration patent patent active ingredient fosamprenavir trade mark right regard particularly valuable expire usa bin europe case generic manufacturer launch attempt paxilseroxatthe patent commercial form active launch generic version patent drug prior normal patent ingredient paroxetine expire cin usa expiry argue relevant patent invalid andor europe litigation relate tothe validityand infringe product significant litigation concern infringement patent protect product ongoing challenge summarise innote financial statement usae generic competition commence usa legal proceeding europe certain market paxil cris protect formulation patent expire patent glaxosmithkline policy obtain patent protection retrovirthere patent active ingredient zidovudine significant product discover develop rd patent cover pharmaceutical formulation contain activity patent protection new active ingredient available zidovudine medical use expire significant market protection obtain new usa europe pharmaceutical formulation manufacturing process new medical use special device administer productsdescription business glaxosmithkline seretideadvairthe patent specific combination active responsibility environment health safety ingredient salmeterol xinafoate fluticasone propionate environment health safety ehsis key element corporate expire usa bin europe responsibility group high priority responsibility application reissue patent file ehs high level corporate group report glaxosmithklinee uk patent revoke uk general counsel overall responsibility provide court patent individual ingredient expire governance leadership ehs issue head group uk usa patent salmeterol xinafoate make regular report corporate executive team cet expire audit corporate responsibility committee board sereventthe patent active ingredient salmeterol xinafoate director business operation manager expire bin europe b responsible ehs support sitebase ehs france b italy usa occupational health professional trizivir patent specific combination lamivudine zidovudine abacavir expire ehs strategy usaand europe glaxosmithkline tenyear strategic plan manage ehs sustainability business ehs plan valtrex patent active ingredient valaciclovir excellence align group strategy year expire usa bin europe litigation special focus theme respond challenging validity patent protect product external challenge time continue focus theme ongoing usae previous year continue drive improvement wellbutrin sr wellbutrin xl andzybanthe patenton theactive programme key risk area ingredient hasexpire generic competition sr instant release ir forms usa europe regulatory respond external challenge datum exclusively provide protection society expect glaxosmithkline responsibility market usa wellbutrin xlis protect environmental impact product formulation patent expire operation focus attention expand production litigationrelating tothe validityand infringement product environmental impact arise stage patent ongoing theusae product life cycle theme ehs plan excellence respond external challenge focus key ziagen thepatenton active ingredient abacavirisnot areas pharmaceutical environment chemical policy expire acin usa bin europe climate change zofran thepatenton active ingredient ondansetronisnot expire cin usa bin europe b complete core programme france bitaly patent use treat emesis expire ehs plan excellence focus complete core litigationchallenge validity ofthe emesis use programme measure improved audit score patent ongoingin usae achievement performance target set trade mark business driver ehs glaxosmithkline pharmaceutical product protect new product development register trade mark major market general product stewardship environmental aspect sustainable mark product market world development principle introduce aspect local variation example usa trade new product development entire life cycle impact mark paxili instead seroxatand advairis instead product consider order address adverse impact seretide optimise resource consume reduce waste produce trade mark protection generally extend long alternative chemistry process review build safety trade mark renew necessary process improve mass productivity glaxosmithkline trade mark pharmaceutical product optimise resource consumption waste generation generally assume increase importance patent address triple line consideration product expire particular country generic version product available product commercialisation ehs help speed product market address regulatory consumer healthcare trade mark particularly important concern development incorporate ehs business brand orientate product decisionmake design packaging label possible patent protection reduce cost differentiate product extend product life include patent term restoration hatchwaxman act b include extension term national european supplementary protection certificate c include extension term paediatric exclusivity aregistere trademark bayer ag e seenote financial statementslegal proceeding glaxosmithklinedescription business regulatory environment continue global competitor ehsimprovement competitive advantage gain improve public trust objective focus emerge issue base apply good business process globally foster pharmaceutical environment chemical policy climate culture continuous improvement optimising process change theme respond external ehs challenge make economically viable potential create numerical target ehs performance improvement set lower price medicine contribute accomplish year progress meet social benefit allow great access global market target track year publish website wwwgskcom date significant progress glaxosmithkline people achieve ehstarget ehs programme focus protect people glaxosmithkline commit work design glaxosmithkline select measure performance improvement workplace minimise workrelate risk safety health base potential adverse impact people provide shirtsleeve environment personal safety environment business continuity business reputation equipment require routine basis protect measure select similar report employee health laboratory manufacturing operation company recommend global reporting initiative longterm multistakeholder international undertaking ehs management develop disseminate globally applicable sustainability glaxosmithkline take systematic approach manage ehs report guideline risk impact framework information programme base global ehsstandard guide management sustainability key aspect impact risk organisation work eventual sustainability glaxosmithkline address economic environmental social issue research ehs audits manufacture sale distribution medicine governance responsibility glaxosmithkline conduct sustainability start healthcare solution find research ehs audits site assess performance ehs development continue sustainable solution standard assign quantitative performance score manufacturing sale group currently look site audit continuous improvement improve operational efficiency future investigate process progress monitor action arise issue use renewable resource overall balance raise audits impact society environment group seek dialogue external stakeholder consider view commitment corporate social responsibility develop approach sustainable development proactive management glaxosmithkline manufacturing information eh programme performance find supply base key contract manufacturer website supplier assess process evaluate management human right ehs risk impact base group requirement contract manufacturer recommendation improvement neededglaxosmithkline corporate governance section discuss glaxosmithkline management structure governance procedure contain company report disclosure corporate governance require thecombine code corporate governance financial reporting council combine code include require statement compliance company report compliance uslaw regulation apply board corporate executive team governance policy dialogue shareholder annual general meeting internal control framework committee report combine code lawand regulation glaxosmithkline corporate governance board dr ronaldo schmitz aged appoint rd sir christopher gent aged nonexecutive director dr schmitz nonexecutive appoint st june director glaxo wellcome plc nonexecutive director chairman sir christopher wasthe chief executive officer legal general group plc member board director vodafone plc retirement july anon rohm haas company cabot corporation executivedirector lehman brothers holdings incadirector international advisory board hakluyt coand senior dr lucy shapiro aged adviser bain co appoint rd nonexecutive director dr shapiro nonexecutive dr jeanpierre garnier aged director smithkline beecham plc ludwig professor appoint rd cancer research department developmental biology chief executive officerdr garnier appoint executive director beckman center molecular genetic director smithkline beecham plc chief medicine stanford university school medicine executive officer april nonexecutive director nonexecutive director anacor pharmaceuticals inc hold united technologies corporation member board phd molecular biology albert einstein college trustees eisenhower exchange fellowship hold medicine phd pharmacology university louis pasteur france mba stanford university usa sir robert wilson aged appoint st november john coombe age nonexecutive directorsir robert nonexecutive chairman appoint rd retire st march bggroup plc economist group previously chief financial officermr coombe executive executive chairman rio tinto plc director glaxo wellcome plc responsible finance investor relation member supervisory drtachiyamadaaged board siemens ag code committee uk appoint st january takeover panelandwas appoint nonexecutive director chairman research development dr yamada wasa non hsbc holdings plconst march executive director subsequently executive director smithkline beecham plc prior join smithkline beecham lawrence culp aged chairman department internal medicine appoint st july university michigan medical school physicianinchief nonexecutive director mr culp president chief executive university michigan medical center member officer danaher corporation prior join danaher hold board director diadexus inc december position accenture previously andersen consult isa trustee rockefeller brothers fund sir crispin davis aged chief financial officer designate appoint st july julian heslop age nonexecutive director sir crispin chief executive reed mr heslop succeed mr coombe chief financial officer elsevi plc prior chief executive aegis group effect st april whenhe join board plc join guinness plc member mr heslop join glaxo wellcomea financial controllerin april main board group manage director united january follow merger appoint distiller spend early career procter gamble senior vicepresident operation controller prior join sir deryck maughan age glaxowellcomehe hold senior finance role grand appoint st june metropolitan plc nonexecutive director sir deryck chairman directors ceo citigroup international salomon brothers inc dr michle barzach mr donald mchenry mr john mcarthur serve board director carnegie hall lincoln center allnonexecutive director retire board follow nyumedical center international advisory conclusion agm th sir christopher board member british american business incand board hogg chairman sir peter job nonexecutive member ofthe american academy berlin trilateral director retire board st december commission serve asvice chairman new york stock exchange detail membership board committee find sir ian prosser aged page appoint rd senior independentdirector sir ian nonexecutive director smithkline beecham plc chairman chief executive bass plclatterly intercontinental hotel plcand chairman world travel tourism council nonexecutive deputy chairman bp plc nonexecutive director saralee corporation member cbi president committeecorporate governanceglaxosmithkline corporate executive team cet david stout presidentpharmaceutical operation jp garni mr stout responsible global pharmaceutical vaccine chief executive officer business join smithkline beecham head chief executive officer dr garnier responsible sales marketingand president uspharmaceutical management group oversee operational aspect current appointment january group includingestablishingpolicie objective initiative direct longterm strategy chief executive chris viehbacher officer smithkline beecham join group presidentuspharmaceutical mr viehbacher responsible uspharmaceutical rupert bondy january join wellcome director senior vice president general counsel continental europe glaxo wellcome mr bondy responsible legal matter group responsible glaxosmithkline european pharmaceutical environmental health safety issue insurance business current appointment security lawyer private practice join smithkline beecham andrew witty presidentpharmaceuticals europe ford calhoun mr witty responsible group pharmaceutical chief information officer operation europe january join glaxo dr calhoun responsible information technology global glaxosmithkline senior vice president asia pacific function enable key business process part current appointment group doctoral postdoctoral training microbiology genetic biomathematic computer science join smith tachiyamada kline french chairmanresearch development dr yamada lead group complex business drug discovery john coombe developmentcreate new medicine research chief financial officerretire st march join smithkline beecham nonexecutive member head finance function mr coombe responsible board chairman rd pharmaceutical activity financial reporting control tax treasury appoint board director st january investor relation finance system internal audit real estate join glaxo group financial controller jennie young appoint group finance director senior vice presidentcorporate communication community partnership marc dunoyer mrs young responsible group internal external presidentpharmaceutical japan communication image partnership global mr dunoyer appoint president pharmaceutical japan community join glaxo wellcome director march join group senior vice investor relationsand appoint current position president regional director japan current european woman achievement appointment award business russell greig jack ziegler presidentpharmaceutical international presidentconsumer healthcare dr greig lead pharmaceutical operation outside usa mr ziegler head global consumer healthcare business europe cover country join produce oral healthcare overthecounter medicine group senior vice president worldwide nutritional healthcare product join smithkline beecham business development rd prior current appointment appoint president consumer march healthcare business dan phelan julian heslop senior vice presidenthuman resource chief financial officer designate mr phelan responsible benefit compensation recruitment mr heslop succeed mr coombe chief financial officer organisation development leadership development succession effect st april whenhe join cet planning human resource information system employee health management lawyer private practice mr heslop join glaxowellcomeas financial controllerinapril join smith kline french appoint follow completion merger appoint senior vice president director human resource smithkline senior vice president operation controller beecham member david pulman mr ingram continue work parttime vice chairman presidentglobal manufacturing supply pharmaceutical act special advisor group dr pulman responsible theglobalmanufacturing andsupply attendingcet meetings capacity organisation global procurementhe join glaxo responsible north american supply network manufacturing strategy logistic current appointment glaxosmithkline corporate governance governance policy board process board authority accountable shareholders board corporate executiveteam ensure company appropriately manage director list board page achieve strategic objective set board discharge board responsible group system corporate responsibility annual programme meeting governance ultimately accountable group activity include approval overall budgetary planning strategy financial performance business strategy chief executive officerceo responsible executive board review companys internal control risk management group assist cetthe management policy approve governance structure cet meet time year necessary code ethic board appraise approve major financing member responsibility list corporate investment contractual decision excess define executive team page threshold addition matter board evaluate monitor performance group include board comprise executive andeightnonexecutive director whilst board consider nonexecutive director engage board meeting ceo executive independent character judgementit determine director member cet appropriate nonexecutive directordr shapiroshould financial operating performance glaxosmithkline consider independent combine codedr shapiro external issue material group prospect consider independent remuneration evaluate progress achievement group receive groupas member ofthe glaxosmithkline financial business objective annual plan scientific advisory board sir christopher gentwa appoint boarda deputy chairmanhe determine monitoring report receive directly board independent take chairmanship committee thesignificant risk face group boardon st january accordance board overall responsibility succession planning combine codehe exclude determination ceo executive director board give half board independent nonexecutive ceo broad authority operate business group director dr shapironor sir christopher gent hold ceo accountable report board position board committee independence require business performance combine code cet member regular presentation board board consider mr culp sir crispin davissir deryck area responsibility board meet cet maughan sir ian prosser dr schmitz sir robert wilson members annual basis discuss collectively group independent accordance recommendation strategy primary element induction process new combine code nonexecutivedirector undertake member cet follow director whoretiredduring year allnonexecutivedirector encourage separate consider board independent accordance informal discussion discretion cetmember combined code dr barzachbecause receive board meet time member attend remunerationfrom group subsidiaryas healthcare consultant follow andmr mchenry andsir christopher hoggdue length number meeting number service mr mcarthurand sir peter jobwho retire hold whilst board member meeting attend yearwere bothconsidere independent sir christopher gent dr jpgarnier date publicationand majority mr j coombe board member exclude chairman independent dr yamada nonexecutive director mr l culp sir christopher hogg chairman sir crispin davis retired board st december sir deryck maughan sir christopher gent appoint deputy chairman effect sir ian prosser st june board agree sir christopher gent dr r schmitz succeed sir christopher hogg chairman effect dr l shapiro st january dr garnier isceo sir robert wilson sir christopher hogg chairman lead board represent board dr barzach ceo cet member necessary board sir peter job meeting ceo manage group implement mr jmcarthur strategy policy adopt board chairman mr mchenry chairmen board committeescommunicate regularly ceo cet member division responsibility addition schedule meeting refer role chairman ceo set board meet quorate basis oneoccasion writing agree board appear thewebsite sir ian prosser senior independent director sid corporate governanceglaxosmithkline independent advice chairman company ceo responsible board recognise occasion evaluate make recommendation board director feel necessary independent legal remuneration nonexecutive director andor financial advice company expense agree procedure enable procedure nomination committee follow explain corporate governance section nomination committee review structure size company website composition board appointment member board cet make recommendation board company secretary appropriate committee monitor plan company secretary responsible board available succession board senior management committee individual director respect board procedure consist entirely nonexecutive directorsof majority company secretary simon bicknell appoint independentand meet year consider barrister join group succession planning necessary thenomination secretary board committees committee report give page board committee corporate responsibility committee board establish number committee provide corporate responsibility committee consist entirely sufficient resource enable undertake duty nonexecutive director provide boardlevel forum current membership committee give table regular review external issue potential impact group business oversight reputation management committee responsible governance corporate audit remuneration nomination responsibility oversight group worldwide donation community support committee meet formally time year sir christopher gent c c meetings consultations asnecessary dr jpgarnier mr j coombe financial results committee dr yamada financial result committee review approve behalf mr l culp board annual report form f annual review sir crispin davis convene annual general meeting sir deryck maughan preliminary quarterly statement trading result sir ian prosser director member committee quorum dr r schmitz c meet member quorate meeting dr l shapiro include chairman chairman audit committee sir robert wilson c ceo cfo committee meet necessary key c chairman member addition director member corporate administration transaction financial result committee corporate administration transaction committee corporate administration transaction committee review follow summary role term reference approve matter connection administration committee current term reference group business andcertain corporate transaction committee obtain company secretary committee consist director cetmember corporate governance section company website company secretary committee meet necessary audit committee evaluation board board committee director audit committee review financial internal reporting performance evaluation board committee process system internal control management risk director normally undertake chairman external internal audit process committee implement collaboration committee chairman propose shareholder appointment external auditor support company secretary follow directly responsible remuneration oversight appointment sir christopher gent june deputy work committee consist entirely independent chairman decide deputy chairman nonexecutive director meet time year undertake performance evaluation board necessary theaudit committee report give committee directorsincollaborationwith committee page chairman company secretary remuneration committee board evaluation conduct wayof remuneration committee determine term service questionnaire follow aprivate discussion remuneration executive director member deputy chairman directorsinclude cet assistance external independent advisor chairmanan external consultant appoint assist evaluate make recommendation board overall evaluation audit committee executive remuneration policy committee consist entirely independent nonexecutive director meet time year necessary information remuneration director give remuneration report pagesto glaxosmithkline corporate governance dialogue shareholder company authorise purchase amaximum ofmillion share million share financial result announce quarterly purchase cancellation andmillion purchase company report formally shareholder twice year hold astreasurysharessee noteto financial statement halfyear fullyear result announce fullyear share capital share premium account exact result include company annual report annual timing future purchase extent repurchase reviewwhich issue shareholder company halfyear share hold astreasuryshare cancel result publish national newspaper shortly determined company dependenton market release ceo cfo presentation fullyear condition factor result institutional investor analyst medium london new york addition teleconference donation political organisation eu political release second quarter result institutional expenditure investor analyst medium annual report annual agm shareholder authorise reviewand quarterlyresultsmay access company donation eu political organisation company website incur eu political expenditure provision political party election referendum act annual general meetingagm take place london year authority renew annually formal notification send shareholder month company notmake intendto advance meetinga business presentation makesuch payment donation political party shareholder director able attend available formally normal meaning expression definitionin legislation meeting informally question ofeu political organisationi wide itcan extend body committee chairman ordinarily attend agm respond company subsidiary wish support shareholdersquestion dr schmitz chairman audit includingthose concern policy review law reform committee unable attend company agm representation business community special interest convalescingsir crispin davis groupssuch concern environment thegroup mr mcarthur unable attend meeting donation noneu political organisation totalling commitment resolution agm decide poll donation require company article association result madetoeu political organisation pollare announce london stock exchange post company website detail agm annual general meeting set section annual general meeting agm hold pm wednesday th ensure nonexecutive director aware queen elizabeth ii conference centre broad sanctuary understand view major shareholder company westminster london swp ee business transact board place process focus sectorspecific issue meeting include general shareholder preference ceo cfo maintain dialogue institutional receiving adopt glaxosmithkline annual shareholder performance plan objective report programme regular meeting speak regularly external conference presentation approve remuneration report remuneration report pagestoset group investor relation department office london remuneration policy operate glaxosmithkline philadelphia act focal point contact investor disclosure director remunerationinclude year require company act director chairman remuneration committee meet remuneration report regulation resolution major shareholder discuss executive remuneration policy propose approve remuneration report nonexecutive director include new appointee available meet major shareholder request retirement election reelection director sir christopher gent sir deryck maughan mr heslop company website give access current financial appoint director business information group agm offer election board share buyback programme dr garnier sir ian prosser drschmitz anddrshapirowill october follow completion billion share retire offerthemselvesfor reelection board buyback programme announce company article company article association announce plan billion share buyback programme programme million account reappointment remuneration auditor million million resolution propose reappoint programme cover purchase companyof share pricewaterhousecooper llp auditor authorise cancellation hold astreasuryshare accordance audit committee determine remuneration authority give shareholder company agm corporate governanceglaxosmithkline special business risk oversight compliance council rocc company seekauthority rocc council senior executive authorise board assist audit committee oversee risk management donation eu political organisation incur internal control activity group membership comprise eu political expenditure cetmember head department director authority disapply preemption right internal control risk management auditandcompliance allot new share connection right issue responsibilitie direct reporting line audit committee maximum cent provide mechanism bypass executive management current issue share capital need arise purchase ordinary share toa maximum cent current issue share capital rocc meet regular basisto review assess significant amendthecompany article associationto enablethe risk mitigation plan rocc respond company certain circumstance meetcosts incur group policy refer provide business unit company associate resolution requisition framework risk management upward report shareholdersto bring thearticle ofassociation line significant risk mitigation planning identification new legislation indemnification director manager overall responsibility management clarify circumstance adr holder give risk requirement speak company meeting risk management compliance board rmcbs internal control framework risk management compliance board rmcbs establish major business unit membership board recognise responsibility present balanced comprise member senior executive team respective understandable assessment group position prospect business unit augment specialist appropriate structure accountability audit operate rmcbs oversee management risk consider glaxosmithkline follow important respective business unit include risk board accountability reviewing approve designate significant glaxosmithklinea adequacy effectiveness internal control operate increase number risk actively manage company include financial operational compliance control acrossthe group risk management board delegate responsibility rmcb regularly report status significant review audit committeewhich receive report risk rocc individual identify committee report page responsibility managementthrough compliancefunction cetto implement board policy risk control cet number risk area specific standard meet exceed responsible identify approve monitoringand enforcing requirement applicable law establish specialist key policy heart group conduct audit compliance group example corporate environment business internal control framework include central direction healthsafety global quality assuranceand worldwide resource allocationand risk management key activity regulatory compliance assist dissemination implementation research development manufacturing marketing sale audit standard legal human resource information systemsand financial practice corporate ethic compliance cec framework comprehensive planning rocc support corporate ethic compliance system annual budget approve board result department responsible support development operating unit report monthly compare implementation practice facilitate employee budget forecast prepare regularly year compliance law group policy extensive financial control procedure selfassessment exercise thrust group compliance effort diligence riskactivitie review group internal auditor prevent detect misconduct noncompliance commercial financial responsibility isclearly law regulation promote ethical behaviour compliance delegate local business unit support regional law regulation corporate responsibility level management structure principle design provide effective compliance system environment central leadership couple local operating autonomy framework exercise accountability cec manage corporate compliance officerwho control group report directly ceo corporate compliance officer chair roccand provide summary report roccs group attach importance clear principle activity group significant risk cet procedure design achieve appropriate accountability auditcommittee regular basis control agrouppolicy risk management legal compliance mandate business unit establish processesfor manage area potentially significant risk monitoringrisk significant business group detail risk affect group noteto financial statement legal proceeding risk factor internal control frameworkalsorelie follow pagesto oversee report risk compliance issue glaxosmithkline corporate governance effectiveness control accordinglytheboard choose nominate internal control framework operation committee member recent relevant financial year review continue operate experienceas define combined code date approval report system internal control arrive conclusionthe board consider follow design manage eliminate risk ofnot point drschmitz chairman committee achievingbusiness objective providereasonableand april prior appointment nonexecutive absolute assurance material misstatement loss director companyhe nonexecutive director audit committee receivesreport onareas significant risk glaxo wellcome plcwhere serve audit committee group relate internal control follow consideration dr schmitz member executive board report theaudit committee report annually director deutsche bank ag retired board board effectiveness control control mitigate charge investment bankingdr schmitz eliminate risk addition area member executive board director group business necessary risk achieve basf include cfo satisfactory return shareholder investment rd hold mba inseadsir ian prosser cfo later acquire new product business case ceo ofbassplc member instituteof charter thegroupsobjective apply expertise prudent accountant england wale sir robert wilson begin management elimination riskthe director review professional career economist chairman bggroup relate company subsidiary extend plc hold senior management position rio tinto plc material associate undertaking joint venture culminate appointment executive chairmanfrom investment retire sir deryck maughan appoint member committee st january board audit committee review chairman chief executive officer citigroup international assessment risk internal control framework vice chairman citigroup incprior creation operate glaxosmithkline consider effectiveness citigroup waschairman cochief executive officer system internal control operationin group salomon smith barneyhe chairman chief executive year cover reportand date approval officer salomon brotherssir peter jobwho retire boardthe process follow board reviewing board st december ceo reuters plc system internal control accord guidance internal andbroughtconsiderable industrial experience control issue turnbull committee role member committee committee report committee support company secretary attend committee meeting available audit committee report financial resource independent professional advice audit committee role flow directly board consider necessary meeting committee attend oversight function authorise board investigate chairman ceo cfo general counsel head global activity term reference committee internal audit gia corporate compliance officerand write term reference approve external auditor board committee report regularly board performance activity assign committee work structured programme committee main responsibility include review corporate activity withstand item committee require accounting financial reporting process monitoring consider meetingtogether matter focus integrity company financial statement evaluate coincide key event annual financial reporting cycle system internal control management risksoverseee external auditor report committee critical activity eachofthe group compliance audit functionsand accounting policy practice company overseeingcompliance law regulation ethical code alternative accounting treatment discuss practice committee oversight role require address management resultant conclusion external regularly relationship management internal auditor material write communication management external auditor understand monitor report restriction access information relationship tier accountability party committee receive regular report member cfo report financial performance company cet senior manager cover key compliance activity technical financial accounting matter group include concern rd manufacture general counsel report material litigation sale marketing ehs company secretary report corporate governance committee entirely compose independent nonexecutive director committee member bring considerable financial head group compliance audit group accounting experience committee work member report auditscope annual coverage audit resource past employment experience finance accounting role result audits conduct year comparable experience corporate activity corporate compliance officerreported activity board determine combine qualification undertake rocc experience committee member take modus operandi givethe committee collectively financial expertise necessary discharge responsibilitiescorporate governanceglaxosmithkline company secretary aschairman disclosure recruit nonexecutive directorsthe committee consider committeereported matter affectedthe quality particular skill knowledge experience benefit timely disclosure financial material information board significantly appointmentbroad selection board public market shareholder criteriaareuse focuson achieve balance enable committee review clarity completeness representation uk market individual disclosure publish annual financial statement ceo experience skill develop sectorsand interim report quarterly preliminary result specialitiesprofessional search agency engage specialise announcement formal announcement relate recruitment high calibre nonexecutive director dossier financial performance prior release board potential nonexecutive appointeesareprovide committee candidatesareshortliste interview audit committee management internal auditorsand consider relevant qualificationsnew nonexecutive boardwork ensure quality company directorsoffer election companysnext corporate accounting financial reporting committee agm appointmentsareannouncedpublicly serve primary link board external internal auditor facilitate necessary independence acustomised induction process conduct management encourage external internal new nonexecutive director focus particular experience auditor communicate freely regularly committee take account different background process committee meet collectively separately include meeting key member cet andother senior external auditor head giawithout member executive case visit particular operational management present facility group committee primary responsibility make case appointment new cfothecommittee recommendation shareholder appointment consider particular skill knowledge experience require reappointment removal external auditor annually cfo glaxosmithkline committee consider assess qualification expertise resource independence number potential external internal candidate external auditor effectiveness audit process recommend board approve appointment mr heslop board approve mr heslops appointmentwhich make assessment committee consider paper publicly announcedin october mr heslopwill offer detail relevant regulatory requirement require external election thecompany agm auditor evaluate report external auditor compliance requirement external auditor committee metthree timesdure session provide nonaudit services committee ensure auditor twiceon quorate basis member present objectivity independence safeguard policy meeting require preapproval audit committee service expenditure audit nonaudit services set remuneration report page remuneration report find pagesto guideline set company policy engage combined code external auditor provide nonaudit servicesinclude ascertaining skill experience external auditor company comply thecode provision suitable supplier nonaudit service adequate safeguard combine codeexcept follow place objectivity independence audit b designing scheme performancerelate compromise fee level relative annual remuneration theremunerationcommittee follow audit fee limit set committee provision schedule code item company wellestablishe policy include code schedule state thatin general basic salary ethic available onitswebsite helpline facility pensionable company position explainedin reporting investigation unlawful conductno remuneration report page waiver codewere c board satisfy member committee meet session time theauditcommittee recent relevant financial time quorate basis session attend experience company position explain page membersexcept sir peter jobwho unable attend thechairman arrange thechairman meeting auditremuneration andnominationscommittee available answer question agm director nomination committee report attend company position explain page nomination committee term reference include responsibility propose appointment board law regulation committee member committee recommendation board appointment number provision law regulation apply sir christopher gent sir deryck maughan andmrheslop glaxosmithkline company share quote new york stock exchange nyse form adss case chairman committee focus identify individual calibre experience require tochair complex global organisation glaxosmithkline corporate governance nyse rule base knowledgetheffinancial statement generalthe nyse rules permit company followuk financial information fairly present materialrespect corporate governance practice instead apply financial condition result operation cash flowsa usaprovide company explain significant variation date andfor periodspresente inthe annual report explanation provide company website form f responsible establish maintain disclosure sarbanesoxley act control procedure ensure material information follow number corporate accounting scandal known evaluatedthe effectiveness usa congress pass sarbanesoxley act control procedure theyear end result sarbanesoxley sarbanesoxley establish newstandard evaluation contain annual reportand corporate accountability company list usa form fand disclosedin annual report form company corporate governance structure believe f change ininternalcontrol financial reporting robust line good practice certain change period cover annual report form f necessary ensure compliance sarbanesoxley havematerially affectedor reasonably likely toaffect recommend security exchange commission materiallythe company internal controlover financial sec glaxosmithkline establish disclosure committee reporting committee report ceo cfo audit disclosedbase ontheirmost recentevaluation committee chair company secretary internal control financial report external auditor member consist senior manager finance legal audit committee significant deficiency compliance corporate communication investor relation material weakness design operation internal external legal counsel external auditor invite control financial reporting reasonably likely attend meetingsperiodically responsibility consider affect adversely company ability record process materiality information andon timely basis determine summarise report financial informationand fraud disclosure treatment information regardless materiality involve person responsibility timely filing report sec significant role company internal control financial formal review annual report form f reporting committee meteighttime ceo cfo complete certificationswhich sarbanesoxley require annual report contain file sec group form f statement member company audit committee audit committee financial expert control procedure group carry evaluation supervision board review qualification background participationof group management include member audit committee determine ceo cfo effectiveness design operation member company audit committee group disclosure control proceduresas audit committee financial expert combine qualification st december inherent limitation experience audit committee member take effectiveness system disclosure control procedure modu operandi audit committee include possibility human error circumvention collectively financial expertise necessary discharge override control procedure responsibility explanation basis board judgement refer page accordingly effective disclosure control procedure provide reasonable assurance achieve control accounting period end thjuly objective base group evaluation ceo cfo sarbanesoxley requires companysform fcontain conclude thatas atst december disclosure report state responsibility management establish control procedureswereeffective provide reasonable maintain adequate internal control financial reporting assurance information require disclose report assess effectiveness company internal control group file submit securities exchange act financial reporting company require amend record process summarise report compliance form fmanagement report require undertaken process ensure position report compliance date nochange group internal control financial reporting duringthat materially affectedor sarbanesoxley introduce requirement ceo reasonably likely affect materiallythe group internal cfo complete formal certification confirm control financial reporting review annual report form f base knowledgeit contain material misstatement omissionsglaxosmithkline remuneration report remunerationreport set remuneration policy operate glaxosmithkline respect director corporate executive team cet member disclosure director remuneration include require director remuneration report regulation regulation accordance regulation follow section remunerationreport subject audit annual remuneration nonexecutive director remuneration share option incentive plansperformance criterion onperformance share plansand share option andpension remain section subject auditneither page refer auditedsection thisreport submit shareholder board approval annual general meeting reference thenoticeof annual general meeting remunerationreport executive director cetmember refer executive reference glaxosmithkline share adss mean respectively ordinary share glaxosmithkline plc p american depository share glaxosmithkline plc ad represent glaxosmithkline share introduction remuneration policy executive director term condition remuneration nonexecutive directorterm condition fee director senior managementremuneration annualremuneration nonexecutive directorsremuneration director interest share option incentive plan pension director senior management director interest contract glaxosmithkline remunerationreport remuneration report introduction remuneration policy remuneration committee committee responsible principle make recommendation board company thefourcore principle underpin remuneration policy remuneration policy term agree policy glaxosmithkline determine total individual remuneration package secure outstanding executive talent executive pay performance performance remuneration policy set report finalise robust transparent governance structure undertake extensive consultation process shareholder commitment leader good remuneration practice institutional body course pharmaceutical industry glaxosmithkline remuneration policy design establish formulate policy committee decide framework remunerationthatis consistent company remuneration structure support need scale scope operation meetsthe recruitment need businessin competitive market place business closely align uk shareholder guideline uk shareholder guideline willbe follow maximum st december company thesecondlarg extent consistent need business pharmaceutical company world revenue operation company maintain regular dialogue shareholder continentswith product sell overcountrie global pharmaceutical company primary pay cent sale generate usa comparator group performance condition base measurable remuneration committee delivery strong financial performance delivery composition committee change year superior return shareholder compare mr mcarthur retired board pharmaceutical company sir robert wilson appoint chairman committee high proportion total remuneration opportunity member committee sir crispin davis base performancerelate remuneration sir peter job mr culp board deem member deliver medium tolong term committee independent nonexecutive director remuneration determined project value accordance combine code method explanation committee metseventime member remuneration structure executive director attend follow cet particular performance condition apply equally longterm incentive award number meeting number meeting hold whilst attend exgratia payment willbe committee member committee member pay structure simple consistent sir robert wilson business need chairman fromth overallthe policy intend provide median total mrlculp remuneration median performance poor performance sir crispin davis result total remuneration significantly pay comparator mr j mcarthur group median opportunity earn upper quartile total chairman untilth remuneration exceptional performance sir peter jobretire st dec strong alignment performance demonstrably onequorate meetingwasheld toapprovethe formal grant interest shareholder provide executive share option performance share award effect unambiguous signal importance deliver success committee decision companys shareholder exception company secretary employee commitment company involve conduct committee committee apply policy consistent meeting dr garni ceo senior vice president human transparent basis significant change measure resource invite attend meeting assess performance discuss shareholder committee require use comparator pay benchmarking committee deloitte touche llpdeloitte appoint use discretion ensure remuneration level reasonable committee provide independent adviceon executive believe change cause concern remuneration shareholder position discuss shareholder prior implementation deloitte provide consulting service glaxosmithkline year provide advice executive remuneration matter committee tower perrinprovide market datum datum analysisto committeeremuneration reportglaxosmithkline pay performance comparator individual element remuneration follow table set company pay balance fix base salary variable annual performance comparison bonus longterm incentive element remuneration change market cap performance chart show anticipate normal company country range mix fix variable payat differentlevel abbott laboratories usa performance ceo typical case astrazeneca uk executive directorsedin year range bristolmyers squibb usa higher lower depend theperformance thecompany eli lilly usa andtheindividual number share subject longterm glaxosmithkline uk incentive awards executive director unchanged johnson johnson usa merck usa novartis switzerland ceo ed pfizer usa roche holdings switzerland sanofiaventis france scheringplough usa takeda pharmaceutical company japan base salary annual bonus longterm incentive wyeth usa base salary merger aventis sanofisynthelabo reduce base salary set reference median relevant size comparator group company market executive pharmaceutical pay comparator glaxosmithklinethecommittee subsequently determine group actual salary level review annually vary number reason include focus operation market depend executive experience responsibility market capitalisation suitable company add value change usually effect st aprilbase salary group dr garni dr yamada change mr coombe base salary increase bythreeper cent benchmarke dr garni receivedmr coombe benchmarke purposestotal remuneration incorporate base anddr yamada salary annual bonus longterm incentive set pay committee regard executive pension annual bonus arrangement bonus determine basis formal review global pharmaceutical industry primary pay annual performance stretch financial target base comparator executive appropriate marketplace profit interest tax subject detailed company senior executive talent instance assessment individual business unit group achievement pay benchmarke publicly available remuneration datum objective bonus payable financial performance company cent target performance individual performance objective increaseordecrease bonus provide context information reference level factor range zeroto bonus tower perrin annual global pharmaceutical pay survey subject upper limit executives pharmaceutical human resources association phra ceorange cent cent base salary ensure global pharmaceutical industry benchmark ceo limit cent subject scrutiny review committee consider pay datum global business primarily consumer annual bonus pay basis ontarget business manufacturing sector performance base salary provide annual cash line median pay comparator group prior determine annual longterm incentive opportunity committee consider range vest level case ceothe bonus target set board achieve base different assumption share price follow end financial year committee review growth performance level etc performance line ceo performance determine bonus payable expectation total remuneration target median recommend board approval ceo make comparator group longterm incentive opportunity set recommendation committee performance way provide position total remuneration level achieve objective executive median recommendation consider committee determine resultant bonus ensure stable benchmark develop reduce impact shortterm fluctuation incentive policy executive choose invest bonus glaxosmithkline global pharmaceutical company assess number share minimum year annual investment year planor equivalent usplan end threeyear hold periodexecutive entitle matching award valuation method cent defer shareholding match project value method benchmark total subject performance condition plan open remuneration method project future value approximately senior executive term remuneration package different performance scenario committee believe arrangement encourage whilst moderate impact market fluctuation theshort shareholding senior executive consider term strengthen focus performance appropriate executive participate onthe term glaxosmithkline remunerationreport set bonus award committee take tsr rank company percentage account achievement management maintain growth glaxosmithkline award vest cer basis whilst absorb billion oflost sale generic longterm incentive executive eligible performance share award share option remuneration policy provide annual longterm incentive award normally performance share award share option award committee consider performance share provide tsr measure prorata basis glaxosmithkline strong alignment shareholder valueand thereforethe performance fall comparator level vest remuneration policy place great emphasis use determine actual relative level tsr simple performance share longterm incentive award determine rank ontarget performance half provide close link shareholder return payment longterm incentive reward derive performance share executive notional dividend reinveste pay grant annual award plan consistent proportion vest award receipt dividend practice pay comparator group lead incorporate benchmarking award level ukcompanies longterm incentive cetare provide addition performance share earn executive basis asthe executive director sell meet relate tax liability year follow end vest period committee believe performance share awards share option deliver align interest executive resident executive form adss award deliver longterm interest shareholder form ordinary share executive resident uk country award plan vest table performance share award grant incorporate dilution limit consistent guideline provide december performance period st january association british insurers national association st december give page pension fund shareholder representative body current estimate dilution exist award b share option glaxosmithkline employee share scheme merger share option allow holder buy share future date approximatelyfiveper cent company share capital share price prevail time grant share option st december grant thanmanager glaxosmithkline include executive share option grant performance share executive link achievement compound executive level performance share vest base annualep growth performance period company total shareholder return tsrrelative committeeconsideredthat eps key measure performance comparator group page threeyear performance business fully reflect measurement period tsrwas choose appropriate business measure extend group ensure comparative measure focus return organisational alignment shareholder wellunderstood test mechanism measure performance allow comparison company set eps targetsthe committee consider company operate different country internal projection analyst forecast glaxosmithkline ep performancea analyst forecast tsr measure sterling performance period pharmaceutical industry represent change value share value reinveste dividend pay order remove impact follow key principle govern use ep vary tax treatment dividend different jurisdiction performance measure dividend reinveste gross adjustment consider major item respect performance share award grant december adjustment judgement committee performance period st january purpose adjustment ensure stdecember glaxosmithkline rank position performance measurement fair reasonable seventhe midpointof performance comparator group participant shareholder cent share vestany rank point discretion exercise committee disclose result share vestingonly glaxosmithkline shareholder annual report company share vest committee set basis decision consider determine vest level committee regard appropriate adjustment company underlie financial performance grant vest increase straightline basis eps performance hurdle set tableon follow remunerationreportglaxosmithkline annualise percentage sharesave plan sharereward plan inland revenue growth ep award vest approve plan open uk employee term mr coombe member sharesave plan rpi contribute month provide option rpi buy share end threeyear saving period line rpi opportunity available uk employee rpi mr coombe contribute month buy share performance condition substantially consistent uk sharereward plan company match number shareholder guideline expectation isdemande share buy month compare thoseoperate global pharmaceutical company consistent policy provide pay executive receive benefit include healthcare performance performance medical dental personal financial adviceandlife assurance cash value benefit receive executive director performance measure financial year follow show page grant option committee decide grant performance reteste executive director term condition remuneration performance condition metafter threeyear periodthe option lapse executive director contract policy executive director contract pension subject extensive review change thepolicy executive participate glaxosmithkline senior executive provide framework contract executive director pension plan pension arrangement structure appoint future accordance plan operate executive country key aspect glaxosmithkline contractual framework executive likely retire benefit normally payable age detail individual arrangement aspect policy executive director set pagein response notice period calendar month future pension regimein uk committee carefully termination consider impact change legislation decide employ company well forward regulation clear market executive consensus emerge view implementation april termination payment x annual salary x annual ontarget bonus share ownership requirement mitigation require align interest executive shareholder executive require maintain significant holding share benefit govern benefit policy glaxosmithkline requirement important include align interest executive shareholder ceo healthcare medical dental require hold share value time base salary personal financial advice executive director require build shareholde life assurance contribution value time base salary member cet vest longterm rule relevant equity incentive require build shareholding value time base incentive plan salarythe executive groupare require pension base exist arrangement build shareholding value time base salary term relevant pension plan executive require continue satisfy shareholde noncompete clause month termination requirement minimum month follow notice date retirement company order share qualify share ownership dr garnier target bonus cent salary mr coombe cent salary dr yamadas isper cent salary requirement hold personally executiveor imposition month noncompete period executive consider spouse minor childrenor earn defer vitally important company order protect group intellectual share programme operate company property light noncompete clause competitor practice committee believe appropriate provide mitigation unexercised share option include calculationas contract review level severance payment committee st december dr garniers shareholde consider investor dti guidance determined line adss mr coombe wasordinary share dr yamadas competitive practice appropriate provide payment salary wasadss holding excess share target bonus termination approve shareholder glaxosmithkline glaxo wellcome smithkline ownership requirement beecham appropriate remuneration element dr garni mr coombe dr yamada agree change executive participate legacy glaxo wellcome previous contractual term compensation come broadly smithkline beecham allemployee share plan uk line new contractual framework include usa glaxosmithkline plan replace reduction contractual notice period calendar month order honour certain aspect old contractual termsthere number individual feature retain glaxosmithkline remunerationreport dr garnier case include entitlement benefit accrue glaxo wellcome uk pension reimbursement excise tax change control relate arrangement augment trustee plan payment life insurance benefit fund company age cent reflect distribution surplus augmentation follow provision relate vest oflongterm apply element ofmr coombe pension earning incentive st march pre awards entitlement termination company cause addition contractual provision outline retirement resignation good reason ie resignation event dr garni dr yamada mr coombes service elect retain director agreement terminate employ companythe company merge company result change follow apply control provide resignation occur day anniversary change control case award glaxosmithkline annual option vest remain exercisable investment plan provide agreement terminate option term performance share vest end cause defer amountany incomeand performance period subject performance gain automatically distribute soon administratively timeapportione practicable termination resign retire termination causethen deferredamount distribute end minimumthreeyear deferral provision apply option subject period performance testing circumstance option performance share award month prior line policy applicable senior executive termination notice date lapse dr garni dr yamada entitle receive continue medical dental insurance mr coombe remain entitled termination cash equivalent month benefit continue medical dental follow merger participant legacy share insurance option scheme elect exchange legacy option option glaxosmithkline share receive additionthe current executive directorsareentitle receive additional cash benefit equal cent grant price year worth pension contribution termination original option additional benefit trigger dr garniers mr coombe contract execute new option exercise lapse qualify rd march take effect st january additional cash benefitparticipant retain option dr garnier contract expire st october second anniversary effective date mr coombe st march day merger monthin reach th birthday dr yamadas contract execute th july take effect outside appointment executive director st january expire onth june outside appointment approve chairman day monthin reach nd birthday behalf board isthe company policy remuneration earn appointment keep individual termination payment respect executive director notice period extend contract expiry date nonexecutive directorterm condition fee individual pensionarrangement uk plan provide pension base twothird final nonexecutive director glaxosmithkline service salary age cash balance plan provide annual contract instead letter appointment company contribution interest sum accumulate cash aim provide nonexecutive director fee balance plan contractual promise provide specific competitive company equivalent size level retirement income complexity year chairman sir christopher hogg ceo recommend board approve glaxosmithkline make annual contribution cent new fee structure effective st october dr garniers annual salary bonus cent nonexecutive director follow dr yamadas annual salary bonus fund increase interest rate base yield year treasury bond standard fee annum company liability make annual supplemental fee follow contribution annum sid audit committee prior usemployee include dr garni chairman dr yamada move final salary pension arrangement annum chairman remuneration current cash balance structure employee corporate responsibilitycommittee cash balance plan contribution base combined annual meet nonexecutive director salary annual bonus undertaking intercontinental travelto meeting mr coombe participate glaxo wellcome define benefit fee pay dollar convert rate plan retirement age entitle receive annual usbee exchange rate apply pension oftwothirdsof final salary twothirdswidow newfee arrangement approve pension inflation proof fee arrangement sir christopher gent describe pageremunerationreportglaxosmithkline enhance link director shareholder follow table show date letter appointment set table glaxosmithkline require nonexecutive applicable thedate leave board director receive significant fee form nonexecutive date letter share effect st october cent director appointment date leave nonexecutive director total fee pay form mrlculp share allocate share account nonexecutive sir crispin davis director opportunity invest sir deryck maughan balance fee share account sir ian prosser prior st october nonexecutive directors dr rschmitz allocate number share dependent position dr lshaprio theirfee elect invest balance sir robert wilson offee share account share pay dr barzach directors retirement board later date sir peter job pay basis dividend reinveste interim mr j mcarthur mr mchenry fee arrangement prior st october follow chairman tsrperformance graph board board deputy follow graph set performance company member committee chairman chairman relative ftse index company cash fee constituent performance comparator group merger th december graph prepare percentage cash fee accordance regulation indication take share likely vest award grant company maximum share incentive plan election automatic share ordinary share allocation adss ordinary ordinary share share adss adss nonexecutive director entitle compensation appointment terminate glaxosmithkline total return tsef total return index chairman glaxosmithkline pharma peer return index sir christopher hogg retire chairman effect st december sir christopher hoggs letter appointment director senior managementremuneration board date th june amend st september record appointment aschairman follow table set director glaxosmithkline effect th sir christopher gents letter plc remuneration earn interest share appointment board date th underwhich glaxosmithkline plc interest share option incentive agree serve company asdeputy chairman plan pension benefit member cet st december st january aschairman company secretary know senior management conclusion annual general meeting follow participate remuneration plan executive anniversary appointment extend director aggregate remuneration interest term year mutual agreementhe receive director senior management provide fee rate annum plus allocation glaxosmithklineshare value annum whilst deputy chairman receive annum plus allocation glaxosmithklineshare value annum chairman nonexecutive director appointment nonexecutive director provide letter appointment agree serve company nonexecutive director conclusion annual generalmeeting follow anniversary appointment case extend term year mutual agreement director serve term long year offer reelection shareholder glaxosmithkline remunerationreport annual remuneration total total fee annual annual fee annual annual salary benefit bonus remuneration salary benefit bonus remuneration footnote executive director dr jp garnier abc dr yamada bc mr jcoombe bcd total executive director current nonexecutive director mrl culp sir deryck maughan dr l shapiro e sir christopher gent sir crispindavis sir ian prosser dr r schmitz sir robert wilson total current nonexecutivedirector nonexecutive director mr j mcarthur mr mchenry mr pallaire dr barzach f sir christopher hogg sir roger hurn sir peter job sir richard syke ag total nonexecutive director total nonexecutive director total remuneration remunerationfor director payrollisreporte dollarsamount convert sterling average rate year follow merger participant legacy share option scheme elect exchange legacy option option glaxosmithkline share grant additional cash benefit equal cent grant price original option additional benefit know exchange offer incentive eoi payable new option exercise lapse market value qualify additional cash benefitparticipant retain option second anniversary effective date merger year dr garnier receive relate option exercise page sir richard syke receive result option lapse market value amount include benefit table b dr garni nonexecutive director united technologies corporationin respect hereceive form defer stock unit andstock option grant price mr coombe member supervisory board siemens ag respect hereceivedandstock appreciation right grant price dr yamadawasa member board director diadexusincin respect whichin hereceivedstock appreciation right grant price amount exclude table retain executive director c follow mergerdr garniermr coombe dr yamadawere awardeda oneoff special defer bonusa member ceteach award anamount equivalent hissalary st december notionally invest glaxosmithkline share adss onth february defer year atst december value share adss notionally acquire respect dr garni anincrease offiveper cent year include dividend reinveste year share notionally acquire respect mr coombe value st december adecrease ofoneper cent year include dividend reinveste year share notionally acquire respect dr yamada value atas st december increase offiveper cent yearthis include dividend reinveste year defer bonus vest th february andthe amount pay equivalent value share oradss notionally acquire february plus dividend reinveste period dr garni receive dr yamada receive mr coombe waive hisdeferre bonusof company acontribution pension plan enhance pension entitlement amount include table aboveremunerationreportglaxosmithkline mr coombe waive annualbonu thecompany acontribution pension plan enhance pension entitlementsthis include fee salary e dr shapiro member glaxosmithkline scientific advisory board receive fee form adss include fee salary f dr barzach receive fee fromglaxosmithkline francefor healthcare consultancy provide include fee salary g addition remuneration receive director set abovesir richard syke receive period st january th relate appointment senior advisor director receive expense year require separate disclosure require regulation nonexecutive director remuneration total cash sharesadss total cash sharesadss fee salary current nonexecutive director mrlculp sir deryck maughan dr l shapiro sir christopher gent sir crispin davis sir ian prosser dr r schmitz sir robert wilson nonexecutive director mr jmcarthur mr mchenry mr pallaire dr barzach sir christopher hogg sir roger hurn sir peter job total table set remuneration receive nonexecutive director glaxosmithkline accordingly include dr barzachs fee receive glaxosmithkline france healthcare consultancy provide dr shapiros fee receive member glaxosmithkline scientific advisory board st january th september nonexecutive director require receive fee form sharesor adsswith balance receive cash st october st december nonexecutive director require cent total fee form share allocate share account case elect receive cash payment form sharesoradss total value share adss date awardtogether cash payment form total feeswhich include annual remuneration table fee salary table set value fee receive form cash share adss share adss notionally award nonexecutive director allocate interest account include director interest table page accumulate balance share adss notional dividend subsequently reinveste pay nonexecutive director retirement retirement nonexecutive director receive share adss cash equal value share adss date retirement glaxosmithkline remunerationreport table set accumulate number share adss hold nonexecutive director st december movement account year number share adss dividend nonexecutive director share arrangement allocate elect reinveste pay current nonexecutive director sir christopher gent mrlculp adss sir crispin davis sir deryck maughan sir ian prosser dr r schmitz dr l shapiro share adss sir robert wilson nonexecutive director dr barzach sir christopher hogg sir roger hurn sir peter job mr jmcarthur ads mr dmchenry adss mr jyoung shares adss table set settlement nonexecutive directorsshare arrangement ontheir leave board value award value award payment date ofleave onallocation onleavinga b dr barzach sir christopher hogg sir peter job mr jmcarthur mr dmchenryd prior year sir roger hurnc mr jyoungc change value award allocation leave attributable dividend reinveste change share price date ofaward date ofleave b award sirchristopher hogg sir peter jobunder nonexecutivedirectors sharearrangement weresettledin transfer share january c leave board sir roger hurn mr young elect receive settlement nonexecutive directorssharearrangement quarterly annual cash payment respectively addition payment disclose mr mchenry receive payment defer fee relate period mr mchenry director smithkline beckman prior merger beecham group defer fee index total return glaxosmithkline adssand payable follow mr mchenrys retirement nonexecutive director glaxosmithklinethe total accumulate value defer fee pay equivalent glaxosmithkline adssremunerationreportglaxosmithkline director interest follow beneficial interest director company show register maintain company accordance company act share adss th february st december stjanuary th february st december st january footnote dr jp garnier mr jcoombe b dr yamada sir christopher gent cd mrl culp c sir crispindavis c sir christopher hogg ce sir peter job ce sir deryck maughan cd sir ian prosser c dr r schmitz c dr l shapiro c sir robert wilson c glaxosmithkline ad represent glaxosmithkline share include equivalent number ofadsspurchase glaxosmithkline stock fund k plan b include share purchase glaxosmithkline sharereward plan totallingshare st december andshare thfebruary c include share adss receive fee describe nonexecutive director share arrangement dividend receive share adss convert share adss st december include director interest sir christopher gent sir deryck maughan shares date appointment board e sir christopher hogg sir peter job left board st december interest company th february include table interest abovementione director atthfebruary reflect change end financial year date glaxosmithkline remunerationreport share option option adss grant date grant exercise period grant price number exercise dr jp garni dr yamada option share grant date grant exercise period grant price number exercise mr jcoombe na na na na option outstanding st december early late vesting lapse date market price glaxosmithkline share year end give table belowmr coombewasexclude grant option onnd december retire company month date grant weight average vestingdate lapse date dr jpgarnier grant price number early latest early late market price underwater year end vested option market price year end vest option unvested option total ad option st december weight average vestingdate lapse date dr tyamada grant price number early latest early late market price underwater year end vested option market price year end vest option unvested option total ad option st december weight average vestingdate lapse date mr jcoombe grant price number early latest early late market price underwater year end vest option unvested option market price year end unvested option total share option st december glaxosmithkline grant share option executive director senior manager annual basis generally november initial grant follow completion merger march measurement period option grant march commence st january measurement period option grant november december commence onst january respectively director hold option share option plan refer innoteto financial statement employee share scheme director interest option company share follow merger director elect exchange outstanding option legacy share option plan option glaxosmithkline share directorsand participant legacy scheme election receive additional benefit cash sum equal cent grant price original option additional benefit give new option exercise lapse prior share option grant executive director subject performance condition order option vest business performance ep growth exclude currency exceptional item average percentage point annum increase uk retail price index threeyear performance period option grant executive director subject performance condition describe page remunerationreportglaxosmithkline respect grant performance condition meet threeyear measurement period performance measure financial year follow date grant option performance conditioni meet end year option lapse option grant executive director subject performance condition set extent performance condition meet end threeyear performance period option lapse reteste permit grant market option exercise date number price price gain gain dr jpgarnier average exchange rate year gain dr garni amount eoi benefit pay dr garni exerciseof option benefit include table page onth february dr garnierexercise option exercise price give rise gain dr garnier receive respect exchange offer incentive benefit arise exercise option mr coombe exercise share option dr yamada exercise option highest low closing price year end st december glaxosmithkline share respectively high low price glaxosmithkline adss year end st december respectively market price glaxosmithkline share st december st december glaxosmithkline ad st december thepricesonth february wereper glaxosmithkline share glaxosmithkline ad incentive plan performance share planaward dr jpgarni ad market additional number price vest exercise ad vest unvested grant date vest market dividend unvested deferred performance period grant defer number price gain lapse reinveste value award defer drgarnier vest dr tyamada ad market additional number price vestedexercise ad unveste grant date vest market dividend unvested performance period grant defer number price gain lapse reinveste mr jcoombe share market additional number price vest exercise sharesby unvested grant date vest market dividend unvested performance period grant defer number price gain lapse reinveste glaxosmithkline remunerationreport average exchange rate year gainsby dr garnieranddr yamadaamounted respectivelymr coombewasexclude thegrant award nddecember retire company month date grant performance share plan psp mediumterm incentive scheme introduce psp replace longterm incentive plan midterm incentive plan operate respectively glaxo wellcome smithkline beecham term psp number share actually vest determined following end relevant threeyear measurement period dependent glaxosmithkline performance period describe page share award aregrante annually november december measurement period commence follow st january end threeyear onst december threeyear measurement period theaward performance periodcommencingst january end st december base performance glaxosmithkline period centof theaward vest february begin withthe award performance period begin st january dividend reinveste psp award member cetunder term psp participant defer receipt vested award dr garni elect defer receipt award vest untilretirement prior performance period begin st january awards part halfcanbe earn reference glaxosmithkline tsr performance compare ftse company constituent half award isdeliverable company business performance ep growth exclude currency exceptional itemsison average percentage point annum increase uk retail price index threeyear performance periodfor awards glaxosmithklineisrankedin ftse base tsr performance sharesin awardwill vest th position ftse cent share vest glaxosmithkline rank th position sharessubject awardwill vest th th position vest occur slide scale follow vest table appliesto theaward performance period st january st december tsr rank company glaxosmithkline percentage award vest performance comparator group theseawardscomprised company glaxosmithkline aventis sanofisynthelabo comparator groupprior merger form sanofiaventis purpose calculate tsrover performance period award grant december start price share individual company compare price merge company end performance period adjust merger ratio dividend treat reinveste performance period tsr measure prorata basis glaxosmithkline performance fall median comparator level vest determined median actual relative level tsr simple rank vest vested defer dividend defer participation reinveste participation midterm incentive plan adss dr jp garni midterm incentive plan mtip share award scheme operate smithkline beecham plan close new entrant completion merger participation grant final award adss receipt award defer directordr garnier defer receipt amount vestedin deferred award additional adss subsequently receive dividend reinvestment arenot include director interest table pagesincethey retain mtip pay average stock appreciation right sar adss grant price dr l shapiro sar hold drshapiro grant price market price glaxosmithkline ad year end dr shapiro member glaxosmithkline scientific advisory board sab dr shapiro member smithkline beecham sab completion merger glaxo wellcome member sab receive annual grant smithkline beecham sars general vest year date grant expire year date grant grant sars sab member cease sar entitle holder cash sum future date base share price growth date grant date exercise provision financial statement accrue gain sar date grant connection merger previously grant sar immediately exercisableremunerationreportglaxosmithkline pension accrue annual pension benefit transfer value executive director retirement set regulation require disclosure accrue benefit end year change accrue benefit year transfer value beginning end year change transfer value year listing rule require additional disclosure change accrue benefit net inflation transfer value change change change change accrue transfer value accrue accrue accrue transfer transfer year benefit change benefit benefit benefit value value transfer year net accrue year value inflation benefit pa pa pa pa dr jp garnier mr jcoombe dr tyamada change transfer value show net contribution individual pension executive director disclose currency pension payable dr garni dr yamada members employee cash balance pension plan glaxosmithkline make annual contribution calculate percentage employee base salary bonusthe fund increase interest rate set annually inadvance base year treasury bond rate provide cash sum retirement cash sum purchase pension retirement base annuity rate applicable time entitlement spouse pension pension increase otherthan reduce initial pension normal retirement age plan year age drgarnier pension arrangement bring line termsof service agreement assume retirement age reduce similarly dr yamadas assume retirement age reducedto transfer value cash sum dr garnier plan increase byover year result phase transfer previous scheme accumulation interest contribution pay thecompany transfer value cash sumof dr yamadas plan increase year result accumulation interest contribution pay company dr garni dr yamada alsomember usretirement saving plan money purchase scheme open usemployee contribution invest range fund value accumulate fund pay retirement contribution pay scheme company respect dr garni invest glaxosmithkline share stock ownership account respect dr yamada contribution pay scheme invest glaxosmithkline share stock ownership account share hold account include director interest table page mr coombe transfer value calculate basis actuarial advice accordance actuarial guidance note gn transfer value represent present value future payment pension plan whilst mr coombes annual accrue benefit increase exclude effect inflation transfer value increase year increase arise primarily result follow factor mr coombes pensionable salary increase account increase accrue benefit increase transfer value accrue benefit st december annual increase transfer value large close individual retirement term mr coombes service agreementhe retire age stmarch mr coombe approach retirementthe transfer value pension increaseto reflect level fund require meet annual accrue benefit payment mr coombe waive annual bonus special defer bonus company contribution pension plan enhance pension benefit discretionary increase apply uk pension plan uplift increase uk retail price indexlevel plan member result sir richard syke receive adiscretionary increase accrue benefit glaxosmithklineremunerationreport director senior management report purpose necessary provide information compensation interest director senior management asagroup group purpose disclosure group define director members cet company secretary respect financial year total compensation pay member group period serve capacity aggregateincrease accrue pension benefit aggregate payment define contribution scheme member group grant option overshare adss awardedsharesadss performance share planand share restrict share plan atth february thencurrent member group comprisingperson ownedshare andadss constitute cent issue share capital company group hold date option purchase share andadssshare andadss award performance share plan include share adss vest deferredshare andadss legacy smithkline beecham midterm incentive planinclude share adss vest deferredadss award legacy smithkline beecham stock appreciation rightsand share award restricted share planthese holding issue executive share option plansdescribe note financial statement employee share scheme director interest contract describe noteto financial statement relate party transaction end financial year director connect person material interest contract significance relation group business group company director remuneration report approve board director sign behalf sir christopher gent chairman ndmarch glaxosmithkline operate financial review prospect operate financial review prospect discuss operate financial performancethe financial outlook financial resource group result year compare primarily result precede year follow heading financial trend ratio year result year st december compare year st december financial position resource st december outlook risk factor additionally accordance requirement year result year st december compare year st december exchangerate group multinational business operate countriesand earn revenue incur cost currency result report sterling affect bymovement exchange rate sterling overseascurrencie average exchange rate prevail period areuse translate result cash flow overseas subsidiary associate undertaking joint venture sterling period end ratesare translate net asset undertaking currency influence translation usdollar euro japanese yen order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year cer represent growth constant exchange rate represent growth actual exchange rate business performance year business performance primary performance measure management present exclude merger item integration restructuring cost disposal business management believesthat exclusion item providesa well comparison way business manage givesan indication performance group term element revenue expenditure local management able influence completion programme group reporting result statutory basis growth rate present compare result business performance result statutory result management consider comparison statutory result business performance result give appropriate indication group performance period review commentary present basis state information provide addition statutory result prepare uk gaap appear pagesand assist shareholder gain clear understanding underlying performance business increase comparability period present glaxosmithkline operate financial review prospect financial trend ratio statutory result growth restate growth restate cer cer turnoverpharmaceutical consumer healthcare total cost sale sell general administration research development trading profit profit taxation earning basic earning share penny p p p merger restructure disposal subsidiary cost sale sell general administration research development trading profit profit taxation earning business performance result turnover cost sale sell general administration research development trading profit profit taxation adjust earning adjust earning share penny p p p research development statutory pharmaceutical consumer healthcare total interest net interest payable interest cover time time time interest cover calculate statutory profit interest divide net interest payable tax rate business performance statutory result borrowing net debt gearing gearing ratio calculate net debt percentage shareholder fund net debt minority interestsoperate financial review prospectsglaxosmithkline year world economy world market pharmaceutical record oil pricesthe continue threat terrorismand tighten global pharmaceutical sale increase bynineper cent monetary policy major economy feature billion global economy despite continue strong growth china usa sign economic world market value growth recovery main economy europe albeit slow geographic region bn total cer usa growth usawasper cent wide europe prediction wouldsee expansion keep germany cent federal reserve board raise interest ratesfive times france stave inflationary pressure uk continue concern country budget deficit effect italy global economy corrective action japan adopt usa remain main driver asia pacific global growth strong support asia despite adverse latin america impact high oil price middle east africa japans economydeclinedper cent recovery canada economy anticipate mid althoughin china official total measure moderate pace countrys economic expansionweretaken growthof nineper centwas achieve growth theus marketha slow remain double digit emerge economy asia hit oil price rise represent cent global prescription reasonable growth continue country taiwan pharmaceutical market compare toper cent decade ago thailand singapore th september glaxosmithkline heldsecondposition eugdp grow centwheregrowth large world pharmaceutical market market share economy vary fromp cent uktoper cent percent pfizer market share ofper cent germany interest rate unchanged european central glaxosmithkline hadeightproduct world bank oil price expect adverse impact pharmaceutical product areaugmentin avandia main european economy continue modest imigranimitrexlamictalseretideadvair seroxatpaxil wellbutrin growth predict zofran ukincrease government consumer spending fuel world market value growth initial expansionthat wasdampene later concern therapeutic class bn total cer interest rate house price final growth rate cardiovascular meet government forecast bank england raise interest central nervous system ratesfourtime year hold cent alimentary tract metabolic sign emerge slow economy concern antiinfective bacterial inflation recede viral fungal exclude vaccine respiratory follow substantive recovery global equity market share price index show subdued advance note datum base month thseptember despite positive economic corporate news year pharmaceutical turnover exchange growth rate include review turnover constant currency influence group result exchange rate cer state sterling growth dollar euro japanese yen rate find table pharmaceutical turnover pound hit high level dollar therapeutic area pageand geographic region fouryear climb yearend euro gain page cent sterle eightper cent dollar total pharmaceutical turnover wasmillion thesecond consecutiveyear dollar compare million increase ofone fall value eurodue tothe impact continue centcerin sterling term turnover decline cent unrest iraq tension world concern principally tothe weakness dollar economy group portfolio turnover new product launch major market year account forper cent total turnover grow byper cent million turnover establish franchise product amount tomillion representingper cent total turnover decline fiveper cent compare year turnover old product actively promote million decline ofsevenper cent representingper cent total turnover glaxosmithkline operate financial review prospect year continue global pharmaceutical turnover fourth quarter strong growth glaxosmithkline epilepsy bipolar increase threeper cent reflect turnoverincreaseof disorder treatment lamictalcontinue sale cent fourper cent tomillion europe turnover million ongoing growth cent million grewtwoper cent tomillion international turnover drive indication maintenance treatment grewfiveper cent tomillionturnover usawa bipolar disorder receive year impactedby generic competitionfor wellbutrinand paxil exclude sale product turnover grow cent antiviral usa global hiv product sale rise cent billionand sale usa increase cent million pharmaceutical turnover therapeutic area glaxosmithkline continue grow hiv franchise despitethe launch new product competitor glaxosmithkline ability continue deliver pharmaceutical turnover growth despite generic competition hiv performance enhance launch epzicom new product primarily exceptionally broad product combination product epivirziagen usa august portfolio fastgrowe highvalue product eu kivexa january include therespiratory product seretideadvairup sale herpe treatment valtrex exceed millionfor cent billionthe diabete treatment avandiaavandamet time cent million cent billionlamictalfor epilepsybipolar disorder performance drive usa cent cent billionvaltrexfor herpe billionup million product clear market leader cent coregfor heart diseaseup cent billion treatment genital herpe andvaccinesup cent billion antibacterial glaxosmithkline product sale antibacterial sale decline cent worldwide million cent usa reflect generic competition region respiratory metabolic glaxosmithkline continue global leader respiratory thediabete treatments avandiaavandametcontinueto perform pharmaceutical sale key product strongly overall sale billion cent seretideadvair flixotidefloventand serevent amount billion cent sale seretideadvair group sale theusagrew cent million encouragingly large product grow cent billion avandiaavandametarealso grow verystronglyin europe contribute decline sereventand flixotide constituent international market sale cent cent product respectively strong performance market isdriven grow acceptance opinion leader physicians usa advairsale grow cent billion growth benefit new product improve control ofseretidein europe strong cent diabetic patient million report growth fourth quarter adversely impact oneoff rebate adjustment germany vaccine wholesaler destocke italyinternational sale grow thevaccine business strong year sale cent cent reflect good growth geographic area billion key product drive growth old respiratory product ventolinand becotidecontinued pediarixinfanrixup cent million priorixup decline patient convert new product cent millionandfluarixup cent million central nervous system cns oncology emesis cns sale decline cent billion sale decline sale zofrangrew cent million drive region performance cent million total sale paxilfranchise cent cardiovascular urogenital billion result generic competition paxil ir sale coregfor heart disease sale grow cent decline cent million mitigating decline million strong performance product japanup cent millionand performance paxil crwhich generate therapeutic area sale million cent sale zantac fall cent million decline total sale wellbutrinproduct fall cent million region wellbutrin irand sr sale fall cent million result generic competition impact partially offset exceptionally strong performance wellbutrin xl new oncedaily product achieve sale million year marketoperate financial review prospectsglaxosmithkline pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major product total cer cer cer cer respiratory serevent seretideadvair flixotideflovent seretideadvair flixotideflovent serevent flixonaseflonase cns depression seroxatpaxil paxilir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl migraine imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir agenerase lexiva herpe valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccine hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascularand urogenital coreg levitra avodart zantac cer represent turnover growth constant exchange rate represent growth actual exchange rate analysis turnover quarter give financial record pagesto glaxosmithkline operate financial review prospect year continue regional analysis parallel trade occur occasionally world sufficiently material affect significantly turnover data turnover report table represent sale invoice market present invoice basis glaxosmithkline local entity customer local market plus copromotion income market pharmaceutical turnover europe region turnover create basis pharmaceutical turnover geographic region invoice basis turnover market europe adjust effect parallel trade turnover basis country region growth major market total cer product finally consume product sell glaxosmithkline usa europe region invoice adjustment create invoice adjustment create france major market uk europe italy france germany uk spain italy poland germany europe spain international poland asia pacific europe japan middle east africa pharmaceutical turnover geographic region latin america turnover create basis canada region growth major market total cer cer represent turnover growth constant exchange rate represent growth usa actual exchange rate europe individual government determine pricing medicine france country europe result wide price variation uk product parallel trade occur party italy exploit price differential purchasing product market germany low price enforce selling government spain purchaser market high price poland agree parallel trade permit single europe market rule european union glaxosmithkline international derive benefit profit resale high price asia pacific japan result management believe european region middle east africa turnover market invoice basis present latinamerica properly represent consumption product canada market glaxosmithklineemployeesbase market instrumental promotion group product market create product sale final consumption cer represent turnover growth constant exchange rate represent growth market follow tablegive adjustment actual exchange rate analysis turnover quarter give financial record pagesto orderto restate turnover market europe turnover create basis adjustment glaxosmithkline estimate base recent datum independent external source value sterle relevant exchange rate management believe turnover create basis report turnover market provide well reflection performance business market europe total turnover europe region unaffected restatementoperate financial review prospectsglaxosmithkline usa international usa report flat turnover year despite significant internationalregion report year year turnover growth impact generic competition paxiland wellbutrin exclude centstrong growth asia pacific upeight percent sale product turnover grow cent latin america upeightper centwasoffset flat sale australia business represent cent total pharmaceutical turnover decline percent subsahahraafricaeightper cent middle eastnorth africa percent canada canada sale decline generic erosion paxil ir advairmaintaine strong growth sale million exclude element canada grow cent cent adversely affect sale constituent product floventand sereventwhich show japan record turnover growth cent despite routine decline flonase indicate treatment perennial rhinitis government price reduction implement paxilup grow cent cent sereventup cent valtrexup cent perform particularly offsetting small decline zantacand sale wellbutrinproduct fall cent million zovirax wellbutrin ir srsales fall cent million result generic competition impact partially offset market international key product drive exceptionally strong performance wellbutrin xl growthwere seretide grow cent record sale new oncedaily product achieve sale million million avandiaavandamet grow cent year market million vaccine franchisewhich record growth cent achieve sale million total sale paxil franchise cent million result generic competition paxil irsale consumer healthcare sale decline percent million mitigate growth decline performance paxil cr generate sale cer million cent otc medicine analgesic sale antiviral therapeutic area grow cent hiv dermatological product cent valtrex herpe grow cent gastrointestinal drive bypatient switch suppression therapy respiratory tract sale ofavandiaavandametincrease cent anti smoking control bacterial sale decline cent result generic natural wellness support competition begin quarter coregsale increase cent continue benefit wide oral care range indication nutritional healthcare vaccine grow cent reflect good performance pediarix growth consumer healthcare sale ofthreeper cent billioncomprise otc medicine sale increase oftwo europe cent nutritional healthcare sale increase offiveper cent discussion individual market performance europe oral care sale increase offourper cent region aturnover create basisrather aturnover invoice basis otcmedicine europe region contribute cent pharmaceutical turnover otcmedicine sale billion cent sale overall turnover growth region growthfrom smoking control product usaup cent cent good growth record spain andsouthernand europeup centhelpe offset decline eastern europe government healthcare reform include price dermatological product weredown cent reimbursement restriction adversely affect turnover generic competition cutivate usa expansion france italy germany panadol brand international market helpedanalgesic grow seven cent seretide glaxosmithkline large selling product europe grow cent report notable growth inspain uk july glaxosmithkline obtain theotcmarkete right seretideand constituent product sereventand flixotidegrew usa orlistat fdaapprove prescription product obesity cent management market roche xenical decline sale theherpe franchise mainly result oral care generic competition zoviraxpartially offset patient oral care sale billion cent strong switch new product valtrex growth internationalofnineper cent lead seroxatsale cent reflect generic competition sensodyne polidentand poligripbrand inthe ukand france nutritional healthcare antibacterial sale decline cent generic sale nutritional healthcare product grow cent competition region billion lucozade grow seven cent million vaccine grow seven cent drive thehepatitis franchise andinfanrix glaxosmithkline operate financial review prospect year continued trading profit statutory result trade profit overall trading margin decline percentage point group reporting result statutory basis trading profit million decline cent sterle analysis trading profit subsequent discussion term constant exchange rate trading profit increase compare result statutory result cent margin decrease percentage point reflect completion merger manufacturing restate growth restructure programme low charge relate cer programme deliver future cost saving offset high turnover legal provision increase rd expenditure cost sale sell general profit taxation statutory result administration analysis discussion profit taxation relate research statutory performance development trading profit operating incomeexpense royalty income group adopt uitf abstract revise operate expense abstract relate share hold esop trust share option award comparative information income equity investment restate accordingly trade profit profit tax disposal reduce million net asset st december million operating expense include litigation cost provision cost sale relate legal claim withdraw product product cost sale percentage turnover remain line withdrawal antitrust matter claim respect sale prior year reduce merger manufacturing restructuring marketing reimbursement income equity investment cost offset significant weakening dollar disposal include equity investment carrying value relative year loss high margin paxil irand adjustment arise stock market change product disposal wellbutrin srsales generic adverse product mix equity investment sale merger manufacturing restructuring cost nil million operate expense million year compare million charge reflect provision sell general administration relate litigation matter legal matter partly off sell general administration sga cost decline minor product divestment sale equity investment cent seven cent sterling term reflect saving income net charge legal provision gain general administration partly offset increase sale equity investment low compare advertising promotion selling cost cost year increase cent account percentage point increase total sga general administration cost share profitslosse joint venture associate decline cent account percentage undertaking point reduction total sga low charge share profit associate arise principally relate programme deliver future cost saving equal group hold inquest diagnostic inc percentage point reduction total sga general expense reduction equal percentage point decline disposal ofinter associates total sga reduction partly offset high group dispose million share provision legal matter equivalent percentage point investment quest diagnostic inc cash proceedsof increase total sga net currency movement million reduce group shareholde overall reduction percentage point relative st december cent recognise forexpense express percentage turnover chargeof millionfor goodwill previously write reservesa profit million recognise high provision legal matter include charge million inquarter relate introduction ibnrincurre report actuarial technique determine net interest payable reasonable estimate group exposure unasserted interest payable claim relation number product liability matter investment income research development share interest payable associate rd expenditure increase seven cent reflect increase clinical trial activity pharmaceutical rd expenditure represent cent pharmaceutical turnover year net interest payable increase compare largely result high average effective group interest rate high borrowingsoperate financial review prospectsglaxosmithkline profit ordinary activity taxation statutory research development result research development rd increase cent take account net operating incomeexpense reflect increase clinical trial activity pharmaceutical rd contribution associate business disposal net interest expenditure represent cent pharmaceutical payable statutory profit tax million compare turnover year million increase cent cent decline sterling trading profit trading profit million cent decrease trading profit business performance cent decline sterle term compare business performance trading margin decline percentage point year business performance compare net currency movement primary performance measureuse management margin decline percentage point reflect high rd present exclude merger item integration expenditure high cost ofsale favourable product restructuring cost disposal business management mixand higherprovisionsfor legal matter partially offset cost believesthat exclusion item providesa well comparison saving initiative general administration low charge business performance period present related toprogrammesto deliver future cost saving completion programme group reporting result statutory basis analysis trading profit taxation business performance profit subsequent discussion compare result business performance result accordingly information analysis discussion profit taxation provide supplement contain inthe consolidated relate tostatutory performance business statement profit loss pagesandprepare performance accordance ukgaap operating incomeexpense restate growth royalty income cer operating expense turnover cost sale income equity investment sell general disposal administration research development operating expense include litigation cost provision trading profit relate legal claim withdraw product product withdrawal antitrust matter claim respect sale marketing reimbursement income equity investment cost sale disposal include equity investment carry value cost salesincreaseda percentage turnover result adjustment arise stock market change product disposal significant weakening usdollar relative loss equity investment sale high margin paxil ir wellbutrin sr sales generics andan adverseproduct mix operate expensewasmillion year compare million charge reflect provision sell general administration relate tolegal matter partly offset minor product sgacost decline twoper centseven cent sterling term divestment sale equity investment income reflect saving general administration partly offset increase advertising promotion selling cost share profitslosse joint venture associate cost increase percent account undertaking percentage point increase total sga general share profit associate arise principally administration cost decline percent account group hold inqu diagnosticsinc percentage point reduction total sga low chargesrelate programme deliverfuture cost saving disposal ofinter associate equal percentage point reduction total sga group dispose million share general expense reduction equal percentage investment quest diagnostic inc cash proceed point decline total sga reduction partly offset million reduce group shareholde higherprovisionsfor legal matter equivalent percentage st december cent recognisinga point increase total sga net currency movement charge million goodwill previously write overallreduction percentage point relative reservesa profit million recognise forexpense express percentage turnover high provision legal matter include charge million quarter relate introduction ibnrincurre report actuarial technique determine reasonable estimate group exposure unasserted claim relation number product liability matter glaxosmithkline operate financial review prospect year continue irs claimsfor year upheld group net interest payable additionally liable interest late paymentestimate interest payable billion net federal tax reliefat investment income st december give totalof billionfor year group expect filea petition thetax share interest payable associate claim april include claim refund taxis ask tax court consolidate irs claim year single triala provisional trial date claim set october net interest payable increase compare largelyas result high average effective group interest rate higher similar tax issue remain open date borrowing glaxosmithkline expect receive substantial claim irs yearsglaxosmithkline continue believe profit ordinary activity taxation business profit report subsidiary period date performance pay taxis usa sufficient take account net operating incomeexpense reflect activity operation contribution associate net interest payablestatutory thegroupis continue discussion inland revenue proffit taxwasmillion compare withbusiness respect uk transfer pricing dispute performance profit tax million increase oftwoper centdecline sterle term cent glaxosmithkline use good advice determine transfer pricing methodology seek manage transfer pricing merger manufacturing restructuring issue satisfactory conclusion basis ofexternal merger manufacturing programme substantially professional advice continue believe adequate complete consequently group reporting provision liability likely arise open assessment statutory result cost programme million million tax continue wide difference view group irs inland revenue relevant taxation taxationauthoritie open issue exist ultimate liability matter vary amount provide restate dependent outcome litigation proceeding business performance negotiation relevant tax authority merger restructure disposal show annual report provision subsidiary taxation arise distribution profit total retain overseas subsidiary associate undertaking ground remittance profit retain st december integrate nature group worldwide operation require way incremental tax arise involve significant investment research strategic manufacture limited number location consequential earning growth crossborder supply route numerous endmarket give rise restate cer complexity delay negotiation revenue authority statutory earning profit individual group company liable basic earning share p p tax disagreement revenue authority basic earning ad intragroup transaction particular price good transfer group company different tax adjust earning jurisdiction produce conflict claim revenue adjust earning share p p authority profit tax individual territory adjust earning ad resolution issue continue fact life weight average number glaxosmithklinethe group open issue revenue share millions authorities usa uk japan canadaby far large relate glaxo heritage product respect adjust earning adjust earning share present internal revenue service irs uk inland revenue order illustrate business performance compete contradictory claim year business performance glaxosmithkline attempt settle dispute primary performance measure management direct discussion irs subsequently present exclude merger item integration discussion uk authoritie term restructure cost disposal business management double tax convention country believesthat exclusion item providesa well comparison discussion terminate july th january ofbusinessperformancefor period presentedfor irs issue notice deficiency year completion programme group reporting claim additional taxis billion nd april result statutory basis group file petition tax court dispute irs claim seek refund billion taxeson th january irs issue notice deficiency year claim additional taxis billionoperate financial review prospectsglaxosmithkline adjust earning increase cent adjust earning group large business pharmaceutical share increase cent reflect reduction market complex arrangement rebate weight average number share result group discount allowance follow briefly describe share buyback programme interest cost programme nature arrangement existence group impact group earning pharmaceutical business actual rate exchange adjust earning share medicaid programme stateadministere decline cent adverse currency impact ep programme provide assistance certain poor percentage pointsreflect significant weaken vulnerable patient medicaid drug rebate dollar relative compare cent adverse programwas establish reduce state federal currency impact turnover difference principally arise expenditure prescription drug glaxosmithkline different mix currency profit compare turnover participate provide rebate state provision medicaid rebate calculate base specific statutory eps pence compare term individual state agreement combination pence sterling base decline statutory eps historical experience product population growth cent reflect significant weakening dollar anticipate price increase impact contracting exclude effect ofcurrency statutory eps grow cent strategy reflect completion group merger restructure programmesin underlie business growth glaxosmithkline arrangement certain key party party able buy product wholesaler dividend low price chargeback represent difference board declare fourth interim dividend ofpence invoice price wholesaler indirect customer share make total year ofpence share contractual discount price provision estimate compare total dividend penny share chargeback calculate base thetermsofeach equivalent dividend receivable adr holder iscent agreement historical experience product growth rate ad base exchange rate dividend customer rebate offer key manage care group exdividend date th february purchasing organisation direct indirect pay th april shareholders adr holders record customer arrangement require customer th february achieve certain performance target relate value product purchase formulary status predetermine critical accounting policy market sharesrelative competitor provision consolidatedfinancial statement prepare accordance rebate estimate base specific term ukgenerally accept accounting principle follow agreement historical experience product growth rate accounting policy approve board describe cash discount offer customer encourage noteto financial statement accounting policy prompt payment accrue time management require estimate assumption invoice adjust subsequently reflect actual affect amount asset liability revenue expense experience report thefinancial statement actual amount result differ estimate follow consider historical experience customer return critical accounting policy adopt glaxosmithkline record provision estimate sale return apply historical experience customer return turnover amount invoice market relate information revenue recognise title risk loss pass stock level wholesaler anticipate price increase customerand reliable estimate relevant andcompetitor activity deduction gross turnover reduce rebate discount reconciliation gross turnover net turnover allowance product return give expect give pharmaceutical business follow vary product arrangement buy group arrangement purchase organisation dependent submission claim time initial gross turnover recognition saleprovision aremade time sale estimate rebate discountsor allowancespayable usgovernment state programme returnsto base available market information chargeback historical experience amount estimate manage care group purchasing fully reflect final outcomeandtheamount organisation rebate subject change dependent thing cash discount type buy group product sale mix level provision customer return reviewedand adjust quarterlyin light historical experience actual rebate discount allowance give total deduction return change arrangement future event net turnover cause assumption theprovisionsare base change affect future result group glaxosmithklineoperate financial review prospect year continue total provision rebate discount allowance return intangible asset pharmaceuticals business st december intangible asset acquire glaxosmithkline st december wereas follow party cost acquisition capitalise licence compound development amortise estimate st st december december useful life exceed year estimate useful life review annually impairment review undertake event occur question carry value usgovernment state programme asset brand acquire business capitalise chargeback independently separable longterm manage care group purchasing value group brand amortise estimate organisation rebate useful life exceed year end cash discount useful economic life foresee brand customer return amortise subject annual impairment review impairment review base riskadjusted future cash flow total discount appropriate riskfree interest rate future cash flow base business forecast amonthly process operate monitorstock level inherently judgemental future event cause value wholesalersfor abnormal movement process usesgross intangible asset impair sale volume prescription volume base party datum adverse effect future result group source information receive key wholesalersthe aim maintain stock consistent level year year pension postretirement benefit base pattern consumption cost provide pension postretirement benefit charge profit loss account accordance ssap basis pharmaceutical stock level wholesaler period benefit derive distribution channel st december estimate employee service cost assess accordance month ofturnover calculation advice receive independent actuary basis use party information accuracy assumption select management assumption include totally verify believe sufficiently reliable future earning pension increase discount rate expect purpose long term rate return asset disclose noteto financial statement employee cost expect long term legal dispute rate return asset determine base long term glaxosmithkline provide anticipate settlement cost government bond rate adjust risk current market reasonable estimate likely outcome expectation note give additional disclosure dispute andlegal otherexpense arise fromclaim require frs retirement benefit selection different thegroupthe company director take legal advice assumption affect future result group establish provision take account insurance agreement regard relevant fact product right goodwill circumstance matter accordance accounting addition critical accounting policy outline requirement provision product liability claim certain accounting policy product right goodwill deem product anincurre report basis important respect balance sheet prepare sufficient history claim settlement accordance accounting principle usgaap available provision unasserted merger glaxo wellcome smithkline beecham claim claim reasonable estimate likely account acquisition give rise product right outcome ultimate liability pende billion goodwill billion recognise unasserted claim vary amount provide goodwill product right determine indefinite dependent outcome litigation proceeding life amortise review annually investigation possible settlement negotiation impairment impairment review assess business projection prepare group annual budgeting planning impairment fix asset process determine impairment value carry value fix asset subject depreciation goodwill occur business projection include amortisation review impairment assumption future event change future event indication value asset impair cause assumption business projection change impairment determine reference high net consequent adverse effect future result group realisable value value use measure reference risk report usgaap adjust future cashflow discount appropriate riskfree interest rate future cashflow base business forecast inherently judgemental future event cause assumption impairment review change consequent adverse effect future result groupoperate financial review prospectsglaxosmithkline financial position resource financial position group observe stringent procedure use specialist skill manage environmental risk activity environmental restate issue date operation modify discontinue report responsibility environment goodwill health safety page noteto financial intangible fix asset statement legal proceeding glaxosmithkline believe tangible fix asset facility adequate current need investment investment fix asset glaxosmithkline heldinvestmentswith carrying value st december ofmillion million equity investment market value st december million stock million investment include associate debtor joint venture mainly equity share hold liquid investment derive directly group business investment cash bank include stake company group research current asset collaboration provide access biotechnology loan overdraft development potential interest interest company creditor arise business divestment creditor amount year debtor net current asset debtor increase reflect timing yearend total asset current liability receipt higher defer tax asset insurance receivables additional cash contribution ukpension plan loan creditor provision creditor amount year group carry provision million st december provision liability charge respect estimate future liability million relate legal dispute net asset million relate pension postretirement call share capital benefitsfor employee share premium account provision tax legal dispute reserve indemnify disposal liability cost manufacture profit loss account restructure merger integration extent equity shareholder fund balance sheet date actual constructive obligation exist reasonably estimate nonequity minority interest equity minority interest net debt capital employ group net debt st december comprise tangible fix asset total costof group tangible fix asset cash liquid investment st december billion net book value borrowing repayable year billion land building represent billion borrowing repayable year plant equipment billion computer software billion net debt asset construction billion glaxosmithkline invest million new andrenewal property plant net debtincreasedby million million equipment mainly relate large number project primarily tothe negative impact foreign exchange improvement expansion facility worldwide operate cash flow redemption preference share site property mainly heldfreehold new investment finance issue subsidiary settlement legal matter group liquid resources st december group acquisition fraxiparine arixtra business capital contractual commitment future expenditure sanofisynthelabo million operating lease commitment million pension glaxosmithkline business sciencebase technologyintensive group continue account pension arrangement highly regulate governmental authority allocate accordance ssap transitional provision significant financial resource renewal maintenance frs disclose pension asset liability group property plant equipment minimise risk interruption st december net deficit allow deferred production achieve compliance regulatory taxation million millionspecial cash standard number process use chemical hazardous contribution million reduce material funding deficit uk plansthis position review annually andfurther contribution appropriate glaxosmithklineoperate financial review prospect financial position resource continue shareholder fund commitment contingent liability summary movement equity shareholder fund financial commitment summarise noteto set financial statement commitment contingent liability obligation respect short longterm debt set restate noteto financial statement contingent liability noteto financial statement net debt begin yearas previously report amount provide pension postretirement benefit prior period adjustmentimplementation restructuring integration plan legal environmental uitf revise uitf dispute set innoteto financial equity shareholdersfund begin statement provision liability charge ofyeara restate profit year contractual obligation commitment dividend follow table set group contractual obligation share issue exercise share option commitment fall payment share purchase investment esopshare total yr yrs yrs yrs exchange movement goodwillwrittenback loan unrealise lossprofit ondisposal finance lease obligation intellectual property operating lease tax exchange movement commitment unrealise gain intangible fix asset end year tangible fix asset commitment equity shareholder fundsincreasedfrom million total st december million st december increase arise retain earningspartly offset share group enter number research collaboration purchase cancelledor hold astreasury sharesand develop new compound pharmaceutical exchange movement overseas net asset company term arrangement include fee equity investment loan commitment fund share purchase specify level research addition group esop trust market purchase agree payment future milestone share glaxosmithkline plc nil share hold achieve agreement relate compound trust satisfy future exercise option award early stage development milestone payment group share option award scheme proportion continue number year compound share hold trust respect award rule successfully development process generally scheme require company satisfy exercise close product marketing approval great market purchase issue new share share possibility success payment show represent hold trust match option award grant maximum pay milestone achieve diminish dilutive effect new share issue shareholder number commitment license capital earning agreement principally withtheravance inc tanabe rd october glaxosmithkline announce second seiyaka co ltd exelixis inc human genome sciencesinc share repurchase programme billion annual pension commitment provide note financial general meetingshareholder renew approval statement employee cost glaxosmithkline market purchase share exact time future purchase depend contingent liability market condition factor glaxosmithkline follow table set contingent liability comprise purchase total million share cost billion discount bill performance guarantee item arise programme total share purchase million normal course business expect share cost million cancel remain expire million share cost million hold treasury share total yr yrs yrs yrs st december esop trust hold million guarantee glaxosmithkline share carry value million contingent liability market value million future exercise share option share award total operate financial review prospectsglaxosmithkline normal course business group provide investment appraisal indemnification guarantee respect business disposal glaxosmithkline formal process assess potential legal dispute subsequently arise investment proposal order ensure decision align provision reasonable estimate group overall strategy process include analysis likely outcome dispute include note impact profitand assessment return base financial statement provision liability discount cash flow discount rate perform financial charge analysis decide internallyto allow determination extent investment cover group cost capital specific group policy provide settlement cost investment discount rate adjust account assert claim environmental dispute reasonable country risk weighting estimate prior point liability record legal environmental cost discuss risk factor capitalexpenditure financial investment pagesto cash payment fortangible intangible fix asset amount glaxosmithkline use good advice determine transfer million milliondisposal realise pricing methodology basis external professional million million cash payment acquire equity advice continue believe adequate provision investment ofmillion million madein liability likely arise open taxation assessment year sale equity investment realise million ultimate liability matter vary significantly million amount provide dependent outcome litigation proceeding negotiation relevant tax authority future cash flow discuss noteto financial statement group expect future operate cash flow taxation sufficient fund operate debt service cost satisfy normal level capital expenditure meet obligation cash flow exist licensing agreement meet routine outflow include tax dividend subject risk factor discuss summary consolidated cash flow statement set page group time time additional demand finance acquisition restate group access source liquidity bank financial institution addition cash flow net cash inflow operating activity operation forsuch need dividend joint venture associate undertaking payment policy return investment servicing finance group company responsible monitoring manage taxation pay work capital term sale collection supplier capital expenditure financial investment paymentsreflect local commercial practice acquisition disposal equity dividend pay uk company uk subsidiarie net cash inflowbefore management policy ensure supplier pay time particular liquid resource finance uk company seek management liquid resource settle term payment supplier agree share purchase term transaction financing ensure supplier aware agree term increasedecreasein cash year ofpayment abide term payment reconciliation net cash flow movement net debt policy include arrangement accelerate payment small supplier net debt begin year payment performance increasedecreasein cash year st december average number day purchase cash outflowfrom management represent trade fix asset creditor parent liquid resource company wasnil nil respect company net increase longterm loan uk subsidiarie aggregate wasday day net repayment shortterm loan exchange movement net debt end year net cash inflow operating activity million adecreaseof million arise thenegative impact foreign exchange settlement legal matter glaxosmithklineoperate financial review prospect financial position resource continue treasury policy liquid asset surplus immediate operating requirement group company generally investedand manage glaxosmithkline plcreportsin sterling paysdividend centrally corporate treasury requirement group sterling profit role corporate treasury glaxosmithkline company operating finance meet possible manage monitor group external internal central resource funding requirement financial risk support group corporate objective treasury activity govern policy external borrowing mainly manage centrally corporate procedure approve board monitor treasury comprise portfolio long mediumterm treasurymanagement group instruments shortterm finance glaxosmithkline maintain treasury control system procedure glaxosmithkline hold issue derivative financial monitor foreign exchange interest rate liquidity credit instrument trading purpose group treasury policy financial risk specifically prohibit activity transaction financial instrument undertake manage risk arise liquidity underlie business activity speculation group operate globally primarily subsidiary company establish market group trade fund maturity counterparty risk nature group business patent protection group invest centrally manage liquid asset ingovernment ofthe product group portfolio group bond shortterm corporate debt instrument minimum product compete largely product efficacy price shortterm credit rating ap money market fund sell margin sufficient cover normal operating cost credit rating aaaaaa fully collateralise preference share group operating subsidiary substantially cash generative investment credit rating show standard poor operate cash flow fund investment research moodys investor service respectively development new product routine outflow capital group manage net borrowing requirement expenditure tax dividend repayment mature debt portfolio long mediumterm borrowing include bond group time time additional demand shortterm finance billion finance share purchase acquisition commercial paper programmein april million glaxosmithkline operate high level interest cover year cent coupon bond million year low level net debt relative itsmarket capitalisation cent coupon bond amillion year cent addition tothe strong positive cash flow normal trading coupon bond issue theusshelf registration activity additional liquidity readily available itscommercial establish march paperprogramme shortterm investment group group mediumterm borrowing mature date uncommitted euro medium term note programme billion private financing mature long million issue st december date sterling bond mature longdate dollar march group establish usshelf registration bond mature private financing redeemed billion st december million glaxosmithkline time particular event issue accelerate event increase cost funding group glaxosmithkline longterm debt rating aa treasury operation standard poor aa moodys investors services objective treasury activity manage posttax net agency shortterm ratingsfor paper issue costincome financial operation benefit group group commercial paper programmearea p earnings corporate treasury operate profit centre respectively glaxosmithkline use variety financial instrument include derivative finance operation manage market risk foreign exchange risk management operation financial instrument comprise cash glaxosmithklineforeign currency transaction exposure arise liquid resource borrowing spot foreign exchange contract normal trade flowsin respect external intragroup tradeis hedge glaxosmithkline policy minimise number derivative financial instrument manage exposure overseas operating subsidiary transaction risk market risk treasury operation derivative instrument bymatche local currency income local currency cost principally comprise forward foreign currency contract interest forthispurpose intragroup trading transaction match rate currency swap swap borrowing liquid centrally intragroup payment term manage reduce asset currency require group purpose risk exceptional foreign currency cash flow hedge selectively manage exposure funding risk change foreign management corporate treasury exchange rate interest rate significant proportion group borrowing include glaxosmithkline balance use borrowing liquid asset commercial paper programme dollar benefit regard cash flow operating activity liquidity dollar denominate capital market certain thecurrencie earn tax cost intragroup borrowing swap currency distribution currency business asset require group purpose group seek denominate denominate posttax cost borrowing compare borrowing currency principalasset totheposttax return liquid assetsoperate financial review prospectsglaxosmithkline borrowing denominate swap foreign currency financial asset liability match investment overseas group asset treat analysis net debt give noteto financial hedge relevant net asset statement net debt analysis financial asset liability carry value fair value reconciliation net debt base composition net debt st december give innoteto financial statement financial instrument cent appreciation sterle major currency relate disclosure discussion derivative result reduction group net debt financial instrument quantitative disclosure market approximatelymillion cent weaken sterling riskin accordance requirement financial report major currency result increase standard group net debt approximately million group continue benefit strong positive cash flow interest rate risk management group net debt decrease significantly year glaxosmithkline policy interest rate risk management require st december group purchase net borrowing fix rate increase share market billion ratio forecast net interest payable trading profit financial asset liability st december group use limited number interest rate swap representative treasury policy strategy redenominate external borrowing intothe interest rate coupon glaxosmithkline apply consistently year require group purpose duration swap match significant change policy year duration theprincipal instrument interest rate derivative instrument account hedge relevant asset liability possible group manage centrally shortterm cash surplus borrowing requirement subsidiary company use forward contract hedge future repayment originate currency sensitivity analysis consider sensitivity group net debt hypothetical change market rate assume variable remain constant base composition net debt st december percentage point basis point increase decrease average interest rate result negligible change group annual interest expense equity risk management equity investment classify current asset available sale group manage disposal meet overall business requirement arise group regularly monitor value equity investment enter hedge selectively approval board glaxosmithklineoperate financial review prospect outlook risk factor outlook noteto financial statement legal proceedingsfor discussion patentrelate proceeding group sale growth exist product launch newproduct involve arekey driversof glaxosmithklinesbusiness performanceit anticipate number new product launch generic drug manufacturer seek market generic version typically sale exist product declinedramatically group important product include generic competition introduce eitheron patent expiry seretideadvair avandiazofran wellbutrin xl imitrexlamictal early successful challenge group patent andvaltrex prior expiration group patent glaxosmithkline engage legal proceeding exhibit readiness product validity infringement group patent relate future generic product competitive augmentinpaxil productsthese discuss inrisk factorsbelow wellbutrin sr launch usa noteto financial statement legal proceeding respectively significantimpact group overall turnoverand earning base report international financial reporting standard ifrs glaxosmithkline publish earning guidance weakness intellectual property protection certain group expect todeliver ep percentage country growth constant exchange ratesin low doubledigit range country group operate patent group net debt billion low relative protection significantly weak usa itsmarket capitalisationand position advantage european union addition effort control public health opportunity arise build business crisis develop country south africa brazil consider plan substantial reduction scope risk uncertaintie inherent business patent protection pharmaceutical product particular affect future performance include expect earning country facilitate competition market growth discuss risk factor generic manufacturer unable introduce compete product number year loss risk factor patent protection include abrogation patent right risk uncertaintie relevant group business compulsory licensing likely affect adversely group factor list group think operating result national market expect cause group actual result differ materially material group overall absence adequate patent expect historical result protection limit opportunity look market future sale growth risk rd deliver commercially successful new product risk substantial adverse outcome litigation continue development commercially viable new product government investigation critical group ability replace sale old product noteto financial statement legal proceeding decline expiration exclusive right increase overall discussion proceeding governmental investigation sale develop new product costly lengthy uncertain group currently involve unfavourable resolution process new product candidate fail stage similar future proceeding investigation mayhave process latestage product candidate amaterialadverse effect onthe group financial result fail receive regulatory approval group material provision relate legal proceeding investigation reduce earning new product candidate appear promise development group makeadditional significantprovision relate significant investment fail reach market legal proceedingsandinvestigation future limited commercial success result efficacy safety reduce earning case practice plaintiff bar concern inability obtain necessary regulatory approval claim damage compensatory punitive statutory difficulty excessive cost manufacture infringement amount bear relationship underlie harm patent intellectual property right inability accordingly potentially mislead quantify potential differentiate product adequately exposure claim proceeding investigation type compete successful development group research describe note development pipeline particular importance light recent anticipate expiration patent datum exclusivity recent insurance loss experience include pharmaceutical product number group large selling product liability exposure increase cost ofandnarrowe coverage afford insurance pharmaceutical company risk loss expiration patent marketing exclusivity generally include group patent infringement litigation order contain insurance cost inand group effort generic manufacturer involve challenge continue adjustit coverage profile accept great validity patent orassertion thatthe alternative compound degree uninsured exposurein addition future claim infringe group patent group successful aremade insurance policy insurersmayreservethe right patent protectionor data exclusivity periodsin deny coverage groundsif denial coverage maintain exclusive right market major ultimately upheldon claim result material product particularly usa group high additional chargestothe group earning turnover margin groupsturnoverand margin adversely affectedoperate financial review prospectsglaxosmithkline product liability litigation group hadproduct millionin annual preclinical clinical trial conduct development global sale product arepaxilirand potential product determine safety efficacy augmentinir respect group face product use human follow approval regulatory generic competition andzofran imitrex valtrex lamictaland body notwithstanding effort drug vaccine avandia respect group currently defend introduce marketplace unanticipated effect intellectual property right usa flonase evident group currently defendant number fda approve generic version follow expiry product liability lawsuit include class action involve patent mid substantial claim damage relate group group major product pharmaceutical product subject problem loss patent protection litigation particularly usa inherently unpredictable unexpected effect regulatory proceeding publicity affect excessive verdict justify evidence occur doctor patient confidence pressure competitive class action sweep person prescribe product new effective treatment group product inflate potential liability force introduce adverse impact group revenue number claim pain suffer punitive damage operating result significant particular group face frequently assert product liability action allow intense competition manufacturer generic pharmaceutical represent potentially openende exposure product major market generic product enter market expiration antitrust litigation patent data exclusivity period group products usa increasingly common follow introduction generic product typically lead dramatic loss adverse outcome prosecution patent infringement action sale reduce group revenue margin defendant direct indirect purchaser payer proprietary product expiration date patent initiate antitrust action claim direct indirect group major product set page legal purchaser payer typically file class action proceeding involve patent challengesare setoutin note relief seek include treble damagesand restitution thefinancial statement legal proceeding claimsdamage adverse antitrust verdict subject automatic trebling usa governmental payer control pharmaceutical product subject price control pressure governmental investigation restriction market include japan germany groupoperate globally complex legal regulatory france italy government intervene directly set environment vary jurisdiction failure price addition market major purchaser comply applicable law rule regulation pharmaceutical product governmental agency jurisdiction result incivil andcriminal legal proceeding private health care provider economic power exert usa example group respond federal substantial pressure price term acces formulary state governmental investigationsinto pricing marketing reimbursement ofitsprescription drug product group predict exist control increase investigation result related restitution civil false claim new control introduce reduce group act litigation behalf federal state government margin affect adversely ability introduce new product asrelated proceeding initiate againstthe groupby profitably behalf consumer private payer proceeding example usa group high margin result trebling damage award fine respect sale country pricing pressure significantly violation law criminal proceeding initiate increase implementation pharmaceutical benefit group company individual medicare event state programme control cost ofpharmaceuticalare adopt medicare risk competition price control limitation sale programme initiate outpatient pharmaceutical coverage party competition beneficiariesin government private insurer group operate highly competitive business coverage offer enormous pharmaceuticalsbusiness face competition purchasing power programmecould demand discount proprietary product large international manufacturer implicitly create price control prescription drug producer genericpharmaceutical significant product additionally number state propose implement innovation technical advance intensification price scheme control price senior citizen drug competition competitor adversely affect group programme include importation country bulk operating resultscontinue consolidation pharmaceutical purchasing drug growth number patient cover industry adversely affect group competitive position large manage care institution usa islikely continue consolidation group customer increase implementation medicare amendment increase pricing pressure increase pricing pressure group product trend adversely affect group revenue margin sales usa term implementation medicare pharmaceutical benefit finalise possible quantify impact benefit group financial result glaxosmithklineoperate financial review prospect outlook risk factor continue regulatory control reliance information technology group comply broad range regulatory control group increasingly dependent information technology testing approval manufacturing marketing system includinginternetbase system internal pharmaceutical consumer healthcare product particularly communication communication customer usa countries european union affect supplier significant disruption system cost product development time require computer virus outside incursion reach market uncertainty successfully materially adversely affect group operation stricterregulatory control heighten risk withdrawal taxation regulator ofapprovalspreviously grant reduce effective tax rate group earning benefit revenue result product recall product liability fact portion earning tax favourable rate lawsuit addition case group voluntarily jurisdiction outside ukchange tax law cease marketing product example withdrawal application respect matter transfer pricing lotronexshortly initial launch usa face decline risk double taxation relate portion sale base concern efficacy safety group earning tax favourable rate increase scientifically justify absence regulatory action group effective tax rate adversely affect financial developmentofthe postapproval adverse event profile resultsthe group open issue revenue authority product product class major impact usa uk japan canada far large relate marketing sale product glaxo heritage product respect internal revenue service uk inland revenue compete risk interruption product supply contradictory claimsthese matter discuss note manufacture pharmaceutical product constituent financialstatement taxation material require compliance good manufacturing practice regulation group manufacture site subject review global political economic condition approval fda regulatory agency group conduct substantial portion operation compliance failure supplier key material group outside theuk group management foreign exchange manufacturing facility lead product recall rate discuss operate financial review prospect seizure interruption production delay approval foreign exchange risk management fluctuation exchange new product pende resolution manufacturing issue rate betweensterle currency especially noncompliance result fine disgorgement dollarthe euro japaneseyen materially affect profit interruption supply fine disgorgement remedy group financial result materially adversely affect group financial result group cidra puerto rico facility currently subject group control change inflation interest fdaobservation possible deficiency manufacturing rate foreign currency exchange rate control practicesa refer innoteto financial statement economic factor affect business possibility legal proceeding group undertake business political unrest legal regulatory change nationalisation continuity planning single source certain component bulk jurisdiction group operate factor active material finish product create risk failure materially affect group future result operation supply event regulatory noncompliance physical disruption manufacturing site accounting standard new revise accounting standard rule promulgate risk concentration ofsale wholesaler time time bythe uk internationalaccounte standard usa line pharmaceutical company set board material adverse impact group group sell product small number wholesaler report financial result adoption international addition hospital pharmacie physician group financial reporting standard ifrs change market sale large amount approximately valuation certain financial instrument equity collar cent group pharmaceutical sale group link group investment questdiagnostic expose concentration credit riskin respectofthese option link group strategic alliance theravance wholesaler affected impairment equity investment reflect financial difficulty materially adversely affect group report result gain loss actually group financial result realise significant impact profit loss statement give periodthe group believe complie environmental liability appropriate regulatory requirement concern environmental law jurisdiction impose actual financial statement disclosure company potential obligation group remediate contaminate experienced investigation potential noncompliance site group identify potentially account disclosure requirement result responsible party comprehensive environmental significant penalty response compensation liability act number site remediation cost relate group use ownership human resource sitesfailure tomanage properly environmental risk grouphasapproximatelyemployeesaround result additional remedial cost materially world subject law regulation concern adversely affect group operation noteto employee range discrimination harassment financialstatement legal proceedingsfor discussion personal privacy labour relation vary significantly environmentalrelate proceeding group involve jurisdiction jurisdiction failure comply applicable requirement significant adverse affect groupoperate financial review prospectsglaxosmithkline year accordance ussec disclosure requirement follow pharmaceutical turnover discussion compare result year st december growth rate include review turnover constant result year st december exchange rate cer state sterling growth growth rate include review turnover constant rate find table pharmaceutical turnover exchange rate cer state sterling growth therapeutic area page rate find table pharmaceutical sale total pharmaceutical turnover million therapeutic area page compare million increase cent approximately cent overall growth come exchange price increase growth sterling term cent currency influence group result significantly impact weakness dollar dollar euro japanese yen currency pound hit high level dollar group portfolio turnover new product launch year climb euro gain cent major market year account dollar year dollar fall cent total turnover grow cent million value euro investor weigh impact turnover establish franchise product amount continue unrest iraq tension world million represent cent total turnover concern economy grow cent compare year turnover old product actively promote million world market pharmaceutical decline cent represent cent total turnover global pharmaceutical sale increase cent cer cent sterle billion global pharmaceutical turnover fourth quarter decline cent reflect turnover decline world market value growth cent million europe turnover grow geographic region bn total cer cent million international turnover usa grow cent million turnover decline europe generic competition paxilwhich begin september germany france uk pharmaceutical turnover therapeutic area italy glaxosmithkline ability continue deliver pharmaceutical japan turnover growth despite generic competition asia pacific product primarily exceptionally broad product latin america portfolio fastgrowe highvalue product middle east africa canada include respiratory product seretideadvair billion total cent diabete treatment avandiaavandamet billion cent wellbutrinfor depression market buoyant maintain billion cent emesis treatment zofran double digit growth represent cent global billion cent lamictalfor epilepsy billion prescription pharmaceutical market compare cent cent trizivir hiv billion cent decade ago valtrexfor herpe billion cent coregfor heart disease billion cent pediatric vaccine th september glaxosmithkline hold second position infanrixpediarix billion cent world pharmaceutical market market share cent pfizer market share cent central nervous system cns glaxosmithkline seven product world cns sale grow cent million sale usa pharmaceutical products augmentin avandia europe grow cent international sale grow imigranimitrex seretideadvair seroxatpaxil wellbutrinand cent zofran sale seroxatpaxil glaxosmithkline lead product world market value growth depression anxiety disorder decline cent therapeutic class bn total cer million sale decline cent million cardiovascular follow launch generic paroxetine september central nervous system glaxosmithkline innovative new product paxil cr increase alimentary tract metabolic share total paxil prescription brand generic antiinfective bacterial generic launch cent cent paxil crsale viral fungal exclude vaccine million europeseroxatsale decline respiratory cent million reflect competition pricing pressure international sale grow cent million note datum base month thseptember lead continued strong growth japan glaxosmithkline operate financial review prospect year continue sale wellbutrin depression grow cent metabolic million reflect increase physician awareness worldwide sale metabolic category billion product outstanding efficacy favourable sideeffect profile cent avandiafranchise avandiaand avandamet new oncedaily formulation wellbutrin xl launch grow cent year sale cent september formulation account cent million brand wellbutrinprescription early february avandamet combination avandiaand metformin hci seven cent sale expand avandiametabolic franchise launch limited generic competition wellbutrinbegan usa fourth quarter europe avandiahas benefit january mg dose increase physician acceptance sale million cent franchise benefit eu glaxosmithkline medicine epilepsy lamictal continue approval avandametin december avandiaalso grow region achieve sale million international market sale million cent june fda approve lamictalfor long cent term maintenance treatment bipolar disorder vaccine respiratory sale vaccine grow cent billion support glaxosmithkline continue global leader respiratory infanrixpediarix franchise cent million pharmaceutical sale key product hepatitis franchise decline cent million reflect seretideadvair flixotidefloventand serevent amount competitive pressure usa europe billion cent sale seretideadvair group large product grow cent billion usa glaxosmithkline new pediarixvaccine launch contribute decline sereventand flixotide constituent january pediarixadd protection hepatitis b product seretideadvairis pharmaceutical poliomyelitis theinfanrixcombination result brand world usa sale grow cent few injection infant million cardiovascular urogenital seretide continue perform strongly europe coregsale grow cent million benefit cent international market cent recent datum show highly significant statistical growth prospect advairwere strengthen difference survival coregand metoprolol patient fda approval use treatment ofcopdin fourth heart failure quarter levitra vardenafil new agent treatment erectile old respiratory product ventolinand becotidecontinued dysfunction launch usa august decline patient convert new product europe half year levitrawa research develop bayer agand copromote glaxosmithkline antiviral hiv medicine grow region total billion oncology emesis sale cent sale trizivir glaxosmithkline triple sale zofrangrew cent million drive combination therapy grow cent million lexiva astrong performance cent million hiv launch december initial sale million therapeutic area global sale valtrex receive fda approval august sale zantacfell cent million decline reduce risk transmission genital herpe rise inall region cent million antibacterial antibacterial sale decline cent worldwide cent usa augmentinsussale cent year result generic competition begin quarter usa glaxosmithkline new antibiotic augmentin es children augmentin xrfor adult record combine sale million spite generic competitionoperate financial review prospectsglaxosmithkline pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major product total cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory serevent seretideadvair flixotideflovent seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antiviral hiv trizvir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic avandiaavandamet vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovasular urogenital coreg levitra avodart zantac cer represent turnover growth constant exchange rate represent growth actual exchange rate glaxosmithkline operate financial review prospect year continued usa international usa report cent turnover growth year cent turnover growth international region business represent cent total pharmaceutical reflect mixture good growth middle east africa turnover canada japan asia pacific latin america grow strongly mexico rebound follow poor economic condition advairmaintaine strong growth sale million realignment wholesaler stock level drive overall respiratory growth cent adversely affect sale constituent product flovent overall international growth drive seretide seroxatpaxil serevent show decline flonaseindicate avandia partly offset decline zantacand zovirax treatment perennial rhinitis grow strongly cent asia pacific area grow performance seretide sale growth cent central nervous system avandia strong growth number market partly product include sale wellbutrinup cent reflect offset decline cent large market australia performance new day formulation wellbutrin xl reflect reduced sale zybanzantacand old antibiotic paxil sale decline cent launch generic growth japan reflect strong growth paxil serevent paroxetine september glaxosmithkline innovative new valtrexpartly offset decline zovirax zantac product paxil cr increase share total paxilprescription government price reduction brand generic generic launch cent cent paxil crsale million middle east africa area follow trend market growth seretide avandia vaccine sale antiviral therapeutic area grow cent canada growth drive seretide avandia hiv lead strong performance trizivirup cent partially draw sale constituent product valtrex consumer healthcare sale herpe grow cent drive fda approval growth reduce risk transmission genital herpe cer sale avandiaincrease cent benefit otc medicine analgesic launch avandametin november antibacterial sale dermatological decline cent result generic competition begin gastrointestinal quarter coregsale increase cent respiratory tract reflect benefit recent datum show highly smoke control significant statistical difference survival betweencoregand natural wellness support metopropol patient heart failure oral care europe discussion individual market performance europe nutritional healthcare region turnover create basis turnover invoice basis page detail growth consumer healthcare sale cent europe region contribute cent pharmaceutical turnover million comprise otc medicine sale increase overall turnover growth region cent nutritional healthcare sale increase cent good growth record italy central eastern cent oral care sale increase cent europe government healthcare reform include pricing reimbursement restriction adversely affect turnover france otcmedicine spain germany seretide glaxosmithkline large sell overthecounter medicine sale billion cent product europe report notable growth france italy sale smoking control gastrointestinal product uk partly offset expect decline significantly usa primarily flat market condition sereventand flixotide trizivirshowe strong growth private label competition growth smoking control major market region decline sale herpe product recently launch europe sale dermatological franchise mainly result generic competition zovirax product acquire early year helped offset decline partially offset patient switch new valtrexproduct oral care oral care sale billion cent glaxosmithkline sensodyne brand continue grow region nutritional healthcare nutritional healthcare product grow cent billion lucozade sportand lucozade hydroactivecontinue drive growth categoryoperate financial review prospectsglaxosmithkline trading profit statutory result profit taxation statutory result statutory result include merger item integration analysis discussion profit taxation relate restructure cost disposal subsidiary statutory performance restate restate growth operating incomeexpense cer royalty income turnover operate expense cost sale sell general income equity investment administration disposal research development trading profit operating incomeexpense include litigation cost provision relate legal claim withdraw product product withdrawal antitrust matter equity investment cost sale carry value adjustment arise stock market price cost sale reduce percentage turnover result change royalty income product disposal equity benefit arise merger manufacturing restructuring investment sale saving favourable product mix small pricing benefit offset adverse exchange impact merger operating expense million year manufacturing cost incur million million compare million year year low movement reflect high provision product liability antitrust claim partially offset high selling general administration proceed product disposal equity investment sale sell general administration sga cost decline cent reflect reduced merger integration cost operational business disposal excellence cost saving initiative partly offset profit disposal business million reflect increase selling cost support new product launch charge final settlement disposal healthcare relate cost saving programme increase pension cost service business merger integration cost sga grow cent drive selling cost increase account share profitslosse joint venture associate percentage point increase charge relate operational undertaking excellence pension cost increase individually add share profit associate arise principally percentage point cost saving reduce growth group hold inquest diagnosticsinc percentage point produce reduction percentage point relative expense express net interest payable percentage turnover interest payable investment income research development rd decline cent reflect reduced merger integration share interest payable associate cost partly offset increase clinical trial inlicense activity reinvestment merger synergies pharmaceuticals rd expenditure represent cent pharmaceutical turnover net interest payable increase compare largely year result unwind discount provision longterm receivables trading profit statutory trading profit million growth profit ordinary activity taxation statutory cent strong turnover growth cent result demonstrate improved trading margin percentage take account net operating incomeexpense point principally low merger integration cost contribution associate business disposal net interest cost saving derive merger integration manufacturing payable statutory profit tax million compare initiative partly offset charge relate operational million increase cent excellence cost save programme high pension cost glaxosmithkline operate financial review prospect year continue trading profit business performance profit taxation business performance illustrate glaxosmithkline performance analysis analysis discussion profit taxation trading profit subsequent discussion exclude relate business performance merger item integration restructuring cost disposal business management believe exclusion operating incomeexpense item provide well reflection way royaltie income business manage accordingly information provide operate expense supplement contain consolidated statement profit loss pagesandprepare accordance income equity investment ukgaap disposal restate restate growth cer operating incomeexpense include litigation cost turnover provision relate legal claim withdraw product cost sale product withdrawal antitrust matter equity investment sell general carry value adjustment arise stock market price administration change royalty income product disposal equity research investment sale development operating expense million year trading profit compare million yearonyear movement reflect high provision product liability cost sale antitrust claim partially offset high cost sale reduce percentage turnover result proceed product disposal equity investment sale benefit arise merger manufacturing restructuring saving favourable product mix small pricing benefit share profitslosse joint venture associate offset adverse exchange impact undertaking share profit associate arise principally sell general administration group hold inquest diagnosticsinc sell general administration sga cost grow cent reflect increase selling cost support new product net interest payable launch charge relate operational excellence cost save interest payable programme increase pension cost partly offset cost investment income save initiative cost save initiative relatively small restructuring activity estimate operational excellence charge sga share interest payable associate grow cent drive principally sell cost increase pension cost increase add percentage point offset cost save initiative produce net interest payable increase compare largely reduction percentage point express percentage result unwind discount provision long turnover term receivables research development profit ordinary activity taxation business research development rd increase cent reflect performance increase clinical trial inlicense activity reinvestment take account net operating incomeexpense merger synergies pharmaceuticals rd expenditure represent contribution associate business disposal net interest cent pharmaceutical turnover year payable business performance profit tax million compare million increase trading profit eightper cent business performance trading profit million growth ofeightper cent strong turnover growth cent demonstrate improved trading margin point cent compare principally cost saving derive merger integration manufacturing initiative partly offset charge relate operational excellence cost save programme high pension cost focus operational excellence value creation elimination waste bureaucracy programme integral way business manage charge book business performanceoperate financial review prospectsglaxosmithkline merger item restructuring cost disposal business group receive claim additional taxis irs assert legacy company glaxo wellcome owe year merger manufacturing restructure statutory notice deficiency billion glaxosmithkline good progress merger billion tax principally relate allocation profit manufacture restructuring plan merger programme glaxo heritage product usa weresubstantially complete end combine country extent irs successful claim programme produce annual saving exceed interest payable glaxosmithkline estimate publish target billion interest claim date approximately cost million incur year respect billion billion net federal tax relief similar tax merger manufacturing restructure aftertax relief issue remain open date glaxosmithkline expect million net charge million cost receive claim irs year include severance asset writedown professional fee site glaxosmithkline exhaust administrative remedy closure open thegroupplan contest claim additional taxis file petition ustax court trial block drug company inc expect glaxosmithkline acquire block drug january cost incur integrate business million glaxosmithkline continue believe profit report include redundancy asset writedown site closure subsidiary period date pay taxis usa sufficient reflect disposal business activity usoperation profit disposal business million reflect glaxosmithkline use good advice determine transfer final settlement disposal healthcare pricing methodology seek manage transfer pricing service business issue satisfactory conclusion basis external professional advice continue believe taxation adequate provision liability likely arise open restate restate assessmentshowever continue wide difference view group irs ultimate liability business performance matter vary significantly amount provide merger restructure disposal dependent outcome litigation proceeding subsidiarie negotiation relevant tax authority total credit taxation merger restructuring item amount million reflect actual tax rate applicable integrate nature group worldwide operation transaction territory arise involve significant investment research strategic late position taxation taxation theyear manufacture limited number location operate financial review prospect page consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax disagreement revenue authority intragroup transaction particular price good transfer group company different tax jurisdiction produce conflict claim revenue authority profit fall tax individual territory resolution issue continue fact life glaxosmithkline group open issue revenue authority usa uk japan canada far large relate glaxo heritage product usa usa number years glaxosmithkline significant open issue relate transfer pricing glaxosmithkline attempt settle dispute direct discussion usinternal revenue service irs subsequently discussion usa uk authoritie term double tax convention country glaxosmithkline understand view tax authority different unable reach agreement discussion terminate july glaxosmithklineoperate financial review prospect year continue earning growth restate restate cer statutory earning basic earning share p p basic earning ad adjust earning adjust earning share p p adjust earning ad weight average number share millions adjust earning adjust earning share present order illustrate business performance primary measure management adjust earning increase seven cent adjust earning share increase cent reflect reduction weight average number share result group share buyback programme interest cost programme impact group earning adjust earning shareincrease cent sterling term compare cent cer term adverse currency impact eps cent year reflect significant weakening dollar relative compare cent adverse currency impact turnover difference principally arise different mix currency profit compare turnover take expense taxation business disposal result basic eps pence compare penny diluted ep pence compare pence merger manufacturing restructuring cost low result sterling base growth basic eps cent significantly higher cerbase growth adjust ep despite overall negative impact currency dividend board declare fourth interim dividend penny share make total year penny share compare total dividend penny share glaxosmithkline expect similar increase total dividend declare allocation quarterly dividend rebalance glaxosmithkline intend increase interim dividend penny pence remainder total dividend year allocate fourth quarter dividendglaxosmithkline financial statement section comprise director statement responsibility independent auditor report financial statement financial statement consist principal financial statement support note director statement responsibility independent auditor report financial statement consolidate statement profit loss consolidate statement total recognise gain loss consolidate statement cash flow consolidated balance sheet reconciliation movement consolidate equity shareholder fund company balance sheet note financial statement presentation financial statement accounting policy new accounting policy future requirement exchange rate merger glaxo wellcome smithkline beecham segment information merger item restructuring cost divest business operate incomeexpense operating profit joint venture associate undertaking net interest payable taxation earning share dividend goodwill intangible asset tangible fix asset fix asset investment equity investment stock debtor creditor provision liability charge contingent liability net debt commitment share capital share premium account nonequity minority interest reserve legal proceeding post balance sheet event relate party transaction acquisition disposal financial instrument relate disclosure employee cost employee share scheme reconciliation accounting principle principal group company glaxosmithkline director statement responsibility director statement responsibility relation internal control financial statement board audit committee review director assessment risk internal control framework operate glaxosmithkline consider effectiveness responsible ensure maintenance proper accounting system internal control operation inthegroup record disclose reasonable accuracy financial year cover report date approval position group time financial board director statement beprepare comply company act thecombine code require law prepare financial statement board consider glaxosmithkline plc apply principle financial period true fair view state thecombine codeon corporate governance financial affairs company group end report council asdescribe corporate governance financial period ofthe profit loss period pagesto complied itsprovisionsexcept responsible ensure operation system describe page internalcontrol take reasonable step safeguard require listing rule financial service authority asset group prevent detect auditor haveconsidere director statement fraud irregularity compliance relation point thecombinedcode financial statement year end st december specify theirreview comprise principal statement support note set infinancial statement onpage report annual report director confirm suitable accounting policy annual report year end st december consistently apply preparation financial statement comprise report director remuneration report support reasonable prudent judgement estimate financial statement additional information investor asnecessary applicable accounting standard follow approve board director sign financial statement prepare go behalf concern basis responsibility auditor relation financial statement set independent auditor report pageopposite financial statement year end st december include annual report publish sir christopher gent hardcopy print form available website chairman director responsible maintenance integrity ndmarch annualreport website accordance uk legislation govern preparation dissemination financial statement access website available outside uk comparable legislation different director remuneration remuneration report page report set remuneration policy operate glaxosmithkline disclosure director remuneration disclosable information relate director officer interest prepare accordance company act complie section b thecombine codeon corporate governance go concern basis make enquiry director reasonable expectationthat group company adequate resource continue operational existence foreseeable future forthis reason continue adopt go concern basis inprepare financial statementsglaxosmithkline independent auditor report members glaxosmithkline plc audit financial statement comprise basis audit opinion consolidated statement profit loss consolidate statement conduct audit accordance withauditingstandard total recognise gain loss consolidate statement issue theauditing practice board audit include cash flow consolidated company balance sheet examination test basis evidence relevantto amount relate note prepare historical cost disclosure financial statement andthe auditable convention accounting policy set statement thedirectorsremunerationreport include accounting policy audit disclosure assessment significant estimate judgement required schedule company act thedirector preparation financial statement contain thedirectorsremunerationreport auditable accounting policy appropriate companyscircumstance consistently apply adequately disclose respective responsibility ofdirector andauditor plan perform audit obtain thedirector responsibility prepare theannualreportand information explanation consider necessary thefinancial statement accordance applicable united order provide sufficient evidence reasonable kingdom law accounting standard set assurance thefinancial statement auditable statement ofdirector responsibility thedirector directorsremunerationreport free material responsible prepare thedirectorsremunerationreport misstatement cause fraud irregularity responsibility audit financial statement error form opinion evaluate overall auditable thedirectorsremunerationreport accordance adequacy presentation information financial relevant legal regulatory requirement united statements kingdom auditing standard issue auditing practice board report include opinion prepare opinion company member body accordance opinion section company act purpose give opinion accept assume responsibility financial statement true fair view state purpose person report affair company group st december show hand come save expressly andthe profit cash flow group theyear agree prior consent writing end financial statement properly prepare report opinion financial accordance company act statement true fair view financial part thedirectorsremunerationreport require statement auditable thedirectorsremuneration schedule company act report properly prepare accordance properly prepare accordance company act company act report opinion thedirectorsreportis consistent financial statement company keep proper accounting record receive information explanation require audit information specifiedby law regardingdirector remuneration transaction disclose pricewaterhousecooper llp read information contain theannualreport charter accountant register auditor consider implication report aware embankment place apparent misstatement material inconsistency london england financial statement information comprise financial summary description business unauditable directorsremunerationreport joint statement ndmarch chairman chief executive officer operate financial review prospect corporate governance statement review corporate governance statement reflect company compliance thenineprovision frc combine codespecified review list rule financial service authority report require consider theboard statement internal control cover risk control orform opinion effectiveness company group corporate governance procedure risk control procedure glaxosmithkline consolidate statement profit loss year end st december statutory note turnover cost sale gross profit sell general administrative expenditure research development expenditure trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking profit disposal interest associate product divestment lossprofiton disposal business profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation equity minority interest preference share dividend earning profit attributable shareholder basic earning share p adjust earning share p dilute earning share p profit attributable shareholder dividend retain profit consolidate statement total recognise gain loss year end st december profit attributable shareholder exchange movement overseas net asset unrealise lossprofit disposal intellectual property tax exchange movement unrealise gain total recognise gain loss relate year prior year adjustment implementation uitf revise uitf total recognise gain loss consolidate statement profit lossglaxosmithkline merger merger business restructuring business restructuring performance disposal statutory performance disposal statutory restate subsidiary restate restate subsidiary restate p p p p p p restate restate glaxosmithkline consolidate statement cash flow year end st december reconciliation operating profit operating cash flow restate restate note operate profit depreciation impairment asset write amortisation goodwill intangible fix asset loss sale tangible fix asset profit sale equity investment increasein stock increase trade debtor increasedecreasein trade creditor decreaseincrease provision net cash inflow operating activity cash flow statement net cash inflow operating activity dividend joint venture associate undertaking return investment servicing finance taxation pay capital expenditure financial investment acquisition disposal equity dividend pay net cash inflowbefore management liquid resource finance management liquid resource finance increasedecreasein cash year reconciliation net cash flow movement net debt net debt begin year increasedecrease cash year cash outflowinflow management liquid resource net increase longterm loan net repayment shortterm loan net repayment obligation finance lease net noncash fund subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year consolidated statement cash flowglaxosmithkline analysis cash flow note restate restate return investment servicing finance interest receive interest pay dividend pay minority shareholder dividend pay preference share capital expenditure financial investment purchase tangible fix asset sale tangible fix asset purchase intangible asset product divestment purchase equity investment sale equity investment acquisition disposal purchase business disposal business investment joint venture associate undertaking disposal interest associate financing issue share capital redemption preference share issue asubsidiary share capital purchase cancellation share capital purchase hold treasury share proceed share employee share option finance cash flow increase longterm loan repayment longterm loan net repayment shortterm loan net repayment obligation finance lease analysis change net debt exchange cash flow cash bank overdraft debt year commercial paper eurobond mediumterm note debt year eurobond mediumterm note private financing management liquid resource liquid investment net debt information significant change net debt notenet debt glaxosmithkline consolidated balance sheet st december restate note goodwill intangible asset tangible asset investment fix asset equity investment stock debtor liquid investment cash bank current asset loan overdraft creditor creditor amount year net current asset total asset current liability loan creditor creditor amount year provision liability charge net asset capital reserve call share capital share premium account reserve profit loss account equity shareholder fund nonequity minority interest equity minority interest capital employ approve board nd march sir christopher gent chairman reconciliation movement consolidate equity shareholder fund year end st december restate note equity shareholder fund previously report prior period adjustment implementation uitf revise uitf equity shareholder fund begin ofyeara restate total recognise gain loss period dividend ordinary share issue ordinary share purchase cancel ordinary share purchase hold treasury share proceed share employee share option employee share scheme goodwill write exchange movement goodwill write reserve equity shareholder fund end year glaxosmithkline company balance sheet st december note share subsidiary company cost fix asset amount owe group undertaking taxation cash bank current asset dividend payable amount owe group undertaking creditor amount year net current liability net asset capital reserve call share capital share premium account reserve profit loss account equity shareholder fund approve board nd march sir christopher gent chairman glaxosmithkline note financial statement presentation financial statement additional information accordance requirement usgenerally accept accounting principle gaap include description business note financial statement notea statement glaxosmithkline major global healthcare group difference reconciliation net income shareholder engage creation discovery development manufacture equity uk gaap provide marketing pharmaceutical product include vaccine overthecounter otc medicine healthrelate consumer presentation statement profit loss product glaxosmithkline principal pharmaceutical product year acolumnar presentationwas include medicine follow therapeutic area adopt statementof profit loss order illustrate central nervous system respiratory antiviral antibacterial underlie business performancea thiswasthe primary measure vaccine oncology emesis metabolic cardiovascular management purpose certain itemswere urogenital identify separately andexclude business performance comprise merger integration item include product financial period divestment cost relate previously announce manufacture financial statement cover financial year restructure theeffect disposal subsidiary st january stdecember comparative figure management believe exclusion item provideda financial year st january st december well reflection year way business st january tost december wasmanage give indication performance group term element revenue expenditure composition group local management able influence list subsidiary associate undertaking opinion director principally affect profit completion programme group net asset group give principal group reporting result statutory basis growth rate company note present compare result business performance result statutory result management composition financial statement consider comparison statutory result consolidate financial statement draw accordance business performance result give appropriate indication uk generally accept accounting principle ukgaap group performance period uk accounting presentation trading profit reflect turnover cost sale comprise financial statement comprise cost ofmanufacture external royalty sell general administrative expenditure comprise cost sell consolidated statement profit loss distribution medical support currently market product consolidated statement total recognise gain loss cost administration cost research consolidate statement cash flow development create future product sale consolidate balance sheet reconciliation movement consolidate equity accounting convention shareholder fund financial statement prepare historical company balance sheet cost convention note financial statement permit section company act accounting standard profitand loss account company present financial statement comply withapplicable uk accounting standard consolidate statement total recognise gain loss include accounting principle policy realise profit attributable shareholder reflect preparation financial statement conformity theconsolidate statement profit loss generally accept accounting principle require management unrealised gain loss value group estimate assumption affect report overseas net asset relate foreign currency borrowing amount asset liability disclosure contingent attributable currency movement period asset liability date financial statement tax item report amount revenue expense report period actual result differ estimate reconciliation movement equity shareholder fund comprise item contribute increase decrease financial statement prepare accordance period shareholder fund item include company accounting policy approve board describe note total recognise gain loss period dividend pay propose proceed share issue period cost share purchase treasury share cancellation theshare buyback programme change goodwill arise acquisition prior st january set directly reservesnote financial statement glaxosmithkline accounting policy foreign currency transaction foreign currency transaction group company book consolidation inlocal currency exchange rate ruling date consolidate financial statement include transaction forward rate hedge forward asset liability result cash flow exchangecontract foreign currency asset liability company subsidiary undertaking include employee translate local currency rate exchange rule share ownership plan esop trust balance sheet date forward rate exchange difference group share net asset result joint venture areinclude trading profit associate undertaking revenue financial statement undertaking consolidate revenue recognise profit loss account good st december supply available external customer order undertaking group material interest receivedandwhen title risk loss passesto customer account subsidiary group exercise dominant turnover represent net invoice value deduction influence joint venture group exercise joint control discount give point sale accrual estimate associate group exercise significant future rebate return methodology assumption influence estimate rebate return monitor adjust regularly light ofcontractual historical information interest acquire undertaking consolidate past experience turnover include copromotion income effective date acquisition interest sell consolidated group record share revenue upto date disposal relate cost sale value add tax sale taxis transaction balance subsidiary undertaking exclude revenue eliminate profit take sale subsidiary undertaking sale joint venture associate undertaking expenditure product sell customer outside group expenditure recognise respect good service receive supply accordance contractual term provision goodwill arise acquisition interestsin subsidiary obligation exist future liability respect undertaking joint venture associate undertaking past event obligation reliably represent excess purchase consideration estimate advertising promotion expenditure charge group share separable net asset acquire capitalise profit loss account incur shipment cost inter asa separate item case subsidiary undertaking company transfer charge cost sale distribution cost cost investment case joint venture sale customer include sell general associate undertaking goodwill denominate currency administrative expenditure restructuring cost recognise inwhich acquisition financed case respect direct expenditure business reorganisation acquisition prior goodwill write plan sufficiently detail advanced reserve subsequent disposal asset acquisition appropriate communication affect related goodwill remove consolidated reserve undertake balance sheet date charge consolidated profit lossaccount group interest joint venture account research development thegross equity method group interest associate research development expenditure charge profit undertaking account equity method loss account period incur tangible fix asset research development depreciate defer taxation relief unrealise intragroup profit accordance group policy account extent consider recoverable asset liability overseas subsidiary associate environmental expenditure undertaking joint venture include related goodwill environmental expenditure relate exist condition result translate sterling rate exchange rule balance past current operation current sheet date result cash flow overseas subsidiary future benefit discernible charge profit loss associate undertaking joint venture translate account group determine liability sitebysite basis sterling average rate exchange exchange adjustment record liability time probable arise open net asset profit theyear reasonably estimate liability include group retain overseas subsidiary associate undertaking portion cost portion potentially joint venture translate sterling exchange difference responsible party cost probable arise relate foreign currency borrowing take directly able satisfy respective share cleanup obligation reserve report statement total recognise recovery reimbursement virtually certain gain andlosse record asset translate sterlingasset liability result cash flow pension postretirement benefit overseas subsidiary associate undertaking joint cost provide pension employee postretirement venture report currency hyperinflationary economy benefit charge consolidated profit loss account adjustment aremade reflect current price level loss systematic rational basis base actuarial assumption net monetary assetsis charge consolidated profit loss period benefit derive employee service account difference charge contribution pay include asset liability consolidate balance sheet glaxosmithkline note financial statement account policiescontinue brand value independently fair value business acquire party brand legal dispute value substantial longterm brand provision foranticipated settlement cost sell separately rest business acquire reasonable estimate likely outcome legal brand areamortise estimated useful life long dispute group addition provision year end useful economic life legaland expensesarising fromclaim receivedorother brand foresee disputesin respect product liability claim relate toproduct sufficient history claim settlementsan prior acquire minor brand similar intangible incur report ibnr actuarial techniqueisuse eliminate group balance sheet reserve year determine reasonable estimate group exposureto acquisition unasserted claim productsand provision basis provision ismade unasserted claim tangible fix asset obligation exist dispute possible tangible fix asset state cost provision reasonable estimate cost associate claim depreciation impairment cost acquire develop group party charge profit loss computer software internal use internet site external account incur use capitalise tangible fix asset software site support significant business system expenditure employee share plan lead creation durable asset incentive form share provide employee depreciationi calculate write cost tangible fix share option share award scheme respect certain award asset exclude freehold land equal annual instalment scheme andshare option grant company provide finance expect useful life normal expect useful life esoptrust purchase company share open market major category tangible fix asset review annually meet company obligation provide share employee exercise option award anyexcess fair valueof share date award overthe exercise price freehold building year optionsorawards charge profit loss account leasehold land short lease term period service respect option award building year grant respect share option grant share option plant machinery year exercise account share issue exercise price fixture equipment year additional employer cost respect option award erp system software year charge profit loss account period service computer software year asset liability esop trust include group enterprise resource planning erpsystem software generally balance sheet cost run thetrust charge profit involve significant customisation prior implementation loss account company share hold thetrust deduct expect useful economic life seven year reserve hold value whichrecognisesany maximum year computer software ondisposal shortfall proceed receivable employee exercise tangible fix asset cost relate accumulate ifthere deem permanent impairment value depreciation remove financial statement reflect transfer profit loss account reserve net proceed take consolidated profit loss account goodwill goodwill state cost provision amortisation lease amortisation calculate write cost equal annual leasing agreement transfer group substantially instalment expect useful life useful life benefit risk ownership asset treat normally expect exceed year finance lease asset purchase outright asset include intangible fix asset capital element intangible fix asset leasing commitment show obligation finance intangible asset state cost provision amortisation lease asset hold finance lease depreciate acquire licence patent knowhow marketing right short ofthe lease term useful life asset amortise estimate useful life equal instalment interest element lease rental charge profit long year item capitalise restricted lease operating lease annual rental relate specific compound product charge profit straightline basis lease term develop commercial application estimate useful life determine amortisation charge review annually impairment fix asset andtake account estimate time take bring carry value fix asset review impairment compound product market marketable product indication asset impair anydevelopment cost incur group provision impairment charge profit year areassociate acquire licence patent knowhow concern firstyear impairment review conduct marketing right write profit loss account acquire goodwill intangible asset certain intangible whenincurre consider anindefinite life amortise intangible subject annual impairment test impairment determine byreference high net realisable value value use measure reference discount future cash flowsnote financial statementsglaxosmithkline accounting policiescontinue gain loss foreign exchange contract designate hedge forecast foreign exchange transaction defer investment joint ventures associate include measurement relate foreign currency investment joint venture associate undertaking transaction period occur gain loss balance carry consolidated balance sheet group share sheet hedge accrue take directly reserve oftheir net asset date acquisition post forward premiumsdiscount recognise interest acquisition retain profit loss goodwill life contract arise acquisition net amortisation interest differential interest swap agreement recognise stock profit loss account adjustment ofinter expense stocksare include financial statement low life agreement cost include manufacturing overhead appropriate net realisable value cost generally determined debt instrument firstout basis debt instrument state net proceed adjustedto amortise issue cost debt evenly taxation termof debt group account taxation defer accelerate reason timing difference originate new accounting policy future requirement reverse balance sheet date defer tax asset december urgent issue task force issue abstract recognise extent consider recoverable amend abstract relate account future taxable profit defer tax retain presentation esoptrustsand share option award grant earning overseas subsidiary provide employee requirement mandatory bind commitment distribute past earning future period report require share hold esop trust defer tax measure average tax rate expect show deduction arrive shareholder fund apply period time difference charge profit loss account employee share option expect reverse defer tax liability asset restrict intrinsic loss difference market discount price exercise price date grant comparative datum prior period restate comparabilitytrade profit current asset investment profit tax reduce million current asset investment state low cost net net asset st december million realisable value practicable quantify effect different measurement basis adopt case security acquire significant premium discount maturity value intend hold redemption june council european union adopt cost adjust amortise premium discount life regulation require list company member states tomaturity security float rate bond state cost prepare consolidated financial statement accordance interest income take profit loss account international financial reporting standard ifrs receivable basis glaxosmithklineha complete itsconversion projectsubject change standard pronouncement andunaudite equity investment include current asset regard information restate anifrs basisis asavailable sale give pagesto derivative financial instrument exchange rate group hold issue derivative financial instrument trading purpose group use average exchange rate prevail period translate result cash flow overseas derivative financial instrument manage exposure subsidiary joint venture associate undertaking market risk treasury operation principal derivative sterling period end rate translate net asset instrument currency swap forward exchange contract undertaking thecurrencie influence interest rate swap derivative contract treat translation relevant exchange rate inception economic hedge underlie financial instrument matching accounting treatment cash flow derivative contract high correlation specific average rate financial instrument hedge inception hedge period derivative instrument long euro designate hedge restate market value future yen change value take directly profit loss account period end rate currency swap forward exchange contract fix euro value relate asset liability contract currency yen contract rate accrue profit loss account life contract glaxosmithkline note financial statement merger glaxo wellcome smithkline beecham combination glaxo wellcome plc smithkline beecham plc treat merger th december ukgaap mergerrelief provision company act share issue glaxosmithkline plc acquire glaxo wellcome smithkline beecham accountedfor par share premium arise share acquire glaxosmithkline glaxo wellcome smithkline beecham similarly account nominal value share issue consolidated financial statement glaxosmithkline result net asset glaxo wellcome smithkline beecham combine book amount subject alignment adjustment segment information analysis turnover profit taxation total assetsandnet assetsby business geographical sector tangible fix asset geographical sector turnover location customerareset business sector consist pharmaceutical prescription pharmaceutical vaccine consumer healthcare oralcare otc medicine nutritional healthcare asset business sector adjust ensure consistency thegeographical sector reflect group significant regional market consistent group regional market management reportingstructure business sector datum include allocation corporate cost sector sale business sector group activity organise global basis geographical sector figure influence location group operate resource particular manufacturing research variation time intragroup trading funding arrangement group copromote product party record sale group record share revenue copromotion income turnover nature copromotion activitiesissuch group record cost sale pharmaceutical turnover include copromotion income million million nil restate restate turnover business sector pharmaceutical consumer healthcare external turnover statutory profit tax business sector pharmaceutical consumer healthcare operate profit share profit joint venture associate undertaking profit disposal interest associate lossprofit disposal business product divestment net interest payable profit taxation profit taxation taxation minority interest preference share dividend statutory earning total asset business sector pharmaceutical consumer healthcare total asset net asset business sector pharmaceutical consumer healthcare net asset note financial statementsglaxosmithkline segment informationcontinue restate restate turnover location subsidiary undertaking usa europe international turnover include intersegment turnover usa europe international intersegment turnover usa europe international external turnover statutory profit tax location subsidiary undertaking usa europe international operating profit share profit joint venture associate undertaking profit disposal interest associate profit disposal business product divestment net interest payable profit taxation profit taxation taxation minority interest preference share dividend statutory earning total asset location subsidiary undertaking usa europe international total operating asset cash bank liquid investment total asset net asset location subsidiary undertaking usa europe international net operating asset net debt net asset glaxosmithkline note financial statement segment informationcontinue plant land equipment computer asset building vehicle software construction total total tangible fix asset location subsidiary undertaking usa europe international total turnover location customer usa europe international external turnover uk segment information give separately respect uk include group europe market region consider group home segment purpose segmental reporting restate restate turnover location customer turnover include intersegment turnover intersegment turnover turnover location subsidiary operating profit total asset net operating asset merger item restructuring cost divest business manufacture restructuring cost incur glaxosmithkline implementation previously announce plan restructure manufacturing activity merger integration cost relate integration glaxo wellcomeand smithkline beecham unify glaxosmithkline business cost include consultancy fee respect integration planning severance cost asset writeoff cost relate early vest lapse performance condition share option share incentive award cost programme encourage staff convert glaxo wellcome smithkline beecham share option glaxosmithkline share option integration cost incur relate integration block drug business cost include professional fee severance cost asset writeoff product divestment income arise relate finalisation disposal famvir kytrilandother product require order obtain regulatory approval merger disposal business relate finalisation disposal clinical laboratory healthcare service note financial statementsglaxosmithkline merger item restructuring cost divest business continue disposal merger restructuring block drug subsidiary total manufacturing restructuring merger integration cost block drug integration cost effect operate profit profit disposal business effect profit tax effect taxation operate item effect taxation nonoperate item effect taxation effect earning disposal merger restructuring block drug subsidiary total manufacturing restructuring merger integration cost block drug integration cost effect operate profit product divestment profit disposal business effect profit tax effect taxation operate item effect taxation nonoperate item effect taxation effect earning operating incomeexpense royalty income operate expense income equity investment disposal royalty income principally core recur income form royalty outlicense intellectual property operating expense include litigation cost provision relate legal claim withdraw product product withdrawal antitrust mattersand claim respect sale marketing reimbursement income equity investment disposal include equity investment carry value adjustment arise stock market change product disposal equity investment sale glaxosmithkline note financial statement operating profit restate restate follow item charge operating profit employee costsnote advertising distribution cost depreciation tangible fix asset own asset lease asset amortisation goodwill amortisation intangible fix asset exchange loss foreign currency depositsloans operate lease rental plant land building audit fee fee auditor work auditor ukfirm auditor overseas firm analysis fee auditor work assurance auditrelated service tax service merger glaxo wellcome smithkline beecham service include audit fee fee relate company audit glaxosmithkline plc include assurance service amount related group preparation adoption international financial reporting standard preparation section sarbanesoxley act tax service relate fee pay corporate tax compliance tax planning advice service include human resource advisory compliance treasury relate service include fee auditor work million pay auditor management consulting practice sell group apply discount certain longterm asset liability riskfree rate return joint venture associate undertaking associate undertaking share profit quest diagnostic inc share loss associate undertaking amortisation goodwill share profitslossesof joint venture share turnover joint venture sale joint venture associate undertaking note financial statement glaxosmithkline net interest payable interest payable bank loan overdraft loan respect finance lease realise loss unwind discount provision share interest payable associate investment income interest income realise gain unwind discount asset taxation restate restate taxation charge base profit period uk corporation tax uk statutory rate double taxation relief overseas taxation defer taxation share taxation charge associate restate restate reconciliation current taxation rate group profit ukstatutory rate taxation overseas taxis average group tax rate effect special tax status manufacturing location share option deduction merger restructuring cost rd credit permanent difference capital allowance excess depreciation intragroup profit reverse time difference tax loss time difference prior year item current tax rate ordinary activity capital allowance excess depreciation intragroup profit reverse time difference tax loss time difference share taxation charge associate prior year item uitf restatement tax rate ordinary activity group operate country tax rate differ uktax rate average group tax rate determine aggregate local standard tax rate weight proportion accounting profit profit arise manufacturing operation singapore puerto rico ireland tax reduce rate effect reduction taxation charge increase earning share pin p p glaxosmithkline note financial statement taxation continue integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delayin negotiation revenue authority profit individual group company liable tax disagreement revenue authority intragroup transaction particular price good transfer group company different tax jurisdiction produce conflict claim revenue authority profit tax individual territory resolution issue continue fact life glaxosmithkline group open issue revenue authority usa uk japan canada far large relate glaxo heritage product respect internal revenue service irs uk inland revenue compete contradictory claim glaxosmithkline attempt settle dispute direct discussion irs subsequently discussion uk authority term double tax convention country discussion terminate july th january irs issue notice deficiency year claim additional taxis billion nd april group file petition tax court dispute irs claim seek refund billion taxeson th january irs issue notice deficiency year claim additional taxis billionif irs claim year upheld group additionally liable interest late payment estimate billionnet federal tax relief st december give total billionfor year group expect tofile petition thetax claim april include claim refund taxis ask tax courtto consolidatethe irs claim year single trial provisional trial date claim setfor october similar tax issue remain open date glaxosmithkline expect receive substantial claim irs forthese yearsglaxosmithkline continue believe profit report subsidiary period date itha pay taxesin usa sufficient reflect activity operation glaxosmithklineis continue discussion inland revenue respect uk transfer pricing dispute glaxosmithkline use good advice determine transfer pricing methodology seek manage transfer pricing issue satisfactory conclusion basis ofexternal professional advice continue believe adequate provision liability likely arise open assessment continue wide difference view group irs inland revenue relevanttaxation authority open issue exist ultimate liability matter vary amount provide dependent outcome litigation proceeding negotiation relevant tax authority show annual report provision taxation arise distribution profit retain overseas subsidiary associate undertaking ground remittance profit retain atst december require way incremental tax arise st december group income tax loss approximatelymillion million capital loss estimate excess ofbillion excess billion related defer tax asset recognisedbecause insufficient evidence loss current defer defer tax creditor tax debtor tax provision tax balance st january exchange adjustment charge profit loss account cash pay movement st december restate defer taxation assetliability accelerate capital allowance stock valuation adjustment intragroup profit product business disposal pension postretirement benefit tax loss legal dispute merger integration manufacturing restructure net timing difference defer taxation provide stock valuation adjustment intragroup profit timing difference show arecurrent defer taxation movement arise origination reversal timing difference net timing difference include accrue expense provisionsnote financial statement glaxosmithkline earning share restate restate p p p basic earning share adjustment merger item restructuring cost disposal subsidiary merger integration transaction cost restructuring cost block drug integration cost disposal business adjust earning share dilute earning share basic adjust earning share calculate divide profit attributable shareholder weight average number ofshare issue period number calculate basic diluted earning share reconciledbelow adjust earning share calculate business performance earningsdure year business performance primary performance measure management present exclude merger item integration restructuring cost disposal business management believe exclusion theseitem provide well comparison business performance period present completion programme group reporting result statutory basis onlythis information provide addition statutory result prepare ukgaap give assist shareholder gain clear understanding underlying performance business increase comparability period present net profit period attributable shareholder earning basic diluted adjustment merger item restructuring cost disposal subsidiary adjust earning weight average number share issue million million million basic adjust dilution share option dilute share hold esoptrustsare exclude trustee waive right dividend share hold esop trust dividend interim second interim interim fourth interim dividend share p p p interim second interim interim fourth interim glaxosmithkline note financial statement goodwill total cost st january exchange adjustment asset write cost st december amortisation st january exchange adjustment provision year asset write amortisation st december net book value st january net book value st december licence intangible asset patent etc brand total cost st january exchange adjustment addition disposal asset write cost st december amortisation st january exchange adjustment provision year disposal asset write amortisation st december impairment st january exchange adjustment impairment loss disposal impairment st december total amortisation impairment st december net book value st january net book value st december addition licence patentsin year relate thepurchasesof fraxiparineand arixtraproduct rightsfromsanofisynthelabo otc marketing right orlistat rocheand compound rightssee note brand largely comprise portfolio product acquire acquisition sterling winthrop inc panadol solpadeine hedex product acquire acquisition block drug company sensodyne polident andpoligrip consider indefinite life give strength durability brand level marketing support accordingly amortise thevaluation sterling brand review annually year cash flow forecast basis original independent assessment acquire posttax discount rate cent valuation block drug brand review annually year cash flow forecast posttax discount rate centnote financial statementsglaxosmithkline plant land equipment computer asset tangible fix asset building vehicle software construction total cost st january exchange adjustment addition disposal reclassification cost st december depreciation st january exchange adjustment provision year disposal reclassification depreciation st december impairment st january exchangeadjustments impairment loss disposal impairment st december total depreciation impairment st december net book value st january net book value st december net book value st december group land building comprise freehold propertiesmillion st january million property lease year moremillion st january million property lease yearsmillion stjanuary million include plant equipment vehicle st december lease asset cost ofmillion st january million accumulate depreciation million st january million net book value million st january million impairment loss principally arise decision rationalise facility calculate base net realisable value value use typically usinga discount rate cent joint associate equity fix asset investment venture undertaking investment total st january exchange adjustment addition impairment transfer disposal retain profit year goodwill amortisation st december investments joint ventures comprisemillion share gross asset million andmillion share gross liability million principal associate undertaking quest diagnosticsinc clinical laboratory business list new york stock exchange investment book value st december ofmillion million market value ofmillion million st december group ownedpercent quest cent book value include goodwill amortise year amortisation charge wasmillion million goodwill st december amount tomillion million goodwill ofmillion relate continue group interest clinicallaboratorie asset attribute quest remain eliminate group reserve equity investment comprise list investment ofmillion million unlisted investment ofmillion million market value list investment st december million million glaxosmithkline note financial statement equity investment total st january exchange adjustment addition impairment transfer disposal st december equity investment include list investment ofmillion million themarket value list investment million million stock raw material consumable work progress finish good debtor amount year trade debtor debtor prepay pension contribution prepayment accrue income amount year debtor prepayment accrue income defer taxation note debtor include trading balance ofmillion million joint venture associate undertaking debtor year include insurance recovery receivable discount riskfree rate return creditor restate amount year trade creditor taxation note social security creditor accrual defer income dividend payable amount year creditor ccrual defer income accrual include obligation wage salary ofmillion millionnote financial statementsglaxosmithkline provision pension legal liability charge postretirement manufacturing merger defer benefit restructure integration dispute taxation provision total st january exchange adjustment charge year unwind discount apply reclassification movement st december group special cash contribution totallingmillion million uk pension scheme contribution relate pension scheme include amount apply provision contribution relate uk pension scheme increase pension prepayment show debtor innote group recognise costsin previous year respect plan manufacturingtheother restructuring initiate follow merger glaxo wellcome smithkline beecham acquisition block drug plan largely complete cost recognise provision principally respect identify severance site announce manufacturing activity cease expect incur mainly cost asset writedown recognise asimpairmentsof fix asset group recognise cost inprevious yearsin respect plan integration glaxo wellcome smithkline beecham business implementation integration follow merger substantially complete cost recognise provision respect identify severance expect incur respect programme encourage staff convert glaxo wellcome smithkline beecham share option glaxosmithkline share option employee exercise option provision discount million millionuse riskfree rate return glaxosmithkline involve number legal dispute include notification possible claim provision legal disputesinclude amount relate antitrust product liability contract termination selfinsurance environmental cleanup property rental company director take legal advice establish provision take account insurance agreement regard relevant fact circumstance matter andin accordance accounting requirement provision discount bymillion millionuse riskfree rate returnglaxosmithkline undertaken review product liability claim assess number product history claim settlement make possible use ibnr incur report actuarial technique determine reasonable estimate group exposure unasserted claim relation productsapart ibnr provision provision unasserted claim ultimate liability matter vary amount provide dependent outcome litigation proceeding investigation possible settlement negotiation nature group business number matter include provide ibnr actuarial technique subject negotiation litigation severalyear large individual amount provide expect settle year discussion legal issue refer note legal proceeding contingent liability st december contingent liability comprise guarantee discount bill item arise normal course business amount tomillion million discussion tax issue refer note taxation legal issue refer note legal proceeding glaxosmithkline note financial statement net debt liquid investment cash bank loan overdraft year cent medium term note cent sterling euro bond float rate european medium term note cent chf bond commercial paper bank loan overdraft loan obligation finance lease loan year cent medium term note cent sterling euro bond cent note cent medium term note cent euro european medium term note cent sterle european medium term note cent euro european medium term note cent medium term note cent sterle european medium term note cent medium term note loan stock bank loan loansand private financing obligation finance lease net debt balance sheet date group liquid investment aggregate market value ofmillion millionliquid investment include redeemable preference share fully collateralise highly rate bond billion billion loan overdraft year commercial paper comprise billion programme million millionwa issue st december million million back committed facility day duration million million million millionrenewable annually liquid investmentsas show table weight average interest rate commercial paper borrowing st december wasper cent cent weight average interest rate bank loan overdraft year st december wasper cent loan year threebond issue theusmedium term note programme million cent coupon bond ausbillionper cent coupon bondand aus millionper cent coupon bond loan year repayable period follow year year year year year loan repayable year carry interest effective rate betweenper cent andper cent repayment date range note financial statementsglaxosmithkline net debt continue secure loan loan amount tomillion million secure charge fix current asset finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total futurerental payment future finance charge total finance lease obligation financial instrument information give note commitment capital commitment contract provide financial statement intangible fix asset tangible fix asset number commitment licensing agreement principally theravance incexelixis inc tanabe seiyaku co ltdand human genome sciences inc group commitment ofmillion million relate revenue payment licence alliance principally exelixis inc commitment operating lease pay rental year operating lease land building expire year year year operating lease plant equipment vehicle expire year year year commitment operating lease pay rental future year glaxosmithkline note financial statement share share capital share premium account ordinary share p p ccm oi uu nm number share capital authorise st december st december st december share capital issue fully pay st january share capital issue share option scheme share capital purchase cancel st december share capital issue share option scheme share capital purchase cancel st december share capital issue share option scheme share capital purchase cancel st december st december st december st december number share issuable outstanding optionsnote number unissue share option st december issue share capital share hold esop trust share hold treasury share free issue october glaxosmithkline commence new billion share buyback programme followedthe completion billion buyback programme announce total billion spend new share buyback programme billion spend exact time future purchase repurchased share hold treasury sharesor becancelle determine company dependent market condition factor share purchase period st january th february periodth february th february furthermillion share purchasedat cost ofmillionall purchase publicly announce buyback programme table set monthly purchase current share buyback programme average share price exclude number share commisson stamp duty month january nil february march april june july august september october nil november december total detail substantial shareholding refer substantial shareholding page nonequity minority interest st january smithkline beecham holdings corporation sbh corp subsidiary incorporate delaware usa issue million flexible auction market prefer stock flex amp comprise share issue serie sbh corp issue million auction rate preference stock arp comprise share issue series arp flex amp constitute preference share represent nonequity minority interest redeem march april note financial statement glaxosmithkline profit reserve reserve loss account total restate restate restate st december previously report prior year adjustment implementation uitf revise uitf st december restate exchange movement uktax exchange movement ordinary share purchase cancel investment esopshare profit attributable shareholder dividend unrealise profit disposal intellectual property st december exchange movement tax exchange movement unrealise profit ordinary share purchase cancel investment esopshare profit attributable shareholder dividend unrealise profit disposal intellectual property revaluation goodwill exchange st december goodwill write exchange movement tax exchange movement unrealise profit ordinary share purchase cancel ordinary share purchase hold treasury share investment esopshare profit attributable shareholder dividend unrealise loss disposal intellectual property revaluation goodwill exchange st december goodwill arise acquisition st january write profit loss account reservesamount million include goodwill million previously hold goodwill reserve offset againstprofit loss account reservesin goodwill write relate disposal group hold quest diagnosticsinc disposal group hold glaxosmithkline pharmaceutical chongqe limited goodwill denominate local currency subject revaluation amount million st december goodwill acquisition st january capitalise accordance accounting policy set note exchange movement take reserve include loss million loss million loss million foreign currency loan deposit gain million gain million gain million retranslation net asset million million nil goodwill eliminate reservesthe tax exchange movement unrealise profit inof million million million relate taxable element foreign currency loan deposit unrealise profit take reserve exchange adjustment debit reserve cumulatively million million million reserve include merger reserve create merger glaxo wellcome smithkline beecham amounting million st december million million reserve include capital redemption reserve create result share buyback programme amount million st december million million follow implementation uitf investment share hold esoptrust amount million st december million million show deduction reserve total reserve amount million st december million million million million million relate company million million million relate joint venture associate undertakings profit glaxosmithkline plc year million million million dividend million million million give retainedprofitof million loss million profit million cost share purchase cancel million million million share purchase hold treasury share million nil nil unrealised profit capital reduction subsidiary nil nil million profit loss account reserve st december stand million million million million unrealise million million glaxosmithkline note financial statement legal proceeding july glaxosmithkline file action apotex district court northern district illinois group involve legal administrative infringement group patent paroxetine hydrochloride proceeding principally product liability intellectual property tax hemihydrate apotex file abbreviate new drug antitrust governmental investigation relate private application anda food drug administration litigation group make provision proceeding fdaseeke approval introduce generic form paxil regular basis summarise notesand group follow trial february judge rule additional significant provision legal proceeding glaxosmithkline patent valid infringe apotexs require event development matter product group appeal rule noninfringement consistent generally accept accounting principle litigation court appeal federal circuit cafc particularly usa inherently unpredictable excessive hear appeal district court onpatentmatters rule award justify evidencemay occur group patent infringe invalid base group future incur judgment enter public use clinical trial prior filing date settlement claim result payment exceed usa group file petition cafc rehear current provision material appeal court date report adverse effect group financial condition result decision petition announce operation june glaxosmithkline file action geneva intellectual property claim include challenge validity pharmaceutical subsidiary novartis pharmaceutical group patent product processesandassertion district court eastern district pennsylvania noninfringement patent loss case infringement group patent paroxetine hydrochloride result loss patent protection product issue follow notice genevas anda filing case consequence loss significant decrease consolidate similar infringement action sale product materially affect future result generic company subsequently file anda additional operation group infringement action bring base patent issue legal expense incur relate defence group subsequent original filing apotex northern intellectual property litigation cost provision relate district illinois group file action apotex product liability claim exist product charge sell relate new patent eastern district general administration cost litigation cost provision pennsylvania december judge grant relate legal claim withdraw product antitrust deny summary judgement motion file apotex pricing matter charge operating incomeexpense result issue validity infringement provision take appropriate legal advice new patent remain trial group petitioned reasonable estimate likely outcome district court permit interim appeal cafcof summary dispute group establish actuarially determine ruling new patent certain claim provision product liability claim incur report invalid june group request describe note st december group fdato remove patent relate paxilfrom register aggregate provision legal dispute include tax pharmaceutical patent maintain fda orange book matter describe taxation note justover delist affect validity patent billion ultimate liability legal claim vary relate patent litigation follow fda approval anda amount provide dependent outcome litigation apotex subsequently launch generic version paxil proceeding investigation possible settlement negotiation september significant matter describe group continue pursue patent infringement claim litigation eastern district pennsylvania apotex intellectual property geneva alphapharm andrx teva pharmaceuticals zenith usa bulk supplier basf sumika fine chemical apotex alphapharm basf sumika file counterclaim paxil action allege group violate antitrust unfair usa number distributor generic drug file competition law february cafc hear apotexs application fda market generic version appeal decision district court district paxilseroxatparoxetine hydrochloride prior expiration columbia deny apotexs request fda require group patent paroxetine hydrochloride delist certain group patent paxilfrom orange hemihydrate apotex launch generic version ofpaxilin book october cafc affirm district court september distributor seek bring market decision dismiss casecertain claim anhydrate version paroxetine hydrochloride counterclaim respect geneva alphapharm basf case paroxetine mesylate response group file action sumika settle distributor infringement group patent basis generic anhydrate march glaxosmithkline file action pentech version infringe contain andor convert pharmaceutical district court northern district hemihydrate form andor infringe group patent illinois infringement group patent paroxetine hydrochloride pentech file anda capsule version paxil assert compound presentation infringe group patent patent invalidnote financial statementsglaxosmithkline legal proceeding continue june group commence action district court district new jersey faulding april group reach settlement pentech pharmaceutical company allege infringement method par pharmaceutical pentech grant right use patent ondansetron faulding challenge pentechs anda paroxetine hydrochloride capsule compound patent case date report settlement allow par distribute puerto rico stay pende decision teva reddy kali case substitutable generic paroxetine hydrochloride immediate release august group commence action tablet supply licensed group royalty payable district court district new jersey pliva allege group par entitle distribute product infringement group patent reduce crystal size market apotexs generic version paxilbecame ondansetron expire march take account available september settlement par extension paediatric exclusivity pliva challenge pentech acknowledge glaxosmithkline patent cover compound patent emesis use patent case hemihydrate form paroxetine hydrochloride valid preliminary stage enforceable infringe pentechs propose capsule product bureau competition federal trade january group commence additional action commission review settlement review voluntary district court district new jersey conduct request group par pentech reduce crystal size patent kali apotex pentechs supplier asahi glass co file claim allege contrast previous anda orally disintegrate tablet settlement violate antitrust law claim kali challenge emesis use patent recent anda dismiss court similar claim bring apotex oral tablet challenge compound patent apotex sumika pende district court eastern challenge compound emesis use patent district pennsylvania connection anda zofran lamictal august group commence action district august group commence action district court district new jersey reddycheminor court district new jersey teva pharmaceuticals drreddys laboratories dr reddy certify invalidity usa inc allege infringement group compound patent patent ondansetron active ingredient zofrantablet lamotrigine active ingredient lamictaloral tablet include compound patent expire july patent afford protection january give effect method use patent later expire december expect grant paediatric exclusivity fda instance take account extension defendant hadfile anda fda certification paediatric exclusivity july group file action invalidity group patent hatchwaxman stay drreddys laboratory district court infringement fda approval anda expire trial teva case group patent relate orally disintegrate tablet conclude january follow trial party reach presentation zofran october group file action settlement agreement subject government review pursuant westward pharmaceuticals inc district court group grant teva exclusive royaltybearing infringement group patent relate injectable licence distribute usaa generic version lamotrigine presentation zofran dr reddy disintegrate tablet chewable tablet date later june case westward case consolidate early exclusive right manufacture sell tevas generic version dr reddy case prior trial reddycheminor westward lamotrigine tablets usa expect launch date withdraw challenge compound patent trial infringement group method use process imitrex patent complete june date december group commence action report close argument hold decision district court southern district new york announce dr reddys laboratory allege infringement march group file similar action teva primary compound patent sumatriptan active ingredient pharmaceuticals usa inc district court district imitrex thepatent issue afford protection february delaware allege infringement method use patent give effect grant paediatric exclusivity ondansetron teva certify invalidity noninfringement fda defendant file anda fda method use patent teva challenge certification invalidity compound patent compound patent trial judge rule group favour certify invalidity noninfringement second compound uphold validity method use patent teva appeal patent expire injune give effect paediatric decision cafc oral argument expect exclusivity case early stage generic thirdquarter september november company file andas imitrexbut cobalt january group file action teva pharmaceuticals certify invalidity compound court infringement group patent relate patentat issue dr reddys case group commence injectable orally disintegrate tablet presentation zofran infringement action cobalt recently case consolidated case appeal transfer district court southern district new yorkin february group commence action early ondansetron case involve orally disintegrate zofran usdistrict court district delaware tablets commence group january spectrum pharmaceutical allege infringement thesame kali laboratory district court district new compound patentatissue dr reddys case spectrum file jersey kali group subsequently file motion itscertification invalidity noninfringement patent summary judgement anda filing approval sumatriptan injection case early stage glaxosmithkline note financial statement legal proceeding continue advair september group apply patent valtrex trademark office uspto reissue combination patent group commence action district advair inhale combination salmeterol fluticasone court district new jersey ranbaxy laboratory propionate expire september follow allege infringement group compound patent internal review conclude language valaciclovir active ingredient valtrex patent expire patent accurately describe circumstance defendant file anda fda invention claim invention precisely certification invalidity group compound patent objective seek reissuance strengthen noninfringement patent expire protection afford patent expect list orange book fda approval anda stay administrative process uspto year early october resolution patent application reissue pende patent remain infringement litigation discovery underway case forceand list orange book avandia avandamet group hold patent relate advairwhich august group file action district court affect reissue application include compound district new jersey teva pharmaceuticals usa inc patent relate active ingredient salmeterol afford infringement group patent relate maleate salt protection august give effect expect form rosiglitazone active ingredient avandia grant paediatric exclusivity fda patent relate expire september group file comparable diskusdevice expire period action court dr reddys laboratory allege patent relate hfa formulation relate technology infringement patent maleate salt form expire period dr reddys laboratory teva file anda fda certification invalidity group maleate salt patent fda levitra approval andas stay early november october pfizer inc file action bayer ag resolution respective patent infringement action glaxosmithkline district court district delaware allege manufacture sale levitra teva subsequently file additional certification challenge vardenafil infringe patent newly issue pfizer validity group basic compound patent rosiglitazone ask bayer glaxosmithkline permanently enjoin january group commence action september patent trademark office initiate teva court infringement patent basic reexamination pfizer patent base question compound patent currently expire expiry patentability light prior art pfizer action include expect extend patent additional suit file court follow launch trademark office grant patent term restoration levitrain usa predicate validity patent january group file action district court stay pende outcome reexamination district ofnew jersey teva infringement december party enter agreement settle patentsteva file anda fda patent infringement validity proceeding worldwide generic version avandametwith certification invalidity basis include action noninfringementof patent fda approval anda cervarix stay early june resolution patent february merck co group announce cross infringementaction avandametis protect licence settlement agreement certain patent right relate patent avandia avandiapatent issue find human papillomavirus hpv vaccinethe group receive invalid litigation teva dr reddys rule upfront payment androyaltiesfrom merck base sale wouldbe dipositive avandameta hpv vaccine development launch agreement wellbutrin xl resolve compete intellectual property claim relate december biovail commence action district merck glaxosmithkline hpv vaccine respectively court central district california anchen pharmaceutical inthe district court southern uk europe district florida abrika pharmaceutical case seroxat allege infringement biovail formulation patent wellbutrin follow settlement august group xl patent expire anchen abrika patent litigation synthon bv synthon free market file anda fda certification invalidity paroxetine mesylate product market globally noninfringement biovail patent fda approval obtain marketing authorisation paroxetine mesylate andas stay early different salt form paroxetine market resolution applicable patent infringement action form seroxatpaxilin certain market patent litigation group party action licensee patent synthon ongoing synthon assert counterclaim owner new drug application wellbutrin xlboth unfair competition group case early stagesnote financial statementsglaxosmithkline legal proceeding continue phenylpropanolamine follow report yale haemorrhagic stroke project generic version seroxatpaxilsactive ingredient find suggestion association use paroxetine hydrochloride anhydrate generic product contain phenylpropanolamine ppa decongestant haemorrhagic anhydrate market european country stroke group manufacturer voluntarily whilst product subject continue withdrawnconsumer healthcare product ppa litigation action settled expect active ingredient ppa product withdrawal group settle future uk litigation name defendant numerous personal injury year standing group apotex culminate class action lawsuit file state federal court allege appeal court decision group anhydrate process personal injury increase risk injury use product patent validbutnot infringe decision subject contain ppa unfair deceptive business practice appeal result litigation apotex enjoin plaintiff seek remedy include compensatory punitive launch product year damage refund federal case consolidate market damage enquiry relate theinjunction multidistrict litigation proceed district court place course district washington judge responsible proceeding deny class certification strike class product liability allegation federal personal injury consumer refund paxil class action limit number case group group receive lawsuit claim file behalf manufacturer defendant reach trial patient allege suffer symptom state court class certification deny california discontinuing treatment paxilparoxetine separately state court pennsylvania state court putative class action group receive lawsuit claim patient dismiss leave putative class action pende commenced paxiltreatment commit attempt commit group litigation suicide andor act violencethere private consumer lawsuit allege group conceal misrepresented baycol datum paediatric clinical trial paxil august bayer ag withdraw baycolcerivastatin sodium worldwide light report adverse event include death group receive lawsuit file state federal court involve rhabdomyolosis glaxosmithkline participate usa canada behalf thousand plaintiff marketing baycolin usa pursuant copromotion include purport class action allege paroxetine agreement bayer licenceholder active ingredient paxil addictive cause dependency manufacturer product withdrawal reaction plaintiff seek remedy include compensatory punitive statutory damage cost follow withdrawal bayer glaxosmithkline fund medical monitoring federal judge name defendant thousand lawsuit file state district court central district california deny class federal court usa behalf individual action certification nationwide class california putative class baycoluser number suit statewide class case file federal court district allege plaintiff suffer personal injury include subsequently petition plaintiff counsel federal court rhabdomyolosis use baycol claim person case transfer district court consolidation take baycol injure risk future multidistrict litigation mdl case schedule injury suffer economic damage purchase start trial mdl court baycol plaintiff seek remedy include compensatory determination lawsuit pende punitive statutory damage creation fund medical mdl state court permit proceed monitor glaxosmithkline bayer corporation principal class action subsidiary bayer ag sign allocation agreement bayer corporation agree pay cent group receive number claim lawsuit allege settlement compensatory damage judgement treatment paxilha cause homicidal suicidal party retain responsibility attorney fee behaviour exhibit user product punitive damage federal case consolidate purport class action october fda multidistrict litigation proceed district court announce require black box warning district minnesota numerous case schedule trial suicidality strengthen warning selective serotonin state federal court date statewide reuptake inhibitor ssri product include paxil class medical monitoring class action bayer glaxosmithkline avandia certify pennsylvania class action group receive lawsuit claim file state glaxosmithkline name defendant federal court usa behalf numerous patient allege certify oklahomaa substantial number claim death rosiglitazone active ingredient avandia cause injury settle congestive heart failure liver damage case purport class action case early stage certain state court trial schedule place glaxosmithkline note financial statement legal proceeding continue particular government inquire allege promotion drug offlabel use groupsponsore fenphen continue medical education programme speaker event fda aware report cardiac valvular special issue board advisory board speaker training programme problem individual fenfluramine dexfenfluramine clinical study relate grant fee travel entertainment combination phentermine prescribe original subpoena issue attorney regimen weight reduction request voluntary office colorado scope inquiry nationwide withdrawal fenfluramine dexfenfluramine market group cooperate investigation early report cardiac valvular problem subsequent stage group early respond october letter withdrawal product market spawn numerous fda division drug marketing advertising product liability lawsuit file manufacturer communication request information group allege distributor fenfluramine dexfenfluramine phentermine promotion wellbutrin sr offlabel use number manufacturer phentermine group defendant thousand lawsuit state federal average wholesale price district court usa lawsuit seek relief include glaxosmithkline respond subpoenas office combination compensatory punitive damage inspector general department health medical monitoring refund purchase drug human service department justice state judicial panel multidistrict litigation issue order texas california connection allegation consolidate transfer federal action district pharmaceutical company include glaxosmithkline court eastern district pennsylvania court approve violate federal fraud abuse law federal false global settlement propose defendant wyeth sell claim act respect texas california comparable fenfluramine dexfenfluramine settlement subsequently state law result way average wholesale price awp confirm circuit court appeal include determine report certain drug way phentermine defendant include group medicare medicaid programmes reimburse drug individual plaintiff elect opt class settlement subsequently state respective attorney pursue claim individually ten thousand general county new york state file civil lawsuit plaintiff elect wyeth continue settle state federal court glaxosmithkline individual state court case trial group continue drug company action claimon behalf state dismiss lawsuit settle wyeth payer behalf instate patient consumer thimerosal damage restitution awpbase price reporting glaxosmithkline number pharmaceutical undefined set pharmaceutical product cover state company name defendant numerous individual medicaid programme addition private payer class action personal injury lawsuit state federal district court lawsuit file glaxosmithkline usa allege thimerosal preservative federal district state court federal case manufacture vaccine cause neurodevelopmental disorder consolidate multidistrict litigation proceed injury include autism case district court district massachusetts group purport class action determination oneof company designate fast track discovery case permit proceed proceeding hearing privatepayer plaintiff motion class action number purport class action class certification take place february judge jurisdiction withdraw dismiss plaintiff seek rule motion civil suit file state remedy include compensatory punitive statutory court state attorney general private payer class action damage cost fund medical monitoring case remand state court early stage research lawsuit early stage nominal pricing number case schedule trial group advise department justice lotronex investigate certain group nominal pricing follow voluntary withdrawal lotronexin usa arrangement determine arrangement qualify november number lawsuit file nominal price exception good price reporting group state federal district court include individual requirement medicaid drug rebate programme personal injury action purport class action assert violate civil statute law group cooperate product liability consumer fraud claim plaintiff seek remedy investigation conduct government include compensatory punitive statutory damage class attorney involve awp investigation provide previously certify west virginia decertifie document information nominal pricing action dismisseda large number claim bring arrangement number group product follow withdrawal settle paxilseroxat follow announcement new york state attorney general government investigation office state lawsuit subsequently settle august marketing promotion allege failure disclose datum use paxilin child february glaxosmithkline receive subpoena adolescent similar case purport attorney office colorado group sale class action file state federal court promotional practice relate large sell private plaintiff case early stage product period january presentnote financial statementsglaxosmithkline legal proceeding continue relafen august district court district uk investigation remain pende uk medicine massachusetts rule group patent nabumetone relafen healthcare product regulatory agency mhra determine invalid anticipatory art unenforceable ground group comply pharmacovigilance inequitable conduct august cafc issue decision obligation report datum clinical trial seroxatpaxil affirm district court judgement invalidity decline child adolescent rule judgement inequitable conduct cidra puerto rico manufacturing site follow district court decisionantitrustclaim allege october fdainspectedthe group manufacture competitive injury overcharge file teva eon facility cidra puerto rico cidra site engage tablete pharmaceutical generic manufacturer nabumetone packaging range glaxosmithkline product primarily purport class direct indirect purchaser payer market include paxil paxil cr coreg avandia individual retail chain avandametfollowe inspectionthe fda issue form observation possible deficiency plaintiff claim base allegation fraudulent manufacturing practice groupthe fda carry procurement patent wrongful listing patent inspection november subsequently issue fda orange book prosecution sham patent infringement form litigation case originally file district court district massachusetts eastern district fda observation relate certain aspect production pennsylvania transfer district massachusetts controls process validation laboratory investigationsthe group settle case file teva eon group group continue cooperate fda respondingto major retail pharmacy chain class direct purchaser observation contain form court give preliminary approval tothesettlement assurance remedy fda ultimately seek group reach class indirect purchaser hear final approval settlement schedule antitrust thmay additionally asettlementagreementha paxil signedwith state global claim allege november federal trade commission ftc staff overcharge connection state purchase drug advise group conduct nonpublic investigation determine group violate augmentin section federal trade commission act monopolize district court eastern district virginia attempt monopolize market paroxetine find patent cover augmentininvalid hold hydrochloride prevent generic competition paxiland subsequently affirm cafc follow adverse request group submit certain information connection trial court decision purportedantitrustclass action file investigation october ftc closed behalf class direct indirect purchaser investigation basis find action ultimately consolidate district court eastern warrant district virginia plaintiffs allege group knowingly obtain invalid patent engage anticompetitive follow public reference ftc investigation paxil conduct prevent entry generic product violation purport class action file district court monopolization section usantitrustlaw court eastern district pennsylvania behalf indirect purchaser approve group settlement class action claim include consumer party payer direct purchaser february group reach agreement principle plaintiff claim group monopolize market lek pharmaceutical whollyowne subsidiaryof novartis paxilby bring allegedly sham patent litigation allegedly resolve antitrust lawsuit file lek district abuse regulatory procedure list patent court soughtlost profit treble damage injunctive relief fda orange book court grantedfinalapproval attorney fee settlement direct purchaser class preliminary approval settlement purport class indirect purchaser canadianimportation hearing date final approval indirect purchaser class group name seven purport class action settlement isthmarch group reach final lawsuit pharmaceutical company settlement group chain drugstore state court follow group action toreduceillegal importation purport consumer fraud class action california remain prescription drug canada lawsuit early stage separately state court class action allege company enter unlawful conspiracy california federal class action florida prevent canadian pharmacy sell product purport indirect purchaser class action stay customer pende disposition federal court settlement separate group name defendant action city new york allege overcharge thirteen drug company state court action california early stage plaintiff independent pharmacy allege apotex alphapharm basf sumika file antitrust defendant unlawfully conspire price artificially high unfair competition counterclaim group base usa detriment plaintiff relation allegation similar purport class action matter minnesota state attorney general file identify proceed paragraph discovery complaint allege group violate state antitrust apotex matter early stage action commercial law theseaction early stage stay glaxosmithkline note financial statement legal proceeding continue post balance sheet event wellbutrin sr th january glaxosmithkline announce december january february lawsuit agree transfer european international purport class action file copromotion right levitrato bayer cash consideration district court eastern district pennsylvania million reduction group commitment group behalf direct indirect purchaser wellbutrin sr fund future research development product complaint allege violation antitrust law sham glaxosmithkline retain copromotion comarkete right litigation fraud patent office group obtain levitrain theusa market enforce patent cover wellbutrin sr complaint follow introduction generic competition wellbutrin sr relate party transaction april district appellate court ruling generic glaxosmithkline hold cent interest quest manufacturer infringe group patent case diagnostic inc st december cent early stage group quest diagnostic party longterm contractual relationship quest diagnostic environmental matter primary provider clinical laboratory testing support glaxosmithkline notify potential responsibility group clinical trial testing requirement worldwide relate past operation past waste disposal practice quest diagnostic provide service million certain site primarily usa matter million group subject litigation include proceeding initiate federal state government waste disposal site group shionogi co ltd enter remediation cost tort action bring private party transaction usjoint venture company support research development activity conduct glaxosmithkline advise responsible joint venture company glaxosmithkline provide party approximately site appear service joint venture million million national priority list create comprehensive environmental st december balance glaxosmithkline response compensation liability act superfund joint venture million million proceeding seek require operator hazardous dr shapiro nonexecutive director glaxosmithkline plc waste facilities transporter waste site generator receive fee hazardous waste dispose site clean site form adss subsidiary reimburse government cleanup cost company membership onthe group scientific instance glaxosmithkline involve allege generator advisory board include annual remuneration hazardous waste site remuneration report pagesto glaxosmithkline involve current operator facility superfund provide defendant dr barzach nonexecutive director glaxosmithkline jointly severally liable cleanup cost proceeding plc receive fee subsidiary frequently resolve basis nature quantity company healthcare consultancy provide waste dispose site generator glaxosmithkline include annual remuneration remuneration proportionate liability cleanup cost substantially report determine site refer glaxosmithkline potential liability vary greatly site site cost investigation study remediation site time substantial glaxosmithkline routinely accrue amount related share liability matter tax matter pende tax matter describe notenote financial statementsglaxosmithkline acquisition disposal detail acquisition disposal subsidiary associate undertakingsjoint venture business give book fair value net asset goodwill cost value adjustment acquire capitalise acquisition acquisition fraxiparine fraxodi andarixtra fraxiparine fraxodi andarixtra inseptemberfor cash consideration million group acquire fraxiparine fraxodiand arixtraandrelate asset include manufacturing facility euclid srpartner lp year additional million invest euclid srpartner lpan associate company group cent interest disposal quest diagnostic inc group dispose million share investment quest diagnosticsincfor cash proceed million reduce group shareholde st december cent recognise charge goodwill previously write offto reserve million profit million recognise glaxosmithkline vehicle finance ltd group dispose employee vehicle financingsubsidiaryresulte loss million glaxosmithkline pharmaceutical chongqing ltd group dispose glaxosmithkline pharmaceutical chongqing ltda group subsidiary locate china million profit disposal million realise recognise charge forgoodwill previously writtenoff reserve million beeyar investments pty ltd july group dispose ofbeeyar investment pty ltdasubsidiary locate south africa cash proceed million realisingaprofitof million optilead srl year group hold associate undertake optilead srl sell result loss million fraxiparine gsk gsk fraxodi quest vehicle pharmaceutical beeyar arixtra euclidsr diagnostic finance chongqe investment total cash flow cash consideration pay net cash proceed disposal book fair value net asset goodwill cost value adjustment acquire capitalise acquisition acquisition europharm europharm group complete buyout minority interest europharm holding sa group subsidiary locate romania million give rise goodwill million capitalise iterfi sterilyo payment million pursuant acquisition agreement base financial performance acquire company include defer compensation glaxosmithklinenote financial statement acquisition disposal continue disposal sb clinical laboratory additional cash refund million receive respect indemnify liability arise sb clinical laboratory disposal occur refund follow successful outcome case uscourt appeal iterfi sb clinical sterilyo europharm laboratory total cash flow cash consideration pay net cash proceed disposal book fair value net asset goodwill cost value adjustment acquire capitalise acquisition acquisition iterfi sterilyo human kft iterfi sterilyo group acquire iterfisterilyo group initial cash consideration million payment pay million base financial performance acquire company net asset iterfisterilyo incorporate financial statement provisional fair value adjustment value human kft group acquire vaccine relate asset human kft manufacturing business locate hungary cash consideration million disposal sb clinical laboratory cash refund million receive respect indemnify liability arise sb clinical laboratory disposal occur refund follow successful outcome case court appeal sb clinical iterfi human laboratory sterilyo kft total cash flow cash consideration pay net cash proceed disposal note financial statementsglaxosmithkline financial instrument relate disclosure group apply boardapprove limit credit exposure counterparty employ strict minimum policy credit worthiness criterion choice counterparty discussion group objective policy management offinancial instrument associate risk fair value financial asset liability include treasury policy operate financial table pagepresent carry amount review prospect page uk gaap fair value group financial asset liability st december st december investments debtor creditor year exclude group hold number equity investment frequently entity group enter research collaboration fair value financial asset liability include group seek realise value investment atthe instrument exchange inpart research collaboration help create current transaction willing party force certain investment regard available sale liquidationsale follow method assumption account foras current asset investment purpose estimate thefair value ofusgaap current asset investment classify equity investment market value base quote market available sale price case list investment market value glaxosmithkline hedge equity value reference quote price similar company recent holding large equity investment quest diagnosticsinc financing information case material unlisted series variable sale forward contract contract investment equity collar structure series cash bank approximate carry million quest sharesand mature liquid investment base quote market price similar company recent financing information case group liquid investment represent fund surplus marketable security approximate carry immediate operating requirement account inthe case time deposit short maturity current asset investment purposes usgaap shortterm loan overdraft approximate carry investment classify available sale proceed short maturity instrument sale investment classify available saleunder gaap mediumterm loan market value base quote market weremillionin year end stdecember price case eurobond fix rate proceed include rollover liquid fund shortterm borrowing approximate carry case deposit usgaap gross gain loss reflect offloate rate bank loan loan consolidate profit loss account respect investment forward exchange contract base market price classify available sale million andmillion exchange rate balance sheet date respectively currency swap base market valuation balance sheetdate foreign exchange risk management equity collar fair value determine base option group enter forward foreign exchange contract pricing model inorder swap liquid asset borrowing currencie interest rate instrument fair value determine net require group purpose st december group present value discount cash flow outstanding contract sell purchase foreign currency debtor creditor approximate carry total notional principal million provision approximate carry million majority contract period auction rate preference stockapproximate carry month case float rate instrument end group number currency swap flexible auction market prefer stockbased market inplace respect mediumterm debt instrument borrowing valuation balance sheet date denominate swap foreign currency match investment overseas group asset treat ahedge fair value investment share relevant net asset exchange gain loss group st december investments record reserve share million million fair value million millionbase quote interest rate risk management market pricethe share represent purchase esop trust manage fixedfloate interest rate profile debt satisfy future exercise option award employee group interest rate swap outstanding incentive schemesthey exclude financial instrument commercial bank st december disclosure concentration credit risk credit exposure financialinstrument group believe expose major concentration credit risk financial instrument group expose creditrelate loss event nonperformance counterpartie financial instrument expect counterpartie fail meet obligation glaxosmithklinenote financial statement financial instrument relate disclosure continue classification fair value financial asset liability follow table set classification financial asset liability provide reconciliation group net debt note shortterm debtor creditor exclude financial asset liability provision include contractual obligation settle cash carry fair carry fair value value net debt liquid investment cash bank current asset financial instrument sterling note bond dollar note bond private financing note bond swap dollar currency swap interest rate swap note bond swap yen currency swap euro note bond interest rate swap mediumterm borrowing shortterm loan overdraft total borrowing total net debt fix asset equity investment current asset equity investment debtor year creditor year provision foreign exchange derivative nonhedge derivative auction rate preference stock flexible auction market prefer stock total nonequity minority interest total financial asset liability total financial asset total financial liability appropriatecurrency interest rate swap present alongside underlie principal instrument carrying amount instrument adjust effect currency interest rate swap acting hedge difference carry fair value equity fix current asset liquid investment represent gross unrealised gain million million respectivelynote financial statementsglaxosmithkline financial instrument relate disclosure continue currency interest rate risk profile financial liability financial liability take account currency interest rate swap analyse total financial liability comprise total borrowing million million creditor year million million provision million million nonequity minority interest preference share ofnil millionbut exclude creditor year foreign exchange derivative million nil benchmark rate determine interest payment float rate financial liability table libor noninterest fix rate float rate bearing weight weight average average weight st december interest year average rate rate year total currency fix maturity dollar sterle euro japanese yen currency noninterest fix rate float rate bearing weight weight average average weight st december interest year average rate rate year total currency fix maturity dollar sterle euro japanese yen currency currency interest rate risk profile financial asset total financial asset comprise fix asset equity investment million million current asset equity investment million million liquid investment million million cash bank million millionand debtor year million millionbut exclude foreign exchange derivative nil millionthe benchmark rate determine interest receipt float rate asset tablesbelow libor noninterest fix rate float rate bearing weight weight st december fix average average year rate interest rate total currency rate fix dollar sterling euro japanese yen currency noninterest fix rate float rate bearing weight weight st december fix average average year rate interest rate total currency rate fix dollar sterling euro japanese yen currency glaxosmithklinenote financial statement financial instrument relate disclosure continue currency exposure net monetary assetsliabilitie group currency exposure rise net currency gain loss recognise profit loss account arise principally company sterle functional currency monetary asset liability denominate overseas functional currency andborrowing designate hedge overseas net assetsare exclude table st december functional currency group operation net monetary assetsliabilitie sterle euro yen total hold nonfunctional currency sterle dollar euro japanese yen st december functional currency group operation net monetary assetsliabilitie sterle euro yen total hold nonfunctional currency sterle dollar euro japanese yen finance total total debt lease maturity financial liability year demand year year year gain loss net hedge unrecognise gain loss begin year unrecognised gain loss arise previous year recognise year unrecognised gain loss arise year total unrecognised gain loss end year expect recognise year expectedto recognise year total unrecognised gain loss end year unrecognised gain loss represent difference carry fair value currency swap interest rate swap equity collar foreign exchange derivative commit facility group commit facility commercial paper programme million million million millionof daysdurationrenewable annually st december undrawn commit facility total million million million millionnote financial statementsglaxosmithkline employee cost restate restate wage salary social security cost pension postretirement cost cost sharebase incentive plan severance cost arise integration restructuring activity pension postretirement cost arise integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance information director remuneration give remuneration report pagesto average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial record page pension postretirement cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid scheme unfunded define benefit scheme define contribution scheme unfunded postretirement healthcare scheme postemployment cost pension postretirement cost arise integration restructure pension group undertaking operate pension arrangement cover group material obligation provide pension retire employee thesearrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length ofservice define benefit scheme include define contribution section aredescribe hybrid scheme table majority case contribution define benefit scheme determine accordance advice independent professionally qualified actuary formal independent actuarial valuation group main plan undertake regularly normally year theasset fund scheme generally hold separately administer trust insured asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment glaxosmithklinenote financial statement employee cost continue pension cost define benefit scheme accounting purpose assess accordance independent actuarial advice generally project unit method spread surplus deficit average expect remain service live respective membershipsin certain country pension benefit provide unfunded basis administer trustee company whereasset hold specific purpose matching liability unfunded scheme provision include provision pension postretirement benefit liability generally assess annually accordance advice independent actuary market value asset group fund define benefit pension fund date late actuarial valuation date billion actuarial value asset sufficient cover approximatelyper cent benefit accrue member allow future salary andpension increase uk define benefit pension scheme account approximatelyper cent group plan asset valuation project benefit term define benefit pension scheme account approximatelyper cent group plan asset valuation project benefit term group special funding contribution uk pension scheme totalling million group agree trustee certain pension scheme additional contribution dependent funding status schemesin follow ifrs pension cost group expect approximatelymillion high uk uk define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent uk employee entitle tojoin define contribution scheme relevant assumption calculate pension cost ofall uk define benefit scheme accounting purpose follow pa pa rate increase future earning discount rate expect longterm rate return investment expect pension increase regular cost glaxo wellcome pension arrangement million reduce accounting cost million allowance spread surplus disclose level percentage salary expect future working lifetime exist member someyear recent triennial actuarial valuation fund purpose carry asat st december date asset scheme represent cent actuarial value benefit accrue member allow future salary pension increase themarket value asset hold scheme atst december million regular cost smithkline beecham scheme million increase accounting cost million allowance spread deficit expect future working lifetime current employee scheme year late valuation carry st december date scheme asset represent cent actuarial value accrue service liability base assumption themarket value asset hold scheme st december million usa usa glaxo wellcome smithkline beecham define benefit hybrid scheme merge relevant assumption calculate pension cost accounting purpose follow pa pa rate increase future earning discount rate expect longterm rate return investment cash balance creditconversion rate regular cost main schemesin million whichdecrease accounting cost million allowance spread thesurplusover expect future working lifetime current employee scheme late valuation carry st january date actuarial value scheme asset representedper cent actuarial value theaccrue service liability themarket value asset hold scheme st january million postretirement healthcare group operate number postretirement healthcare scheme principal usa cost usscheme assess assumption pension scheme assumption future medical inflation ofper centreduce cent year cent total provision postretirement benefit st december amount million millionnote financial statementsglaxosmithkline employee cost continue frs disclosure group continue account pension arrangement accordance ssap accounting pension cost transitional provision frs retirement benefit certain disclosure require basis valuation methodology adopt frs define benefit scheme fair value pension scheme asset st december compare future pension liability calculate project unit method apply follow assumption uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earning discount rate expect pension increase na na na cash balance creditconversion rate na na na na inflation rate expect longterm rate return asset determine base actuarial advice fair value asset liability uk define benefit scheme aggregate datum define benefit scheme group follow uk usa rest world group average st december expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value scheme liability value scheme surplus defer tax liability value scheme deficit defer tax asset group total uk usa rest world group average st december expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value scheme liability value scheme surplus defer tax liability value scheme deficit defer tax asset group total glaxosmithklinenote financial statement employee cost continue uk usa rest world group average st december expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value scheme liability value scheme surplus defer tax liability value scheme deficit defer tax asset group total uk define benefit scheme define contribution section account balance total million st december million million define benefit section uk scheme close new member project unit method value pension scheme liability current service cost increase percentage payroll member scheme approach retirement deficit frs reflectthe different basis valuing liability compare ssap liability frs postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation ofper centreduce cent year cent basis liability usscheme assess million million million reduce million million million taking account defer tax define benefit pension postretirement benefit scheme account frs follow amount record profit loss account statement total recognise gain loss year end st december postretirement pension benefit uk usa rest world group group amount charge operating profit current service cost past service cost curtailmentssettlement amount creditedcharge net interest expect return pension scheme asset interest scheme liability amount record statement total recognise gain loss actual return expect return pension scheme asset experience gainslossesarise scheme liability change assumption relate present value scheme liability note financial statementsglaxosmithkline employee cost continue postretirement pension benefit uk usa rest world group group amount charge operating profit current service cost past service cost curtailmentssettlement amount creditedcharge net interest expect return pension scheme asset interest scheme liability amount record statement total recognise gain loss actual return expect return pension scheme asset experience lossesgain arise scheme liability change assumption relate present value scheme liability postretirement pension benefit uk usa rest world group group amount charge operating profit current service cost past service cost curtailmentssettlement amount creditedcharge net interest expect return pension scheme asset interest scheme liability amount record statement total recognise gain loss actual return expect return pension scheme asset experience gainslosse arise scheme liability change assumption relate present value scheme liability glaxosmithklinenote financial statement employee cost continue postretirement pension benefit movement deficit uk usa rest world group group deficit schemes st january exchange adjustment charge operating profit employer contribution finance incomeexpense actuarial loss recognise statement total recognise gain loss deficit scheme st december exchange adjustment charge operating profit employer contribution finance incomeexpense actuarial lossesgain recognise statement total recognise gain loss deficit scheme st december exchange adjustment charge operating profit employer contribution finance incomeexpense actuarial lossesgain recognise statement total recognise gain loss deficit scheme st december postretirement pension benefit history experience gain loss uk usa rest world group group difference expect actual return scheme asset percentage scheme asset st december experience gainslossesof scheme liability percentage present value scheme liability st december total recognise statement total recognise gain loss percentage present value scheme liability st december note financial statementsglaxosmithkline employee cost continue postretirement pension benefit history experience gain loss uk usa rest world group group difference expect actual return scheme asset percentage scheme asset st december experience lossesgain scheme liability percentage present value scheme liability st december total recognise statement total recognise gain loss percentage present value scheme liability st december difference expect actual return scheme asset percentage scheme asset st december experience gainslosse scheme liability percentage present value scheme liability st december total recognise statement total recognise gain loss percentage present value scheme liability st december frs valuation basis apply financial statement instead ssap valuation basis effect profit loss account reserve take account defer tax follows restate profit loss account reserve balance sheet pension liability frs net pension assetunder ssap balance sheet postretirement healthcare scheme frs net postretirement healthcare scheme provision balance sheet profit loss account reserve include frs pension postretirement healthcare liability glaxosmithkline note financial statement employee share scheme group operate share option scheme option grant employee acquire share adss glaxosmithkline plc grant price share award scheme award grant employee acquire share adss glaxosmithkline plc cost subject tothe achievement performance target group introduce new share award scheme restrict share plan award grant employee acquire share adss glaxosmithkline plc cost year period grant restrict share award replace grant option certain employeesas cost scheme readily equate potential gain employee group operate share option scheme savingsrelate share option scheme grant share option scheme normally exercisable year date grant grant savingsrelate share option scheme normally exercisable year save option share option scheme normally grant market price ruling date grant accordance uk practice majority option savingsrelate share option scheme grant price cent market price ruling date grant accordance exemption grant uitf revise charge profit loss accountismade relation savingsrelate share option scheme option outstanding share option share option savingsrelate scheme share scheme adss share option scheme weight weight weight number exercise number exercise number exercise price price price st december option grant option exercise option cancel st december option grant option exercise option cancel st december option grant option exercise option cancel st december range exercise price order encourage employee convert option exclude savingsrelate share option hold glaxo wellcome smithkline beecham share adss glaxosmithkline share adss programme establish additional cash benefit ofper cent exercise price original option provide employeedidnot voluntarily leave group year date merger anddidnot exercise option early month expiry date original option year date merger cash benefit pay option expire unexercised market price exercise price date expiry option outstanding share option share option savingsrelate scheme share scheme adss share option scheme st december weight late weight late weight late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option exercisable option share adss grant savingsrelate share option grant change effective exercise price outstanding option yearnofurther option grant st december andth februarynote financial statementsglaxosmithkline employee share scheme continue option exercisable share option share option savingsrelate scheme share scheme adss share option scheme weight weight weight number exercise number exercise number exercise price price price st december st december st december glaxosmithkline share award scheme performanceshareplan group operate performance share plan award grant director senior executive cost percentage award vest base performance group year measurement period performance condition consist part apply cent award forawardsgrante condition compare glaxosmithkline total shareholder return tsr period tsr company ukftse index period award grant condition compare glaxosmithkline tsr period tsr pharmaceutical company thecomparatorgroup period second performance condition compare glaxosmithkline earning share growth increase ukretail price index year performance period award grant director member cet th december subject single performance condition compare glaxosmithkline tsr period tsr company thecomparatorgroup period award share adss number share adss issuable number number st december award grant award exercise award cancel st december award grant award exercise award cancel st december award grant award exercise award cancel st december restrictedshareplan group operates restrict share plan award grant employee cost award vest yearswith performance criterion attach share adss number share adss issuable number number st december award grant st december glaxosmithkline note financial statement employee share schemescontinue employee share ownership plan trust group sponsor employee share ownershipplanesop truststo acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share onthe open market finance provide group way loan contribution expect cost ofthe obligation deliver share scheme normally spread period service respect award option grant accelerated charge respect outstanding cost provide share award option exercisable solely result merger share hold share award scheme restate number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value result restate follow implementation uitfreviseduitfrevisedrequire minimum expense difference fair value share date award employee require pay share ie intrinsic value award trust acquire hold share meet notional dividend reinveste deferred award smithkline beechammidterm incentive plan trustee waive right dividend share hold employee share ownership trust option pricing purpose value option arrive stockbase compensation adjustment reconciliation accounting principle innote blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life option grant share option scheme year year savingsrelate share option scheme year yearsnote financial statementsglaxosmithkline reconciliation usaccounte principle additionally group reassesse useful live exist recognise intangible asset intangible asset deem analysis reconciliation present note represent indefinite life long amortise instead test financial information prepare basis generally annually potential impairment separable intangible asset accept accounting principle usgaap ukgaap finite life continue amortise useful life summary material difference uk gaap group adopt sfas st january acquisition smithkline beecham implementation sfas result impairment combination glaxo wellcome plc smithkline beecham group goodwill initial impairment million plc account merger pooling interest million net tax indefinitelive asset show accordance ukgaap gaap business cumulative effect accounting change combination qualify pool interest accounting ukgaap cost incur integrate glaxo wellcome determine accounting restructuring wellcome smithkline beecham block drug acquirer purchase business combination business follow acquisition accordingly net asset smithkline beecham fair value respectively charge profit loss account post date acquisition result fair value exercise acquisition usgaap certain cost consider increase value smithkline beecham inventory tangible allocation purchase consideration affect fix asset investment pension obligation recognise goodwill arise acquisition fair market value attribute intangible asset mainly ukgaapcertain intangible asset relate specific product right inclusive patent trade mark inprocess compound product purchase party research development appropriate defer develop commercial application capitalise taxation effect difference cost acquisition usgaap payment compound product fair value asset liability smithkline development receive regulatory beecham record goodwill approval charge directly profit loss account timethat receive regulatory approval capitalise interest uk gaap group capitalise interest usgaap restructuring cost require interest incur cost construct fix ukgaap restructuring cost incur follow acquisition asset capitalise amortise life asset charge profit loss account post acquisition usgaap purpose certain cost recognise computer software liability acquisition opening balance sheet uk gaap group capitalise cost incur acquire develop computer software internal use restructuring cost record provision uk software support significant business system gaap restructuring plan announce expenditure lead creation durable asset gaap provision recognise criterion gaap group apply sop accounting cost meet liability incur accordingly adjustment computer software develop obtain internal use eliminate ukgaapprovision restructuring restrict category cost capitalise cost notmeet usgaaprequirement goodwill intangible fix asset marketable security ukgaap goodwill arise acquisition marketable security consist primarily equity security account purchase method eliminate certain liquid investment ukgaapthese security shareholder fund additionally ukgaap require state low cost net realisable value subsequent disposal closure business goodwill usgaap securities consider available sale previously take directly shareholder fund charge sfas account certain investment debt equity income ukgaap goodwill arise acquisition security carry fair value unrealised gain capitalise amortise period exceed loss net tax record separate component year intangible asset amortise estimate shareholder equity useful economic life case certain acquire brand equity security review annually end useful economic life brand temporary impairment factor consider foresee investee current financial performance future gaap goodwill arise acquisition prior prospect thjune capitalise amortise period general market condition geographic exceeding year intangible asset include brand industry area investee operate amortise finite life july financial accounting duration extent market value standard board fasb issue statement financial accounting ifavailable cost standard sfasgoodwill intangible asset sfas require goodwill long amortise gross unrealised gain loss marketable security estimate useful life group instead identify value million million respectively st december reporting unit purpose assess annually million million respectively st december potential impairment goodwill allocate reporting unit glaxosmithkline note financial statement reconciliation accounting principle continue change account prior year adjustment ukgaap reconciliation profit attributable pension postretirement benefit shareholder equity shareholder fund ukgaap key difference uk ssap usgaap usgaap restate accordingly reconcile relation define benefit pension plan restate ukgaap figure ukgaapthe effect variation cost reconciling difference ukgaap usgaap remain accumulated successive valuation amortise respect charge recognise profit usgaap aggregate basis gaap amortisation share purchase esop trust account transition asset cost past service benefit shareholder equity gain loss issuance share improvement separately track experience gainslosse employee record adjustment shareholder equity deal aggregate basis amortise outside cent corridor guarantor obligation uk gaap allow measurement plan asset liability group adopt fasbs financial interpretation base result late actuarial valuation finguarantor accounting disclosure requirement usgaap require measurement plan asset liability guarantee include indirect guarantee indebtedness date financial statement effect st january month prior date require group recogniseand measure fair value pension adjustment include impact change prospective basis certain guarantee issue modify minimum pension liability include accumulate st december ukgaapsuch guarantor obligation comprehensive income recognise additional criterion meet liability incur group decide align measurement datefor pension postretirement benefit plan derivative instrument st december certain group plan measurement sfas accounting derivative instrument hedge date asset liability th september activitiesas amend sfas sfas impact reflect cumulative effect accounting interpret derivative implementation group adopt change million credit net tax income group effect st january sfas establish accounting reporting standard derivative stockbase compensation instrument include certain derivative instrument embed uk gaapshare option account equity contract collectively refer derivative exercise value issuance price usgaap group hedging activity ukgaap derivative instrument apply sfas accounting stockbase compensationand hedging recognise balance sheet relate accounting interpretation accounting option plan match principle match gain loss require option fair value grant date hedging contract foreign currency transaction include profit loss vest period option profit relate sfas require entity recognise derivative asset liabilities group entitle receive tax deduction consolidate balance sheet measure instrument treat compensation tax rule employee fair value change fair value period record stock option exercise usemployee current earning hedge accounting obtain group year ukgaapthis treat reduction tax designate derivative qualify hedge expense whereasunder usgaapa portion instrument sfassfas prescribe requirement credit equity designation documentation hedge relationship ongoing assessment effectiveness order qualify hedge employee share ownership plan trust account prior uk gaap share group stock hold esop trustswererecorde cost provision represent group evaluate contract embed derivative difference cost option exercise price consider embed derivative account fix asset investment project loss bifurcate separated host contract accordance exercise option cover share record sfas requirement embed derivative exist profit loss account life theoption clearly closely related host contract uitfabstract accounting esoptrustsand relate account separately host contract derivative amendment uitfabstract employee share schemeswere gain loss relate fair value adjustment implement group ukgaap financial statement uitf derivative instrument classify consolidated statement change presentation entitys share hold esop income cash flow accordance nature trust require recognise asset require derivative deduct arrive shareholder fund usgaap uitf revised require minimum expense fair value book value derivative instrument respect difference fair value share financial asset liability st december date award employee disclose classification fair value financial asset require pay share ie intrinsic value award liability table notenote financial statementsglaxosmithkline reconciliation accounting principle continue sale incentive accordance ukgaap certain amount pay group valuation derivative instrument customer record promotional expense include fair value derivative instrument sensitive movement operating income usgaap item record underlying market rate variable group monitor reduction revenue item result net fair value derivative instrument quarterly basis impact income statement usgaap formal review month derivative include classify reduction revenue interest rate swap crosscurrency swap value million million standard valuation model counterparty valuation party valuation standard valuation model group consider variable interest entity relevant discount rate market yield curve valuation january fasb issue interpretation fin date forward currency exchange rate counterparty risk consolidation variable interest entity december significant rate variable obtain market source issue fin r revision interpretation valuation base remain term maturity revise interpretation certain entity know variable interest instrument foreign exchange contract value forward entity vie consolidate primary beneficiary rate observe quote price relevant market entity primary beneficiary generally define possible group assume party longterm contract majority risk reward arise vie economically viable reserve right exercise early additionally vie significant majority termination right economically beneficial right variable interest hold certain disclosure require exist contract group complete review potential vie anda dividend consequenceha consolidated theravance incfrom uk gaap dividend propose provide year note c pageno vie group respect recommend board primary beneficiary identify ofdirector approval shareholders usgaap suchdividend provide declare board recent financial accounting standard board fasb ofdirector pronouncement fasb issue fasb staff position fsp consolidated summary statement cash flow fasaccounte disclosure requirement relate usgaap cash flow statement report change cash medicare prescription drug improvement modernization cash equivalent include shortterm highly liquid act supersede fsp fsp address investment original maturity month accounting implication act entity sponsor onlythree category cash flow report operate postretirement health care plan provide prescription drug activity include tax interest investing activity benefit act introduce usa prescription drug include capital expenditure acquisition disposal benefit medicarea federal subsidy sponsor cashflow available sale current asset investment certain postretirement health care plan company andfinance activity include dividend pay summary elect deferral fsp fsp effective statement ofcash flow present page reporting period commence th june estimate amountof federal subsidy treat prior cash cash equivalent service gain credit profit loss account uk gaapthe cash balance include cash bank average service live employeesunder usgaap cash balance usgaapcash cash equivalent change result decrease million accumulate include cash bank certain liquid investment original benefit obligation reduction million net periodic maturity month postretirement benefit cost year end st december comprehensive income statement requirement sfas report comprehensive income provide comprehensive income statement meet ukgaap statement total recognise gain loss pagesand reclassification certain prior year balance reclassify comparative purpose certain amount previously present aggregate reconciliation profit usgaap ukgaap present separately current year presentation provide information relate adjustment glaxosmithkline note financial statement reconciliation accounting principle continue follow summary material adjustment profit shareholder fund require gaap apply instead uk gaap restate restate profit note profit attributable shareholder ukgaap goodwill amortisation reversal include goodwill associate undertaking amortisation impairment intangible asset b acquisition disposal ofproduct rights b capitalise interest tangible fix asset disposal interest associate disposal goodwill subsidiary product divestment equity investment recognition cost sale fair value stepup inventory pension postretirement benefit f stockbased compensation derivative instrument hedge fair value option grant minority shareholder c guarantor obligation restructure tax benefit exercise stock option defer taxation variable interest entity c net income gaap cumulative effect change accounting principle cumulative effect change accounting principle net income cumulative effect change accounting principle certain item year end st december reclassify comparative purpose earning share usgaap p p p basic net income share cumulative effect change accounting principle usgaap cumulative effect change accounting principle share usgaap basic net income share cumulative effect change accounting principle usgaap diluted net income share cumulative effect change accounting principle usgaap cumulative effect change accounting principle share usgaap dilute net income share cumulative effect change accounting principle usgaap earning ad usgaap basic net income ad cumulative effect change accounting principle usgaap cumulative effect change accounting principle ad usgaap basic net income ad cumulative effect change accounting principle usgaap diluted net income ad cumulative effect change accounting principle usgaap cumulative effect change accounting principle ad usgaap diluted net income ad cumulative effect change accounting principle usgaap note financial statementsglaxosmithkline reconciliation accounting principle continue restate equity shareholder fund note equity shareholder fund uk gaap usgaapadjustment goodwill product right b pension intangible asset b tangible fix asset capitalise interest marketable security investment fair value stepup inventory pension postretirement benefit f restructuring cost derivative instrument hedge fair value option grant minority shareholder c guarantor obligation dividend defer taxation e variable interest entity c shareholders equity gaap consolidate statement cash flow usgaap net cash provide operating activity net cash investing activity net cash financing activity net increasein cash cash equivalent exchange rate movement cash cash equivalent begin year cash cash equivalent end year note profit equity shareholder fund reconciliation goodwill follow table set uk usgaap adjustment require uk gaap statement profit loss balance sheet respect goodwillinclude goodwill respect associate undertaking income statement amortisation ukgaap amortisation usgaap uk usgaap adjustment amortisation include goodwill respect associate undertaking balance sheet goodwill ukgaap goodwill usgaap uk usgaap adjustment million millionusgaap goodwill balance st december million million respect goodwill arise acquisition smithkline beecham glaxo wellcome glaxosmithkline note financial statement reconciliation accounting principle continue follow table present change goodwill allocate group reportable segment consumer pharmaceutical healthcare total st december addition exchange adjustment st december asset write exchange adjustment st december b intangible asset follow table set ukto usgaap adjustment require ukgaap statement profit loss balance sheet respect intangible asset income statement amortisation charge ukgaap amortisation charge usgaap ukto usgaap adjustment amortisation impairment charge ukgaap impairment charge usgaap ukto usgaap adjustment forimpairment cumulative effect change accounting principle uk usgaap adjustment forimpairment period follow initial implementation sfas carry value brand determined indefinite life review impairment million million net tax recognise record cumulative effect change accounting principle addition adjustmentsfor amortisation impairmentsfurther uk usgaap adjustmentsarose year million million million respect acquisition licence patent etc capitalise ukgaap charge directly toresearch development expenseunder usgaap million nil respect disposal product right high carrying value usgaap ukgaap balance sheet intangible asset ukgaap intangible asset usgaap ukto usgaap adjustment pension intangible asset net ukto usgaap product right adjustment intangible asset usgaap analyse follow acquire product licence patent etc brand pension intangible asset usgaap follow table present detail group intangible asset differentiate subject amortisation whichare subject amortisation intangible asset subject amortisation intangible asset subject amortisation intangible asset usgaap note financial statementsglaxosmithkline reconciliation accounting principle continue follow intangible asset subject amortisation product product right right cost accumulate amortisation impairment net carry value certain product right review impairment million record impairment million record million relate paxilwhich impair follow launch usa generic paxilproduct fair value determine discount cash flow model discuss notelegal proceeding number distributor generic drug file application market generic version ofa number group product prior expiration group patent generic version product launch future period early date group currently expect impairment carry value product arise estimate future amortisation expense year intangible asset subject amortisation st december follow year total intangible asset subject amortisation include pension asset million st december million st december certain product right intangible asset relate product right analyse follow cost impairment net impairment charge nilwas recognise million c theravance group form strategic alliance theravanceincto develop commercialise novel medicine variety important therapeutic area term alliance theravance receive million significant relate group purchase theravance share group option increase ownership cent significant premium price pay transaction theravance shareholder option low exercise price cause glaxosmithkline acquire half outstanding stock give maximum number share subject optionthe group obligation cap million group exclusive option license potential new medicine theravance programme august exercise option theravance programme group responsible relevant development manufacturing commercialisation activity depend success programme theravance receive clinical regulatory commercial milestone payment royaltie subsequent sale medicine base assessment perform group primary beneficiary theravance define fin r result theravance consolidate group gaap financial statement net asset acquire measure fair value principaladjustment carrying value net asset theravance balance sheet prior acquisition recognition inprocess research development iprd valuation million iprdwa writtenoff immediately acquisition accordance usgaap purchase accounting effect consolidate theravance todecrease shareholder equityandnet income million additionally group account theravance option discuss accordance sfas account certain financial instrument characteristic liability equity require group record fair value option liability fair value ofthe theravance optionat st december million initial consolidation theravance value option millionin accordance sfas accounting derivative instrument hedge activity option recognise financial statement readily convertible cash glaxosmithkline note financial statement reconciliation accounting principle continue taxation restate restate total tax expense uk gaap current tax expense defer tax creditexpense total tax expense gaap current tax expense defer taxcredit total tax expense cumulative effect change accounting principle total tax expense ukto usgaap adjustment current tax expense defer taxcredit total tax expense cumulative effect change accounting principle total tax expense e defer taxation usgaap classification glaxosmithkline defer taxation liability asset gaap follow restate liability stock valuation adjustment current defer taxation liability accelerate capital allowance product right time difference total defer taxation liability asset intragroup profit time difference current defer taxation asset asset disposal pension postretirement benefit tax loss manufacture restructure legal dispute time difference total defer taxation asset net defer taxation gaap net defer taxation ukgaap uk usgaap adjustment note financial statementsglaxosmithkline reconciliation accounting principle continue f pension postretirement cost usgaap uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid scheme unfunded define benefit scheme define contribution scheme unfunded postretirement healthcare scheme postemployment cost disclosure include additional information require sfas r pension cost uk major overseas define benefit pension plan restate follow table accordance gaap pension cost million million million respect minor retirement plan recalculate accordance requirement sfas exclude net periodic pension costfor major retirement plan service cost interest cost expect return plan asset amortisation prior service cost amortisation transition obligation amortisation net actuarial loss net periodic pension costunder gaap termination benefit curtailment cost adjustment change accounting principle group decide align measurement date pension plan certain group pension plan measurement date pension asset liability th september group elect change measurement date plan th september st december major assumption computingpension cost pa pa pa rates future pay increase discount rate expect longterm rate return plan asset aggregate average international plan assumption vary significantly assumption estimate future benefit payment glaxosmithkline note financial statement reconciliation accounting principle continue change benefit obligation benefit obligation beginning year amendment service cost interest cost plan participant contribution actuarial loss benefit pay termination benefit curtailment cost exchange benefit obligation end year benefit obligation end year pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation st december million st december million change plan asset fair value plan asset begin year actual return plan asset employer contribution plan participant contribution benefit pay exchange fair value plan asset end year fair value plan asset end year pension plan accumulate benefit obligation excess plan asset plan asset consist primarily investment uk overseas equity fix interest security security link uk retail price index property st december uk equities includedmillion glaxosmithkline share million share market value million million normal employer contribution expect approximately million fund status fund status unrecognise net actuarial loss unrecognise prior service cost unrecognised transition obligation net recognise amount recognise statement financial position prepay benefit cost accrue pension liability intangible asset accumulate comprehensive income net recognise note financial statementsglaxosmithkline reconciliation accounting principle continue postretirement healthcare usgaap postretirement healthcare cost uk major overseas postretirement healthcare scheme restate follow table accordance usgaap cost nil million nil recalculated exclude net healthcare cost service cost interest cost amortisation prior service cost amortisation net actuarial loss net healthcare cost major assumption calculate net healthcare cost pa pa pa rate future healthcare inflation discount rate rate future healthcare inflation reflect fact benefit certain group participant cap change benefit obligation benefit obligation beginning year amendment service cost interest cost plan participant contribution actuarial loss benefit pay exchange benefit obligation end year change plan asset fair value plan asset begin year employer plan participant contribution benefit pay fair value plan asset end year fund status fund status unrecognise net actuarial loss unrecognise prior service cost accrue postretirement healthcare cost decrease increase impact cent variation rate future healthcare inflation effect total service interest cost effect provision postretirement benefit glaxosmithkline note financial statement principal group company follow represent principal subsidiary associated undertakings glaxosmithkline group stdecember detail give principal country operation location headquarters business segment business activity equity share capital undertaking wholly own group percentage interest show company incorporate principal country operation state europe location subsidiary undertaking segment activity england brentford glaxosmithkline holdings onelimite phch h brentford glaxosmithkline service unlimited phch brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc ph f brentford smithkline beecham plc phch e h p r brentford wellcome limited phch h greenford glaxo group limit ph h greenford glaxo operation uk limit ph p brentford glaxo wellcome international bvfootnote phch h brentford glaxo wellcome investments bvfootnote phch h stockley park glaxo wellcome uk limit ph h p brentford glaxosmithkline export limit ph e brentford glaxosmithkline research development limit ph dr brentford glaxosmithkline uklimited ph p brentford smithkline beecham investments limited phch f brentford smithkline beecham swg limited ch e brentford smithkline beecham research limit ph brentford staffordmiller limited ch p greenford wellcome foundation limit ph p brentford setfirst limited phch fh glaxosmithkline luxembourg sa footnote ii austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa ph rixensart glaxosmithkline biological sa ph em pr rixensart glaxosmithkline biological manufacture sa ph h guernsey st peter port smithkline beechamlimite phch denmark ballerup glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharmaas ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h pr buehl glaxosmithkline healthcare gmbh ch h greece athens glaxosmithkline aebe phch h hungary budapest glaxosmithkline kft phch e italy verona glaxosmithkline spa ph h mr milan glaxosmithkline consumer healthcare sp ch h luxembourg mamer glaxosmithkline international luxembourg sa phch f hnote financial statementsglaxosmithkline principal group company continue europe location subsidiary undertaking segment activity netherlands zeist glaxosmithkline bv ph zeist glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p warsaw glaxosmithkline consumer healthcarespzoo ch portugal lisbon glaxosmithklineprodutos farmaceutico lda ph republic dublin glaxosmithkline consumer healthcare ireland limited footnote iii ch ireland carrigaline smithkline beecham cork limitedfootnote iii ph p carrigaline smithkline beecham manufacturinglimitedfootnote iii ph p spain tre cantos glaxosmithkline sa ph aranda de duero glaxosmithkline sa ph p alcaladehenare smithkline beecham sa ph p sweden mlndal glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline investments switzerland gmbh phch h muenchenbuchsee glaxosmithkline ag ph zug adechsa gmbh ph e usa usa philadelphia smithkline beecham corporation phch e hm p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h p wilmington glaxosmithkline financial inc ph f wilmington glaxosmithkline holdings americas inc phch h americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc phch p r asia pacific australia boronia glaxo wellcome australia pty ltd phch e p r china hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd ph p r india mumbai glaxosmithkline pharmaceutical limit ph p nabha glaxosmithkline consumer healthcare limitedfootnote iv ch p malaysia petale jaya selangor glaxosmithkline pharmaceutical sdn bhd ph darul ehsan new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch pe philippines makati glaxosmithkline philippines inc phch singapore singapore glaxo wellcome manufacturing pte ltd ph p singapore glaxosmithkline pte ltd ph south korea seoul glaxosmithkline korea ph p taiwan taipei glaxo wellcome taiwan limit ph p glaxosmithkline note financial statement principal group company continue japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline kk phch p r latin america argentina buenos aires glaxosmithkline argentina sa phch p brazil rio de janeiro glaxosmithkline brasil ltda phch p colombia bogota glaxosmithkline colombia sa phch mexico mexico city glaxosmithkline mexico sade cv phch e ps puerto rico guaynabo glaxosmithkline puerto rico inc ph san juan sb pharmco puerto rico inc ph p venezuela caracas glaxosmithkline venezuela phch middle east africa egypt cairo glaxosmithklinesae ph p south africa bryanston glaxosmithkline south africa pty ltd phch p turkey istanbul glaxosmithkline ilaclari sanayi ticaret ph p usa location associate undertaking business usa teterboro quest diagnosticsincorporatedfootnote v clinical testing footnote incorporate netherlands ii originally incorporate luxembourg register guernsey iii exempt provision section company amendmentact ireland iv consolidated subsidiary undertaking accordance section company act ground ofdominant influence v equity account ground significant influence directly hold wholly own subsidiary glaxosmithkline plc business segment phpharmaceutical chconsumer healthcare business activity ddevelopment eexporte ffinance hholde company iinsurance mmarketing pproduction rresearch sservice detail group subsidiary associate undertaking attach company annual return file registrar ofcompaniesglaxosmithkline investor information section include financial record presentinghistorical information prepare ukgaap addition historical information restate accordance international financial reporting standard present section alsodiscusse shareholder return return shareholder form dividend share price movement provide information shareholder financial record information prepare ukgaap quarterly trend yearrecord financial information international financial reporting standardsifrs background ifrs accounting policy ifrsadjustment ifrs pharmaceutical turnover total group ifrsconsolidate income statement ifrsconsolidate balance sheet ifrsconsolidate statement recognise income expense ifrsconsolidate cash flow statement shareholder return shareholder information share capital taxation information shareholder glaxosmithkline financial record quarterly trend unaudite analysis provide quarter group result sterle financial year analysis comprise statutory result business performance result pharmaceutical sale therapeutic area profit loss account statutory month q cer cer turnoverpharmaceutical consumer healthcare total turnover cost sale sell general administrative expenditure research development expenditure operating cost trading profit pharmaceutical consumer healthcare total trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking business disposal profit disposal interest associate profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation equity minority interest preference share dividend earning profit attributable shareholder basic earning share p p profit loss account business performance turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative expenditure research development expenditure operating cost trading profit pharmaceutical consumer healthcare total trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking business disposal profit ondisposalof interest associate profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation equity minority interest preference share dividend adjust earning profit attributable shareholder adjust earning share p pfinancial recordglaxosmithkline month q month q q cer cer cer cer cer p p p p p p p p p p glaxosmithkline financial record pharmaceutical turnover total group q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir agenerase lexiva herpe valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccine hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac total pharmaceutical turnover include copromotion incomefinancial recordglaxosmithkline pharmaceutical turnover usa q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir agenerase lexiva herpe valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccine hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac total pharmaceutical turnover include copromotion income glaxosmithkline financial record pharmaceutical turnover europe q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir agenerasee lexiva herpe valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccine hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac total pharmaceutical turnover include copromotion incomefinancial recordglaxosmithkline pharmaceutical turnover international q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir ageneraselexiva herpe valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandia avandamet vaccine hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac total pharmaceutical turnover include copromotion income glaxosmithkline financial record year record record financial performance provide analysed accordance current reporting practice turnover business segment pharmaceutical consumer healthcare pharmaceutical turnover therapeutic area central nervous system respiratory antibacterial antiviral metabolic vaccine oncology emesis cardiovascular urogenital continue business divest product pharmaceutical turnover geographic area usa europe international asia pacific japan latin america middle east africa canada international pharmaceutical turnover inand include copromotion income consumer healthcare sale otc medicine oral care nutritional healthcare continue business divest product financial recordglaxosmithkline restate restate restate restate statutory result turnover operate profit profit taxation earning profit attributable shareholder dividend retain profit basic earning share p dilute earning share weight average number share issue basic diluted return capital employ cent return capital employ calculate statutory profit taxation percentage average capital employ year merger restructure disposal subsidiary manufacture restructuring merger cost product divestment item lossprofit taxation lossprofit attributable shareholder business performance result turnover rd expenditure cent sale trading profit cent sale net interest payable profit taxation adjust earning profit attributable shareholder year business performance primary performance measure management present exclude merger item integration restructuring cost disposal business management believesthat exclusion item providesa well comparison way business manage givesan indication performance group term element revenue expenditure local management able influence information provide addition statutory result prepare ukgaap give assist shareholder gain clear understanding underlying performance business increase comparability period present statutory result include itemsfor withthe completion programme group reporting result statutory basis amount accordance gaap turnover net incomeloss basic net incomeloss share pence p p p p diluted net incomeloss share pence p p p p information present gaap net incomeloss net incomeloss share result year end st december adjust reverse amortisation expense goodwill indefinitelive intangible asset sfas apply year adjusted net incomeloss adjust basic net incomeloss share penny p p adjust diluted net incomeloss share penny p p glaxosmithkline financial record balance sheet restate restate restate restate net asset fix asset asset liability net operating asset net debt net asset capital employ share capital share premium reserve equity shareholder fund minority interest capital expenditure tangible fix asset amounts accordance gaap total asset net asset shareholder equity number employees usa europe international asia pacific japan latin america middle east africa canada international manufacturing sell administration research development number employee number permanent employ staff end financial period exclude employee employ manage glaxosmithkline contract basis exchange rate guide holder adr follow table set period indicate information exchange rate dollar sterling report federal reserve bank new york noon buying rate average average rate year calculate average noon buying rate day month year feb jan dec nov oct sept high low noon buying rate onthfebruary usglaxosmithkline financial information international financial reporting standard ifrs background financial instrument financial instrument comparative period present annual report ie ifrs project record exist uk gaap basis june council european union adopt accordance ias financial instrument regulation require list company member state disclosure presentationand ias financial instrument prepare consolidated financial statement accordance recognition measurementsee international financial reporting standard ifrs glaxosmithkline annual report prepare ifrs ifrsfinancial informationhas prepare basis year end st december take exemption financial result announcement prepare accordance ifrs quarter financial instrument glaxosmithkline intends adopt ias howeverone group project convert financial report uk exemption available ifrs relax requirement gaap ifrs complete subject change comparative informationpresented annual report standard pronouncement training programmeha comply ias ias glaxosmithkline intends roll finance staff worldwide adjust advantage exemptionand soin historical datum provide comparative information financial instrument willbe account present ifrs prepare uk gaap basis unaudite consolidated result glaxosmithkline plc st january therewasan adjustment opening convert currentuk gaapbasis ifrs basis balance sheet reflect movement uk gaap present pagesto carry value ias ia value willbethe early year ifrs financial statement financial instrument fair value willbe present annual report transition date ifrs glaxosmithkline st january normally financial instrument concern accounting change nature require retrospective hold fair value ifrs movement record application ifrs transitional rule certain equity adjustment onlyhave applied effect equity investment transition date ofst january liquid investment derivative classify cash flow hedging instrument basis preparation datum ifrs financial informationha prepare basis hold fair value ifrs movement record ofall ifrs standing interpretations committee sic income statement international financial reporting interpretation committee ifric equity collar link group investment quest interpretation issue iasb effective reporting diagnosticsinc option link group strategic glaxosmithkline choose adopt iasbs amendments alliance theravanceinc ias employee benefit early permit actuarial gain derivative classify hedging instrument loss difference expect actual return include embed derivative effect change actuarial assumption recognise derivative classify fair value hedge statement ofrecognisedincome andexpense hedge element relevant asset liability financial information presentedunder ifrsis unaudite presentation difference nonequity minority interest repay ifrsexemption ifrsfirsttime adoption international financial reporting ia valuationrule applied standardspermit company adopt ifrs charge profit taxthe large time exemption requirement ifrs element arise quest collar million transition periodglaxosmithkline intend million theravance option follow key exemption million nil valuationsare inherently unpredictable change fair value financial instrument business combination business combination prior havea material impact future resultsand financial transition date st january restate positionof glaxosmithkline ifrs basis employee benefit cumulative actuarial gain loss recognise equity transition date sharebase payment ifrs sharebase paymentapplie equity instrument share optionsgrante th november glaxosmithkline elect adopt retrospective application standard glaxosmithklinefinancialinformation ifrs ifrs accounting policy foreign currency transaction foreign currency transaction group company book follow ifrs accounting policy expect apply inlocal currency exchange rate ruling date glaxosmithkline plc consolidatedffinancial statement transaction foreign currency asset liability retranslate local currency rate exchange rule balance sheet date exchange difference areinclude inthe income statement consolidation consolidated financial statement include revenue asset liability result cash flow revenue recognise income statement good company subsidiary includingesoptrust service supply available external customer group share net asset result joint order receive title risk loss pass venture associate customer turnover represent net invoice value deduction discount allowance givenand accrual financial statement ofundertaking consolidate madeup estimate future rebate return methodology st december assumption estimate rebate return monitor entity group ability exercise control adjust regularly light contractual historical account subsidiarieswhere group ability information past experience turnover include co exercise joint control account joint venture promotion income group records share group ability exercise significant influence revenue relate cost sale value add tax account associate sale taxis exclude revenue interest acquire entity consolidated effective expenditure date acquisition interest sell consolidated upto expenditure recognise respect good service receive date disposal supply accordance contractual term provision transaction balance subsidiary eliminate obligation exist future liability respect profit take sale subsidiary sale joint past event obligation venture associate product sell customer reliably estimate advertising promotion expenditure outside groupdeferre tax relief unrealise intragroup charge income statement incur shipment cost profit account extent consider intercompany transfer charge cost sale distribution recoverable cost sale customer include sell general administrative expenditure restructuring cost recognise goodwill arise acquisition interestsin subsidiary joint respect direct expenditure business reorganisation venture associate represent excess purchase plan sufficiently detail advanced consideration group share fair value appropriate communication affect identifiable asset liability contingent liability acquire undertaken balance sheet date capitalise asa separate item case subsidiarie cost investment case joint venture research development associate goodwill denominate currency research development expenditure charge income operation acquire case acquisition prior statement period incur development goodwill write directly equity subsequent expenditure iscapitalise criterion recognise asset disposal asset acquisition relate goodwill aremetusually point regulatory filing major market remain equity charge consolidated income property plant equipmentuse research development statement isdepreciate accordance group policy result asset liability associate joint venture incorporate consolidated financial statement environmental expenditure equity method account environmental expenditure relate exist condition result past current operation current asset liability overseas subsidiary associate joint future benefit discernible charge income statement venture include related goodwill translate sterling grouprecognisesit liability sitebysite basiswhen itcan rate exchange rule balance sheet date result reliablyestimate liability include groupsportion cash flow overseas subsidiary associate joint venture total cost portion potentially responsible translate sterling average rate exchange party cost probable able exchange adjustment arise open net asset satisfy respective share cleanup obligationrecoverie profit theyear retain overseas subsidiary associate reimbursement record asset virtually certain joint venture translate sterling exchange difference arise related foreign currency borrowing hedge group net investment operation take separate component equity translating sterling theasset liability result cash flow overseas subsidiary associate joint venture report currency hyperinflationary economy adjustment aremade reflect current price level loss net monetary assetsis charge consolidated income statementfinancial information ifrsglaxosmithkline ifrs accounting policy continue property plant equipment property plant equipment ppe state cost pension postemploymentbenefit purchase construction provision depreciation cost provide pension define benefit scheme impairment financing cost capitalise calculate project unit credit method spread period benefit expect derive depreciation calculate write cost ppe exclude employee servicesin accordance advice qualified freehold land straightline basis expect useful actuary pension obligation measure present value life normal expect useful life major category estimate future cash flow discount rate reflect ppe review annually yield high quality corporate bond pension scheme asset measure fair value balance sheet date actuarial gain freehold building year loss difference expect actualreturn leasehold land lease term year andthe effect change actuarial assumption recognise building statement ofrecognisedincome andexpensein plant machinery year year arise fixture equipment year group contribution define contribution plan ondisposal ppe cost relate accumulate charge income statement incur depreciation impairment remove financial statement net proceed take cost postemployment liability calculate income statement similar way define benefit pension scheme spread period benefit expect derive lease employee servicesin accordance advice qualified leasing agreement transfer group substantially actuarie benefit risk ownership asset treat finance lease asset purchase outright legal dispute asset include inppe computer software capital provision foranticipated settlement costswhere element leasing commitment show obligation reasonable estimate likely outcome legal finance lease asset hold finance lease dispute group addition provision depreciate basis consistent similar own asset legalorother expensesarising fromclaim receivedorother lease term short interest element lease rental disputesin respect product liability claim relate product include income statement lease operate sufficient history claim settlement lease annual rental include income statement incur report ibnr actuarial technique straightline basis lease term determine reasonable estimate group exposure unasserted claim product provision goodwill basis provision unasserted claim goodwill state cost lessimpairment goodwill deem obligation exist dispute possible indefinite useful life test impairment annually reasonable estimate cost associate claim group party charge income fair value interest acquire entitys asset statementa incur liability contingent liability exceed consideration pay excess recognise immediately gain income employee share plan statement incentive form share provide employee share option share award scheme theseoption award fair value grant datesand cost charge income statement relevant vest period thegroupprovides finance esoptrust purchase company share open market meet theobligation provide share employee exercise optionsor awardscosts run esop trust charge income statement share hold esoptrust deduct reserve hold value ofthe proceed receivable employee exercise deem apermanent impairment value reflect bya transfer toretaine earning glaxosmithklinefinancial information ifrs ifrs accounting policy continue inventory inventory include financial statement low intangible fix asset cost include raw material direct labour direct cost intangible asset state cost lessprovisionsfor amortisation relate production overheadsandnet realisable value impairment costis generally determine basis licence patent knowhow marketing right separately acquire acquire business combination taxation amortise estimate useful life time defer tax provide liability method available use estimate useful life determine temporary difference arise tax basis asset amortisation charge review annually andtake liability carry amountsin financial account estimate time take bring compound statement defer tax asset recognisedto extent product market anydevelopment costsincurre group probable future taxable profit available andassociate withacquire licence patent knowhow temporary difference utilise marketing right write income statement defer tax provide temporary difference arise whenincurre criterion recognition internally investment subsidiary associate joint venture generate intangible asset met time reversal temporary difference brand value independently fair value control probable temporary difference business acquire party brand reverse foreseeable future value substantial longterm brand defer tax provide rate tax enact sell separately rest business acquire substantively enact balance sheet date defer tax brand areamortise theirestimated useful life liability asset discount consider useful economic lifeis indefinite prior acquire minor brand similar intangible derivative fifnancial instrument hedging activity eliminate group balance sheet reserve year derivative financial instrument manage exposure acquisition market risk treasury operation principal derivative instrument glaxosmithklineareforeign currency swap cost acquire develop computer software interest rateswap forward foreign exchange contract internal use internet site external use capitalise group hold issue derivative financial instrument intangible fix asset software site support trade speculative purpose significant business system expenditure lead creation durable asset erp system software amortise derivative financial instrument initially recognise seven year computer software balance sheet cost thenremeasure subsequent year report date tofair valuehedging derivative classify inception fair value hedge cash flow hedge net impairment ofnoncurrentasset investment hedge carry value allnoncurrentasset review change fair value derivativesdesignateda fair value impairment indication asset hedge record income statementwiththe change impair additionally goodwill intangible asset fair value hedge asset liability indefinite useful livesand intangible asset available forusearetestedfor impairment annually change fair value derivativesdesignateda cash flow provision impairment charge income statement hedge recognise equity amount defer equity year concern transfer income statement line withthe hedged forecasttransaction investment joint ventures associate hedge net investmentsin foreign entity account investment joint ventures associate carry ina similar wayto cash flow hedge consolidate balance sheet group share oftheir net asset date acquisition postacquisition retain profit change fair value derivative instrument loss goodwill arise acquisition qualify hedge accounting recognise immediately income statement availableforsale investment availableforsale investment initially record cost debt instrument remeasure subsequent reporting date fair value unhedgeddebt instrument state net unrealised gain loss availableforsale investment proceedsadjustedto amortise issue costsof debtover recognise directly equity disposal impairment itsterm investment gain loss equity recycle income statement equity investment record noncurrent asset expect sell yearfinancial information ifrsglaxosmithkline ifrs adjustment adjustment sharebased payment expect reduce normal level million asummary principal difference uk gaap considerably high charge arise ifrs apply glaxosmithklineisset main factor relatively share option grant financial effect show pagesto gwsb merger finalise customer allowance catchup grant early year follow adjustment isa reclassification turnover normal annual grant november addition expense profit cash flow effect ifrs detailed grant average share price excess rule relation certain marketing promotional share option exercisable expenditure deduct turnover fall charge charge record expense howeverthese rule exist reflect current share price normal grant level gaap eitf account consideration give vendor customer require marketing advertising coregcapitalisation amortisation promotion payment customer deduct north american right coregwere acquire time turnover significant impact inthe consumer gwsb merger partial consideration require disposal healthcare business payment large retailer instore kytril roche uk gaap account advertise preferential shelfspace product listing etc exchange asset value attribute coreg commonplace balance sheet ifrs require acquire right coregto add intangible asset fair value glaxosmithkline believe reflect good practice revenue date acquisition million amortise recognitionandhence absence detailed guidance remain useful life year adjustment reduce ifrs decide adopt revenue recognition policy profit tax million million ifrs line eitf go forward eps pence pence difference turnover report ifrs turnover report gaap adjustment impact intangible asset amortisation profit tax ep uk gaap glaxosmithkline amortise intangible asset estimate expect useful life acquisition sharebase payment maximum year ifrs permit amortisation present uk gaap approach sharebase payment commence asset available use annual record intrinsic loss grant suffer company impairment testing require point glaxosmithkline mean share option grant market price determine point amortisation productrelate charge income statement share option asset commence ifrs normally regulatory approval grant cost employee eg longterm majority glaxosmithkline intangible asset relate incentive plan income statement charge acquisition right compound development equal market price date award spread reach point amortisation commence lead performance period usually year reduction amortisation charge period present ifrs sharebase payment ukgaap equivalent frs likely reverse future compound reach sharebased payment come force regulatory approval amortisation charge short requirethe fair value equity instrument issue tobe period profit tax increase million charge income statement forshare award grant million eps pence pence senior executive calculation different resultant charge materially different uk gaap goodwill amortisation major difference arise respect share optionsof uk gaap require goodwill amortise estimate million adjustmentin million arise expect useful life glaxosmithkline determine grant share option market price approximately normally long year ifrs employee glaxosmithkline choose recognise goodwilli consider indefinite life unvested option award retrospectively amortisedbut subject annual impairment testing adjustment reverse goodwill amortisation charge glaxosmithkline receive tax credit appropriate relate uk gaap include record profit share share option award exercise base gain associate line relate acquisition group interest theholder makeand dependant tax rule country quest diagnosticsinc business combination deduction claim defer tax asset exemption ifrs goodwill previously write direct represent estimate future tax relief gain reserve uk gaap recycle income statement base potential gain available option award disposal partdisposal subsidiary associate holder balance sheet date movement defer uk gaap adjustment increase tax asset balance sheet nextmayresultin profit tax million million ep tax credit tax charge record income statement penny pence adjustment reduce profit tax million million earning million millionand eps pence pence glaxosmithklinefinancial information ifrs ifrs adjustment continue defer tax intercompany profit uk gaapdeferre tax provision intercompany pension postemployment benefit profit hold inventory calculate supply company glaxosmithkline account uk gaap pension effective tax rate ifrs take balance sheet approach postemployment benefit opebs accordance ssap recognition defer tax result tax rate spread cost provide benefit company hold inventory balance sheet date estimate average service live employee additional apply provision proportion group frs disclosure pension fund surplus deficit inventory hold specific location change significantly liability opebs base valuation methodology balance sheet date significant change require standard value defer tax asset reflect ias employee benefitstake similar valuation approach tax charge year frs accordance transitional provision ofifrs surplus deficit recognise balance adjustment sheet transition date st january addition number minor adjustment follow anamendmentto ias issue iasb december reclassification include permit recognise movement surplus computer software record intangible asset deficit immediately balance sheet outside income form integral operate system statement similar way frs mean tangible fix asset case balance sheet reflect surplus deficit position defer tax brand acquire company fund difference fair value brand group policy charge operating business acquisition thetaxvalue taxable temporary difference service cost element pension charge get arise report withincost salesselle general administrative cash equivalent reclassification liquid investment expenditure orresearch development appropriate maturity month acquisition charge element relate funding deficit include cash cash equivalentsand report sell general administrative expenditure provision reclassificationwhere element provision ias service cost element total charge expect pay year balance sheetdate considerably high ssap funding deficit exception pension opebs present element low lead additional reclassification current liability adjustment income statement expense heading cash flow statement usa recently enact medicare prescription drug ukgaap ifrs change cash improvement modernization act expect lead flow group ifrs cash flow format similar uk payment receive glaxosmithkline gaap present cash flow different category government respect employee healthcare plan different order ukgaap cash flow statement present clear consensus receipt ifrs accounting adjustment net cash generate account ias glaxosmithkline recognise operation intangible asset reclassification receipt asactuarial adjustmentsand impact inclusion liquid investment maturity recognise balance sheetthis treatment change month acquisition relate exchange guidance issue require different accounting treatment adjustmentswithin cash cash equivalent ifrs overall impact adjustment pension opebs decrease profit tax million increase million decrease ep pence nil share profit associate ukgaap share profit associate report profit tax group ifrs require share profit tobe net profit attributable group ie interest tax minority interest associate lead reclassification adjustment remove share associate interest tax minority interest line income statement net share profitsof associate line adjustment reduce profit beforetax million million affect epsfinancial information ifrsglaxosmithkline ifrs pharmaceutical turnover total group month months q q q q respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir agenerase lexiva herpe valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccine hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac total pharmaceutical turnover include copromotion income glaxosmithklinefinancial information ifrs ifrsconsolidatedincome statement statutory month month uk gaap adjustment ifrs growth ukgaap adjustment ifrs cer turnover cost sale sell general administrative expenditure research development expenditure operating cost trading profit operatingincomeexpense operating profit share profitslosse joint ventures associate disposal interest associate disposal business profit interest financecost net profit ordinary activity taxation taxation profit ordinary activity taxation equity minority interest preference share dividend earning profit attributable shareholder basic earning share p p p p p p ifrsconsolidatedincome statement business performance month month uk gaap adjustment ifrs growth ukgaap adjustment ifrs cer turnover cost sale sell general administrative expenditure research development expenditure operating cost trading profit operatingincomeexpense operating profit share profitslosse joint ventures associate disposal interest associate disposal business profit interest financecost net profit ordinary activity taxation taxation profit ordinary activity taxation equity minority interest preference share dividend adjust earning profit attributableto shareholder adjust earning share p p p p p pfinancial information ifrsglaxosmithkline ifrsconsolidatedincome statement statutory q months q ukgaap adjustment ifrs ukgaap adjustment ifrs ukgaap adjustment ifrs turnover cost sale sell general administrative expenditure research development expenditure operating cost trading profit operating incomeexpense operate profit share profitslosse joint ventures associate disposal interest associate disposal business profit interest financecost net profit ordinary activity taxation taxation profit ordinary activity taxation equity minority interest preference share dividend earning profit attributable shareholder basic earning share p p p p p p p p p ifrsconsolidatedincome statement statutory month q q ukgaap adjustment ifrs ukgaap adjustment ifrs ukgaap adjustment ifrs turnover cost sale sell general administrative expenditure research development expenditure operating cost trading profit operating incomeexpense operate profit share profitslosse joint ventures associate disposal interest associate profit interest financecost net profit ordinary activity taxation taxation profit ordinary activity taxation equity minority interest preference share dividend earning profit attributable shareholder basic earning share p p p p p p p p p glaxosmithklinefinancial information ifrs ifrs consolidated balance sheet st december st december ukgaap adjustment ifrs ukgaap adjustment ifrs property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset noncurrent asset noncurrent asset current asset inventory trade receivables liquid investment cash cash equivalent asset hold sale current asset total asset shortterm borrowing trade payable current tax payable shortterm provision current liability longterm borrowing defer tax provision pension postemployment benefit provision noncurrent liability noncurrent liability total liability net asset equity share capital share premium account share hold esoptrust reserve retain earning equity shareholder fund nonequity minority interest equity minority interest capital employ ifrs consolidated statement recognise income expense st december st december ukgaap adjustment ifrs ukgaap adjustment ifrs exchange movement tax exchange movement unrealise gain loss share employee share scheme goodwill write revaluation goodwill exchange unrealisedloss disposal intellectual property actuarial gainslosse define benefit plan net gainslosse recognise directly equity profit attributable shareholder totalrecognise income expense year financial information ifrsglaxosmithkline ifrsconsolidate cash flow statement month months q q q q cash flow operating activity cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase tangible fix asset proceeds sale tangible fix asset purchase intangible asset purchase equity investment proceed sale equity investment purchase business net cash acquire disposal businessesand interest associate investment joint venture associate interest receive dividend joint ventures associate net cash outflow investing activity cash flow financing activity increasedecreasein liquid investment proceed share employee share option issue share capital share capital purchase cancellation purchase treasury share redemption preference share issue subsidiary increasein longterm loan repayment longterm loan net repayment shortterm loan net repayment obligation finance lease interest pay dividend pay gsk shareholder dividend pay minority interest dividend pay preference share finance cash flow net cash outflow financing activity exchange adjustment increasedecreasein cash cash equivalent cash cash equivalent begin period cash cash equivalent end period cash cash equivalent end period comprise cash cash equivalent overdraft glaxosmithkline shareholder return share price dividend share guide shareholder table set dividend share pay year st january year gsk p gw p sb p high year low year st december decreaseincrease table set middle market closing price derive london stock exchange daily official list dividend pay glaxo wellcome smithkline beecham company share pricedecreasedbyfiveper cent shareholder express dividend glaxosmithkline price st januarytoat share st december compare anincreasein ftse index ofeightper cent year dividend ad guide holder adrs tablebelow setsout market capitalisation dividendsper ad pay dollar year market capitalisation glaxosmithkline st december translate dollar applicable exchange rate wasbillion date glaxosmithkline fourthlargest company market capitalisation ftse year gsk gw sb index smithkline beecham plc float rate unsecured loan stock loan stock list exchange holder require smithkline beecham plc redeem loan stock dividend pay glaxo wellcome smithkline beecham par ie loan stock hold business adr holder express dividend glaxosmithkline day march june september december holder wish adsone glaxosmithkline ad represent glaxosmithkline redeem loan stock complete share notice loan stock certificate return registrar arrive day relevant dividend calendar redemption date fourth quarter taxation exdividend date th february general information concern uk tax effect record date th february share ownership set taxation information payable thapril quarter dividend exdividend date th record date th glaxosmithkline pay dividend quarterly board declare payable th july dividend follow second quarter dividend share pence pence exdividend date rd august interimpaid st july record date th august second interimpaid th september payable th october interimpaid th january fourth interimpayable th april quarter total exdividend date nd november record date th november payable th january glaxosmithkline shareholder information ordinary share share price information share price information available company website company share list london stock exchange wwwgskcom information uk available ceefax teletext andfrom ftcityline calling registrar call charge p minute plus vat time company share register administer lloyds tsb registrar provide follow service annual general meeting glaxosmithkline investment plan plan enable shareholder reinvest quarterly dividend queen elizabeth ii conference centreth andor monthly investment company ordinary broad sanctuary westminster share special dealing arrangement london swp ee glaxosmithkline individual saving account annual general meeting company principal forum glaxosmithkline individual saving account isa communication private shareholder addition formal taxefficient way invest company ordinary share resolution meeting presentation chief executive officer performance business glaxosmithkline corporate sponsor nominee future development opportunity question corporate sponsor nominee provide facility board chairmen board committee shareholder hold share need share question matter relate committee certificate shareholder detail hold main share register remain confidential investor hold share company nominee service arrange nominee service appoint shareview service corporate representative proxy respect shareholde shareview portfolio service provide shareholder order attend vote meeting information investment company shareholder register service wwwshareviewcouk adr holder wish attend meeting obtain proxy bank new york enable attend shareview deal service meeting vote business transact adr holder shareview deal service telephone internal share instruct bank new york tothe way deal facility available ordinary shareholder log share represent adrs vote complete wwwshareviewcoukdeale call return voting card provide bythe bankin accordance instruction give american depositary share company share list new york stock exchange financial reporting form american depositary share adss financial reporting calendar evidence american depositary receipt adr represent ordinary share announcement st quarter result th april announcement nd quarter result th july adr programme administrator announcement rd quarter result th october adr programme administer bank new york preliminary announcement annual result th february provide global buydirect service direct ad purchasesale dividend reinvestment plan adr holder publication annual reportreview march share deal facility result announcement hoare govett limited operate postal share deal service result announcement issue london stock company ordinary share enable investor buy sell exchange andareavailable theirnew serviceat share competitive commission charge transaction time shortly afterwardstheyare issue mediamade execute settle pershe security limit detail available website andsent ussecuritie service purchase sale form exchange commission new york stock exchange obtain telephone financial report smith barney citigroup offer share deal service company publish annual report investor company ordinary share adss detail need detail report annual review service obtain contact contact detail available date publication website inside cover annual review send shareholder date provision detail intend publication shareholder elect receive report invitation inducement engage investment activity writing company registrar alternatively shareholder advice share dealing obtain stockbroker elect receive notification email publication independent financial adviser financial report register wwwshareviewcouk copy previous financial report available website print copy obtain registrar uk customer response center usa glaxosmithkline share capital nature trading market glaxo wellcome ordinary share company list london fiscal period stock exchange th december share st january th december pence share list new york stock exchange inthe form american high low depositary share adss date follow table set period indicate high low middle market closing quotation pence share fiscal period london stock exchange derive daily official st januaryto th december list high low report sale price dollar usdollar ad adss new york stock exchange derive high low new york stock exchange composite tape information relate share ad price glaxo wellcome smithkline beecham prior date smithkline beecham themerger give fiscal period glaxosmithkline penny share st januaryto th december pence share fiscal period th december high low high low quarter end st march february january december fiscal period st january th december november usdollar ad october high low september quarter end st december quarter end th september quarter end th june quarter end st march quarterende st december quarter end th september quarter end th june quarter end st march yearended st december yearended st december th st december dollar ad fiscal period th december high low quarter end st march february january december november october september quarter end st december quarter end th september quarter end th june quarter end st march quarter end st december quarter end th september quarter end th june quarter end st march yearended st december yearended st december th st december th february share capitalglaxosmithkline analysis shareholding number total total number analysis shareholding st december account account share share hold share total hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline total bank new york hold hold bny nominees limited represent company adr programme ad represent ordinary share p nominal value atth february number holders record share usa waswith holding ofshare thenumberof register holder adr waswith holding ofadr certain share adrs hold broker nominee result number holder record register holder usa representative number beneficial holder orofthe residence beneficial holder control company far know company directly indirectly own control corporation government thecompany know arrangement operation result change control company substantial shareholding th february company receive notification follow interestsof cent inthe share issue exclude treasury share bnynominee limited holdsshare represent cent share hold behalf holder adr evidence adss legal general investment management limited hold share represent cent barclays plc hold share representingper cent far know company person owner cent share issue exclude treasury share company director officer interest director officer companyas define thecompanie act share option company give theremuneration reportpage exchange control limitation affect securityholder currently uk law decree regulation restrict import export capital affect remittance dividend orother payment holder companys share nonresident uk limitation relate nonresident uk english law company memorandum article association right tobe holder tovote respect company share document display memorandum article association thecompany otherdocument refer annual report available inspection register office company publication year glaxosmithkline produce corporate responsibility report cover performance area include community investment business ethic integrity access medicine rd environmental health safety report publish onthe website end march glaxosmithkline taxation information shareholder information shareholder stamp duty uk stamp duty stamp duty reserve tax sdrt subject summary main tax consequence holder share certain exemption payable purchase share adr citizen resident uk usa rate cent purchase price minimum set complete analysis possible tax charge stamp duty liability arise consequence purchase ownership security intend general guide holder advise consult shareholder adviser respect tax consequence purchase ownership share adr follow summary certain uk taxation usa consequence state local tax law usa federal income tax consideration relevant implication new ukus income tax convention usholder share adrs summary apply shareholder hold share adr capital asset statement base uk tax law practice citizen resident usa domestic corporation date report subject united states federal income taxation new ukus income tax convention come force net income basis respect share adrs st march provision new treaty apply uk resident uk uktax purpose hold share tax purpose st april ukcorporation tax th april purpose trade profession vocation carry uk income tax capital gain tax st uk branch agency withholding taxis ustax purpose provision new treaty apply st withhold taxis taxation dividend st january ustaxes holder share gross dividend receive include amount adr ability elect continue use respect associate tax credit uk withholding tax treat provision previous treaty month follow foreign source dividend income tax purpose new treatys entry force election eligible dividend receive deduction allow advance event new treaty apply corporation dividend adr payable dollar dividend share payable sterling dividend pay holder adrs generally treat owner pound sterling include income dollar underlie share purpose current usauk calculate reference exchange rate day double taxation convention relate income gain dividend receive holdersubject certain income tax convention estate gift taxis estate gift exception individual eligible holder subject tax convention purpose internal revenue taxation maximum rate cent respect qualified code amend code dividend receive shareholder advise follow analysis deal dividend pay th april consult tax adviser confirm eligibility advance corporation tax act abolish taxation capital gain uk shareholder generally holder subject uk capital gain tax subject tax capital gain realise sale taxation dividend disposal share adr th april rate tax credit reduce ninth result compensate reduction rate tax estate gift taxis dividend income increase tax bear uk estate gift tax convention shareholder resident individual shareholder tax credit generally subject uk inheritance tax long repayable shareholder tax liability associate tax credit stamp duty uk stamp duty sdrt subject certain exemption taxation capital gain payable issue transfer share adr custodian uk shareholder liable uk tax gain depository rate cent price issue disposal share adrs entitle consideration provide transfer indexation relief taper relief sale indexation relief sale value transfer consideration calculate market value share st march cost subsequent purchase date sdrt payable transfer adr uk purchase indexation relief individual shareholder stamp duty payable transfer adr cease th april taper relief available individual provide instrument transfer execute remain shareholder hold deem hold share time outside uk stamp duty transfer year sell adr payable rate cent consideration transfer sale underlie share inheritance tax result liability uk stamp duty case individual shareholder liable inheritance tax sdrt rate cent minimum charge transfer share adrs tax charge stamp duty liability arise value shareholder estate reduce result transfer way gift disposal market value gift disposal subject uk inheritance tax estate gift tax estate gift tax convention generally provide tax pay usa credit tax payable ukglaxosmithkline cross reference form f table provide cross reference information include annual report requirement form f item item identity director senior management advisor na financial information consolidate statement financial information offer statistic expect timetable na financial statement item key information legal proceeding select financial datum b significant change risk factor note post balance sheet event information company offer list history development company inside cover share price history b business overview c market product additional information competition b memorandum articles association footnote regulation c material contract na marketing distribution exchange control manufacture supply e taxation research development h document display intellectual property environment health safety quantitative qualitative disclosure market risk access medicine treasury policy investment community note financial instrument relate disclosure c organisational structure description security equity security na property plantsand equipment default dividend arrearage delinquencie na environmental responsibility note segment information material modification right security holder note tangible fix asset use proceed na operate financial review prospect control procedure operate result reserve audit committee financial expert b code ethic b liquidity capital resource c principal accountant fee service c research development patent license etc exemption list standard audit committee na trend information e purchase equity security issuer affiliate e balance sheet arrangement na purchaser f tabular disclosure ofcontractualobligation financial statement na director senior management employee financial statement director senior management independent auditor report footnote ii b compensation consolidate statement profit loss remunerationreport consolidate statement total recognise gain c board practice loss corporate governance consolidate statement cash flow employee consolidate balance sheet glaxosmithkline people reconciliation movement consolidated equity note employee cost shareholder fund financial record company balance sheet e share ownership notesto financial statement glaxosmithkline people exhibit footnote ii note employee share scheme share option incentive plan footnote director interest information responsive item incorporate reference memorandum articles association glaxosmithkline major shareholder relate party transaction page group annual report form f major shareholder year end st december b relate party transaction ii company form f filing security exchange note relate party transaction commission glaxosmithkline glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation advance corporation tax act advance payment uk tax dividend pay direct equivalent american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share adss ordinary share register new york stock exchange calledup share capital ordinary share issue fully pay cer growth growth constant exchange rate combine code guideline require listing rule financial service authority address principal aspect corporate governance company glaxosmithkline plc creditor account payable currency swap exchange currency couple subsequent reexchange currency agree exchange rate date debtor account receivable define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share earning share basic income share employee share ownership plan trust trust establish group satisfy share base employee incentive plan equity shareholder fund aggregation share reserve own shareholder equivalent shareholder equity finance lease capital lease freehold ownership absolute right perpetuity gearing ratio net debt percentage shareholder fund net debt minority interest group glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement bymake offset commitment intangible fix asset asset physical substance brand licence patent knowhow marketing right purchase outside party interest cover number time profit interest exceed net interest payable interest payable interest expense interest receivable interest income nonequity minority interest preference share issue subsidiary outside party preference share share issue vary dividend rate treat outside interest profit income profit loss account reserve retain earning profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue share outstanding statement total recognise gain loss statement comprehensive income stock inventory subsidiary undertaking affiliate glaxosmithkline hold majority shareholding andor exercise control tangible fix asset property plant equipment turnover revenuecontact detail internet information investor company available glaxosmithkline corporate website wwwgskcom head office register office glaxosmithkline plc great west road brentford middlesex tw gs tel united kingdom united states america investor relation investor relation great west road franklin plaza brentford po box middlesex tw gs philadelphia pa tel tel toll free fax tel outside usa fax registrar lloyds tsb registrar adr programme administrator causeway bank new york worthe shareholder relation west sussex bn da po box wwwshareviewcouk church street station new york ny general enquiry annual report orderline wwwadrbnycom corporate nominee service tel toll free tel inside uk tel outside usa tel outside uk customer response center shareholder investment plan tel toll free dividend reinvestment enquiry tel inside uk corporate share deal facility tel outside uk ordinary holder smith barney tel outside uk employees attn gskservice state street monthly saving plan enquirie th floor tel inside uk boston tel outside uk tel toll free isa enquiry tel outside usa tel inside uk fax tel outside uk thetaylorgroupsmithbarneycom glaxo wellcome smithkline beecham corporate pep share centre limited oxford house oxford road aylesbury buck hp sz tel corporate share deal facility smith barney attn gskservice citigroup centre level canada square canary wharf london e lb tel fax thebalaesgroupcitigroupcom print midas press uk paper production document pulp harvestedfrom sustainable forest sawmill residue forest thinning elemental chlorinefreewwwgskcom